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The aim of this project was to develop in vitro models for angiogenesis 
that have the capability of combining pro-angiogenic cells with an 
extracellular matrix (ECM) component that can be monitored under flow 
conditions to learn more about the ‘rules’ of angiogenesis.   
 
Significant advancement has been made in the field of tissue engineering in 
recent years, however one of the current obstacles limiting progression is 
the production of thick, complex tissues due to the lack of rapid 
neovascularisation of the constructs upon implantation.  Blood vessel 
formation is tightly regulated and relies on the chronologically precise 
adjustment of vessel growth, maturation and suppression of endothelial cell 
growth - all of which are controlled by a large number of factors which 
influence each other.  To induce vascularisation within tissue-engineered 
(TE) substitutes the same processes need to occur.  A number of different 
vascularisation strategies have been investigated in an attempt to 
overcome this issue but as yet there is no unified solution to this problem.  
The most promising attempts have used scaffolds with vascular 
architectures, perfusion conditions and relevant cell types.  Although it is 
recognised that perfusion conditions, the cell type and scaffold architecture 
are important with regards to vascularisation strategies many of the 
techniques fail to consider them in combination.  It is therefore important 
to take a step back and understand how these factors work together to 
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promote angiogenesis in order to advance this crucial area.  This lack of 
understanding is further compounded by the deficiencies of current 
angiogenesis models.  Current in vitro models fail to combine the use of 
supporting cells, the extracellular matrix and fluid flow in 3D.  Although 
this complexity exists within in vivo models such assays are primarily 
limited by the species used, organ sites available and complicated analysis 
techniques.   
 
In this project two in vitro angiogenesis models were developed.  The first 
was derived from the decellularisation of a rat jejunum.  Characterisation 
showed the retention of key extracellular matrix (ECM) components and 
the removal of almost all cellular material.  Re-endothelialisation with 
human dermal endothelial cells (HDMECs) of the patent vascular network 
showed enhanced results when co-cultured with human dermal fibroblasts 
(HDFs).  In an attempt to induce angiogenesis, vascular endothelial 
growth factor (VEGF) loaded gels were placed on top of the scaffold whilst 
being continuously perfused with media.  Placing VEGF loaded gels onto 
the recellularised jejunum led to the expression of the Notch ligand Delta-
like-4 (DLL4) by HDMECs indicating their transformation into tip cells 
which are synonymous with sprouting angiogenesis.  
 
The second was produced through the combination of robocasting and 
electrospinning. Nanofibrous poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) scaffolds with hollow channels capable of 
perfusion were produced that could be re-endothlialised with HDMECs.  
Again the addition of HDFs enhanced cellular distribution in the channels.  
Placing VEGF loaded gels onto the surface of the scaffolds led to the 
outgrowth of HDMECs into the gel, forming perfusable tubules.   
 
Overall these two models overcome limitations of current in vitro models 
since they offer the capability of combining pro-angiogenic cells with ECM 
components that can be monitored under flow conditions.  With further 
development they could provide more sophisticated platforms upon which 
to investigate the angiogenic process.  
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Introduction 
 
1.1. Structure and function of the vascular system 
 
Diffusion is a mechanism used widely throughout the body to transport 
substances from regions of higher concentrations to those of lower 
concentrations.  However, beyond a distance of a few cell diameters, it is 
too slow to meet the metabolic requirements of cells.  As a result the 
circulatory system provides an alternative mechanism to transport 
molecules rapidly over long distances between cells and the body’s surface 
and also between various specialised tissues and organs in large, multi-
cellular organisms. 
 
The blood vessels of the circulatory system form a detailed network of 
interconnected tubes that transport blood, pumped by the heart, 
throughout the entire body.  The three main types of blood vessel present 
in the body are the arteries, veins and capillaries; all of which are 
composed of several layers (Figure 1).  All vessels consist of a single cell 
thick inner layer of endothelial cells (ECs) known as the tunica intima that 
lines the lumen forming a smooth, friction reducing surface.  Mural cells 
wrap around this structure stabilising the vascular tube and are contractile 
in nature in order to regulate vessel diameter and consequently blood flow.  
In smaller vessels (capillaries) mural cells are sparse and usually referred to 
as pericytes with little to no elastin present since the expansion and recoil 
of these vessels is low due to the small pressures present.  In larger vessels 
(veins, arteries etc.) they are multi-layered and referred to as smooth 
muscle cells (SMCs) which are reinforced by organised layers of elastic 
tissue that form elastic laminae.  This middle layer, or tunica media, is 
particularly thick in the arteries that must be elastic and strong enough to 
sustain large pulsatile pressures caused by the outflow of blood from the 
heart.  The outermost layer, the tunica adventitia, is composed largely of 
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collagen fibres with SMCs present in larger vessels that are required to 
stretch and recoil, such as veins [1]. 
 
 
Figure 1 - Blood vessel hierarchy and structure 
 
 
1.2. Formation of the vascular system 
 
Since blood vessels are essential in providing tissues with nutrients and 
removing waste from these sites they begin to form in  the early stages of 
embryonic development via three distinct processes: vasculogenesis, 
angiogenesis and arteriogenesis [2].   
 
1.2.1. Vasculogenesis 
 
The formation of the first capillaries takes place by vasculogenesis.  
Initially aggregations of cells called blood islands form in the embryonic 
yolk sac and contain a homogenous collection of cells called 
hemangioblasts, which are the precursors to blood and blood vessels. As 
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these cells develop, two distinct types of cells are formed: hematopoietic 
stem cells (HSCs) and endothelial progenitor cells (EPCs).  As the blood 
islands merge, the HSCs which sit in the centre of the blood island develop 
into blood cells and the EPCs which occupy the periphery of the blood 
island develop into a primitive capillary plexus that grows towards the 
embryo [3] as illustrated in Figure 2. 
 
 
 
Figure 2 - Formation of primitive capillary plexus via vasculogenesis 
 
1.2.2. Angiogenesis 
 
The primitive network then grows and remodels via angiogenesis, invading 
target tissues and giving rise to the more developed capillary plexuses of 
embryonic organs.  It does this through two distinct processes known as 
sprouting and non-sprouting angiogenesis.  
 
Sprouting angiogenesis is a process whereby ECs branch out from an 
existing capillary extending through the surrounding matrix to form a new 
vessel.  The steps involved in this process are outlined below and 
illustrated in Figure 3 [4]: 
 
1. The basement membrane is dissolved and pericytes detach from the 
capillary 
2. ECs migrate towards the extracellular space and form an 
endothelial sprout 
3. ECs start to proliferate downstream of the leading edge of the 
sprout 
4. A lumen forms in the endothelial sprout 
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5. A closed loop forms with another vessel (i.e. anastomoses) 
6. Pericytes are recruited and the basement membrane forms around 
the new vessel 
 
 
Figure 3 - Process of sprouting angiogenesis whereby ECs branch out from an existing 
capillary extending through the surrounding matrix to form a new vessel. 
 
Non-sprouting angiogenesis refers to the process whereby a single capillary 
splits into two from within (Figure 4).  The process takes place via several 
distinct steps [5]: 
 
1. The endothelial walls of the opposite sides of a vessel migrate 
towards each other forming what is known as an ‘intraluminal 
pillar’ 
2. A central perforation is then formed in the centre of the pillar 
3. The pillar is invaded with pericytes and myofibroblasts that deposit 
extracellular matrix (ECM) into the pillar 
4. Several pillars then increase in size and merge, splitting up the 
original capillary into two new capillaries. 
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Figure 4 - Process of non-sprouting angiogenesis whereby a single capillary splits into two 
capillaries from within. 
 
Key factors influencing angiogenesis have been identified and can be 
broadly split into molecular and mechanical mechanisms.  It is important 
to note that most of the information presented has been attained through 
the study of extraembryonic sprouting angiogenesis and the work 
presented throughout refers to this type of angiogenesis [6].       
 
Molecular Mechanisms 
 
Numerous endogenous biochemical factors capable of stimulating or 
inhibiting angiogenesis have been identified.  These are mainly cytokines 
and their receptors, ECM constituents, cell-matrix adhesion molecules and 
matrix degrading enzymes.  A brief overview of the roles these factors play 
in physiological angiogenesis is provided.  Here, whilst the effect each 
factor has throughout the angiogenic process is summarised in Table 1 
readers that require more details in these topics are referred to other 
sources [7–10].        
 
Cytokines and their receptors 
 
Hypoxia occurs when the balance between the supply and demand of 
oxygen (O2) is altered and the level of O2 reaching the cells is depleted.  
The founding member of the hypoxia inducible factor (HIF), HIF-1α 
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regulates a broad spectrum of genes in response to O2 deprivation.  The 
HIF pathway is controlled by prolyl hydroxylase domain (PHD) enzymes.  
At physiological O2 levels HIF-1α becomes hydroxylated by members of 
the PHD family.  Hydroxylation generates a binding site for the von 
Hippel-Lindau (pVHL) tumour suppressor protein and as a result HIF-1α 
is polyubiquitylated and undergoes proteosomal degradation.  When the 
environment is hypoxic and O2 is depleted, the rate of hydroxylation is 
suppressed and so HIF-1α accumulates.  It then dimerizes with a HIF-β 
family member, translocates into the nucleus and leads to gene activation 
[11][12,13] that promotes the short and long term adaptation to hypoxia.       
Long term adaptation to local hypoxia is controlled via stimulating 
angiogenesis.  The HIF pathway regulates a host of angiogenesis related 
genes including vascular endothelial growth factor (VEGF), angiopoietin-1 
(Ang-1) and angiopoietin-2 (Ang-2), platelet derived growth factor 
(PDGF), Tie-2, basic fibroblast growth factor (bFGF), transforming 
growth factor-β (TGF-β) etc. [14].  Pro-angiogenic growth factors signal 
through their receptors on ECs and activate endothelial nitric oxide 
synthase (eNOS).  The action of shear stress also activates eNOS.  Upon 
activation eNOS catalyses L-arginine to L-citrulline and nitric oxide (NO).  
Finally, NO release induces angiogenesis through EC migration, 
proliferation etc. [15]   The effects of such aforementioned cytokines are 
discussed below.   
 
Studies have shown that acidic fibroblast growth factor (aFGF) and bFGF 
induce the production of matrix proteases in ECs that break down the 
ECM and allow migration of ECs into the surrounding matrix allowing the 
formation of capillary like tubes [16].  Fibroblast growth factor (FGF) is 
not only specific to ECs but also acts on most cells derived from the 
embryonic mesoderm and neuroectoderm, including fibroblasts and 
pericytes [17].  It is believed that storage of FGF in the ECM is possible 
and when the matrix is degraded FGF can be released [18].  
 
VEGF is known to be a key angiogenic stimulator.  The VEGF family is 
composed of 7 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-
E, VEGF-F and placenta growth factor.  VEGF-A in particular (referred 
to as VEGF herein) is known to be a major regulator of physiological and 
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abnormal angiogenesis and in turn has many isoforms including VEGF121, 
VEGF145, VEGF165, VEGF183, VEGF189 and VEGF206 [19].  Of these 
isoforms, VEGF165 has been found to have optimal bioavailability 
combined with high biological potency and is therefore used in many 
angiogenesis studies [19,20].  Its effect is mediated by the receptor, 
VEGFR-2 which is expressed predominantly in ECs.  VEGF binding 
causes VEGFR-2 activation, which in turn sets off multiple intracellular 
responses and leads to a complete angiogenic process [21,22].  VEGF is 
produced by many cells and a major regulator in its production is the local 
oxygen concentration.  Cells that experience reduced oxygen levels 
upregulate the production of VEGF, which in turn acts on ECs causing 
them to proliferate and invade the hypoxic tissue in order to provide new 
blood vessels for increased oxygen transfer [14,23]. 
 
PDGF is produced by cells including platelets, fibroblasts, ECs and 
macrophages.  The effects of PDGF are again mediated through its 
receptors, which can be found in ECs, pericytes and SMCs in blood vessel 
walls.  Signalling via PDGF and its receptor are important in blood vessel 
maturation, causing vessels to stabilise and maintain their vascular 
integrity [24].              
 
Members of the TGF-β family are multifunctional cytokines that affect 
many forms of cell behaviour including proliferation, recognition, 
differentiation, apoptosis, inflammation and angiogenesis [25,26].  As a 
result of its diverse nature, TGF-β and its receptors are expressed in a 
range of cells.  Depending on the cell type and extracellular surrounding 
they mediate different and sometimes opposite effects on the same cells 
[25].  This has been observed in many angiogenesis studies where the 
effects of TGF-β have been found to be concentration/context driven [27].  
At low concentrations TGF-β promotes angiogenesis by upregulating pro-
angiogenic factors, stimulating EC proliferation and migration, and the 
production of proteinases that break down the local ECM.  However, at 
high doses TGF-β inhibits EC growth and promotes the reformation of the 
basement membrane whilst stimulating SMC differentiation and 
recruitment to stabilise the vessels [28]. 
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ECs have a specific receptor called Tie-2.  The angiopoietins, Ang-1 and  
Ang-2 are ligands for Tie-2 and play antagonistic roles in angiogenesis [28].  
Ang-1 activates the Tie-2 receptor and promotes the recruitment of 
pericytes and SMCs in order to stabilise and maintain vascular integrity.  
Ang-2 on the other hand competes with Ang-1 for binding of Tie-2 and 
blocks vessel stabilisation from Tie-2 signalling, thereby loosening the 
interactions between ECs and pericytes and the ECM [28]. 
 
 
ECM, Integrins and matrix proteases 
   
The ECM is not only responsible for providing physical support for cellular 
components but it also provides biochemical and mechanical cues that 
regulate cellular function and can affect the angiogenic process [29].  In the 
case of biochemical regulation, studies show that matrix molecules found 
in the basement membrane (more specifically, decorin and tenascin C) 
cause ECs to establish and maintain capillary like structures throughout 
angiogenesis [30].  Molecules such as hyaluronan have been implicated in 
the inhibition of angiogenesis by reducing EC migration and adhesion 
when in its native high molecular weight (HMW) form.  However under 
certain physiological and pathological instances HMW hyaluronan can be 
broken down into smaller segments, termed oligomers, which have been 
found to stimulate EC proliferation and promote angiogenesis.  It has been 
found that hyaluronan oligomers compete with native HMW hyaluronan in 
binding to the receptor CD44 present on ECs.  Unlike HMW hyaluronan, 
the oligomers can trigger intracellular signalling pathways that prompt cell 
proliferation [31].   
 
The effects of ECM components are mediated by their adhesion to cell 
surface receptors, known as integrins.  Of the more than 20 integrin types, 
αvβ3 has been studied extensively for its role in angiogenesis.  It is heavily 
upregulated on ECs by the action of angiogenic growth factors such as 
bFGF, tumour necrosis factor-α (TNF-α) and interleukin-8 (IL-8) and 
enhances EC survival as well as localising degradation proteins to the tips 
of sprouting blood vessels helping to increase cell migration speed and 
matrix degradation in this area [32].  Angiogenesis induced by VEGF 
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depends on another integrin, αvβ5 , which promotes EC migration and 
invasion [32,33].  It has been shown that these integrins promote distinct 
pathways in angiogenesis and drive distinct cellular behaviours [34].   
 
When angiogenesis takes place the local ECM is degraded by matrix 
metalloproteinases (MMPs).  Upon degradation they allow the release of 
angiogenic growth factors stored in the ECM.  Their activity is tightly 
controlled by several mechanisms to prevent excessive breakdown of the 
ECM and to guide directional cell migration and invasion.  Protease 
inhibitors are secreted by cells near areas of active matrix degradation in 
order to protect uninvolved matrices [2,35]. 
 
Mechanical Mechanisms  
 
All cells in the body are subjected to mechanical forces that are either self-
generated or originated from their surrounding environment.  In 
comparison to the wealth of knowledge regarding the molecular 
mechanisms of angiogenesis, there is limited research that investigates its 
mechanical regulation.  This section aims to highlight the implications of 
intrinsic and extrinsic cellular forces on physiological angiogenesis.   
 
Maintaining the structure and shape of a cell requires forces to be 
transmitted from the actin-myosin fibres, via integrins, to the ECM 
proteins and these forces are known as the cell traction forces (CTFs) [36].  
Thus the adherent cell is under tension due to the ECM’s resistance to 
deformation.  As well as the cell{ECM contacts, cells also form cell-cell 
contacts with their neighbours and as a result a continuous cellular tissue 
is maintained.  The amount of cytoskeletal tension can change by 
rearrangement of the cytoskeletal proteins and adhesion sites, whether it is 
in response to external biochemical or mechanical stimuli [37].  This can 
cause a multitude of results critical to angiogenesis such as cell migration, 
matrix remodelling etc.   
 
With regards to cell migration, CTFs are the driving force behind cell 
movement.  Initially the cell propels its membrane forward by orienting 
and reorganising the actin-myosin network at its leading edge.  It then 
attaches to the ECM at the leading edge and releases its contact to the 
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substrate at the trailing edge of the cell pulling itself forward by the CTFs 
generated [38].  Rho is a member of the Ras family of small GTP binding 
proteins.  The Rho GTPase family consists of 3 subfamilies – Rho (RhoA, 
RhoB and RhoC), Rac (Rac1, Rac2 and Rac3) and CDC42.  RhoA is the 
most extensively studied Rho family member and it main target is Rho-
associated kinase (ROCK) [39].  Activation of the Rho/ROCK pathway 
(by cell signalling, growth factors etc.) plays a key role in actin 
cytoskeleton organisation, whereby inhibiting the action of Rho or ROCK 
reduces the capacity of ECs to form tubular networks [40].  The inhibition 
of ROCK also substantially reduces the CTFs and subsequent migration 
speed of ECs [6].  This indicates that the Rho/ROCK pathway and 
resultant CTFs play a role in regulating angiogenesis.               
 
With regards to matrix remodelling it has been found that cells such as 
fibroblasts and ECs distort and rearrange their surrounding ECM, via 
CTFs, when they move across it. The resultant ECM tends to align 
parallel to the migrating cell [41] and during angiogenesis, the production 
of an aligned ECM at the sprouting tip of a new vessel creates a track for 
the trailing ECs to follow [42].            
 
Along with CTFs, the mechanical properties of the ECM also play an 
important role in the assembly and maintenance of the microvasculature.  
The form and function of ECs is highly influenced by the Young’s Modulus 
of the surrounding ECM.  For example, compliant matrices tend to induce 
network formation by allowing ECs to reorganise the ECM through CTFs 
[42].  However, there is believed to be an upper limit of flexibility a matrix 
can have with regards to angiogenesis [43].  It has been found that ECM 
properties are actively modified throughout the process of angiogenesis, via 
the production of MMPs [30].  A better understanding and control of such 
properties could therefore lead to improved vascularisation in both native 
and engineered tissues.     
     
Blood vessels are constantly subjected to external mechanical forces 
originating from either blood flow or the extravascular environment.  The 
action of blood flowing past ECs results in a drag force tangential to the 
apical surface of the cells known as shear stress.  Studies have shown that 
capillaries exposed to higher blood flow velocities (and hence shear 
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stresses) had more sprouts, but capillaries with slow flow gradually 
narrowed and disappeared [44].  Stretching of muscle was also reported to 
stimulate capillary growth in vivo but via a different mechanism  [45].  
Studies show that capillaries formed in stretched muscle are produced 
mainly by sprouting angiogenesis, whereas increased shear stresses cause 
capillary growth via non-sprouting angiogenesis [46].  This implies that the 
molecular events that drive angiogenesis differ with stimuli.  Although 
progress has been made in this area more work is necessary to fully 
understand the roles that externally applied forces play in angiogenesis.   
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Table 1 - Biochemical and mechanical regulators of angiogenesis. 
Event Factor Description 
Angiogenic trigger 
 
 
 
 
Hypoxia 
 
 
Reduction in O2 pressure activates transcription of various 
angiogenesis related genes [14]. 
Shear stress Evidence shows that increased shear stresses are related to an 
increased level of capillary formation [44].  
Destabilisation 
 
 
 
 
VEGF Leads to increased vessel permeability [21,22].   
Ang-2 Loosens interaction between ECs and pericytes [28]. 
MMPs Locally breaks down ECM to provide space for migration of cells 
[35].  
Sprouting 
 
 
VEGF Leads to EC proliferation and invasion of hypoxic tissue [21,22]. 
Ang-2 Maintains loosened interactions between ECs and pericytes [28]. 
FGF Induce production of MMPs that break down ECM and allows 
migration of ECs [16]. 
MMPs Break down ECM to provide space for migration of cells and 
releases stored FGF from ECM [2,35].  
TGF-β 
(low concentration) 
Stimulates EC proliferation and migration and upregulates 
MMPs to break down ECM [28].  
Integrins αvβ3 upregulated on ECs by action of bFGF and enhances EC 
survival as well as localising degradation proteins to tips of 
sprouting vessels, helping to increase migration speed and matrix 
degradation.  αvβ5 upregulation induced by VEGF promotes EC 
migration and invasion [32,34]. 
CTFs Aid in pulling cells forward [38]. 
ECM Modulus Compliant matrices allow ECs to reorganise ECM through CTF 
during network formation [42]. 
Anastomosis/Stabilisation 
 
  
 
 
 
TGF-β 
(high concentration) 
At high doses TGF-β inhibits EC growth and promotes 
reformation of basement membrane.  It also stimulates 
recruitment of pericytes to stabilise vessels [28].   
PDGF Causes vessels to stabilise and maintain their vascular integrity 
[24]. 
Ang-1 Promotes recruitment of pericytes to stabilise and maintain 
vascular integrity [28]. 
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The Interplay between Molecular and Mechanical Mechanisms 
 
It is important to note that although molecular and mechanical factors 
(summarised in Table 1) have been discussed separately, the activity of an 
angiogenic stimulus or inhibitor depends on the presence/concentration of 
other factors in the environment.  These can vary both temporally and 
spatially throughout the angiogenic process and this may explain why 
angiogenic factors often display context/concentration dependent actions 
in various experimental setups [4].  Better understanding of the interplay 
between ECs, molecular and mechanical factors will certainly play an 
important role in understanding the fundamental regulation of 
angiogenesis.      
  
1.2.3. Arteriogenesis 
 
Once pericytes have been recruited, some vessels remain as capillaries and 
others are subsequently covered by a muscular coat endowing them with 
viscoelastic and vasomotor properties necessary to accommodate the 
changing needs in tissue perfusion.  This process is known as arteriogenesis 
[4].  Readers interested in this topic are guided towards other sources 
[47,48].        
 
Although this section is by no means an exhaustive review of all of the 
factors that influence blood vessel formation it does highlight the complex 
nature of the process.  
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1.3. The importance of vascularisation in tissue engineering 
 
Tissue engineering was originally developed as an alternative therapy for 
the treatment of tissue loss or end-stage organ failure, resolving the 
shortage of tissues and organs available for transplantation therapy.  It 
represents a biology driven approach by which constructs are engineered to 
replace damaged, injured or missing tissues through combining materials 
technology and biotechnology [49,50].  Significant progress has been made 
in recent years, however one of the current obstacles in the field is the 
production of thick (≥2 mm), complex tissues due to the lack of rapid 
neovascularisation of the constructs [51].  Blood vessel formation is tightly 
regulated and relies on the chronologically precise adjustment of vessel 
growth, maturation and suppression of EC growth - all of which are 
controlled by a large number of factors which influence each other.  To 
induce vascularisation within tissue engineered (TE) substitutes these 
same processes need to occur.  The complexity of these tightly regulated 
processes explains why this remains one of the major obstacles in the field 
of tissue engineering at present [51].   To overcome this the aim is to 
translate the basic principles of angiogenesis to produce a physiologically 
relevant TE construct fit for use in the clinic.  This section describes the 
current vascularisation strategies that have been adopted for bladder, liver, 
myocardium and skin, the tissues where there have been considerable 
research efforts to overcome these problems for the introduction of 
materials into patients as summarised in Table 2.  These are discussed 
under five headings as follows: prevascularisation systems; scaffold 
functionalisation; harnessing natural vascular architectures; production of 
a synthetic vascular architecture; integrating cellular components and are 
summarised in Figure 5. 
 
1.3.1. Prevascularisation systems   
 
This approach aims to produce TE constructs with a network of functional 
capillaries in order to accelerate anastomosis with the host tissue upon 
implantation.  This has been attempted both in vivo and in vitro.    
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• In vitro prevascularisation.  In this approach the construct is 
cultured in vitro with the aim of producing a three dimensional 
(3D) prevascularised structure that can be implanted and 
subsequently connected with the existing vasculature in the site of 
implantation.  For example, Sekine et al. have attempted to 
prevascularise myocardial cell sheets in vitro using a vascular bed 
and bioreactor system for the reconstruction of heart tissue.  Here 
tissue that contained an artery and vein was resected and connected 
to a perfusion bioreactor to establish a vascular bed.  A tri-layer 
cardiac cell sheet produced with a co-culture of ECs was then 
overlaid onto the vascular bed.  ECs were shown to connect to 
capillaries in the vascular bed forming tubular lumens and 
producing in vitro perfusable blood vessels in the cell sheet [52].  
This method seems promising with the possibility of thicker 
constructs being developed by stacking cell sheets [53].  
 
• In vivo prevascularisation.  Some approaches have used the host’s 
intrinsic vasculature to vascularise the constructs in vivo.  For 
example, in the case of the reconstruction of the bladder autologous 
engineered bladder tissues have used the host omentum to 
vascularise  the implanted tissues [54].  Here, urothelial and SMC 
from patient biopsies were grown in vitro and cultured onto 
biodegradable bladder-shaped scaffolds made of collagen, or 
composites of collagen and polyglycolic acid.  The omentum was 
used as a wrap in some patients and not in others.  Post-operatively 
patients who had this omental wrap, showed the greatest 
improvement in bladder function as it enhanced angiogenic 
ingrowth of vessels and subsequently supported and maintained the 
transplanted cells.  Overall, it was suggested that this method can 
be used in patients who need cystoplasty but additional studies are 
needed before this procedure can be used widely [54].  In cases 
where wrapping the TE construct is impractical due to anatomical 
location, a two-staged approach has been suggested whereby the 
construct is firstly prevascularised by the intrinsic vasculature 
before implanting into the required area.  In the case of heart tissue, 
Dvir et al. took neonatal cardiac cells and seeded them onto an 
alginate scaffold in combination with angiogenic factors.  It was 
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then vascularised for 7 days on the omentum before transplantation 
onto infarcted rat hearts.  After 28 days the scaffold showed both 
structural and electrical integration [55].  Although promising, this 
technique requires a two-step procedure and may suffer from 
complications.  Alternatives to the omentum have also been studied 
and include the use of arteriovenous loops (AVs).  These connect an 
artery and a vein through the use of either an autologous vein or 
synthetic equivalent and this is placed inside a chamber that houses 
a TE substitute to be vascularised which is subsequently placed into 
a well vascularised site within the recipient.  Tanaka et al. 
successfully used an AV shunt within rats to vascularise a sheet of 
artificial skin dermis (PELNAC) [56].  It is suggested that new 
blood vessels are induced as a result of the increased shear stresses 
within the AV [57].  Although a promising technique, the need for 
several surgeries is a concern when considering its clinical 
application.   
 
1.3.2. Scaffold functionalisation: applying growth factors  
 
As discussed previously, growth factors play a key role in controlling 
angiogenesis and it is a therefore not surprising that a common approach 
to induce vascularisation in almost all TE substitutes is to harness this 
potential in order to recruit host vasculature.  In the case of bladder 
regeneration the use of a ‘smart patch’ that alters a scaffold by 
incorporating growth factors such as VEGF [58], bFGF [59] or 
combinations of growth factors such as PDGF and VEGF [60] has been 
investigated to promote angiogenesis and cell proliferation.  Although all of 
these studies report enhanced vascularisation when implanted into animal 
models, none describe the production of a robust and functional vascular 
supply.  The same growth factors have been applied to scaffolds in an 
attempt to revascularise TE liver scaffolds.  The use of VEGF alone 
showed a short term enhancement of hepatocyte (HC) survival as a result 
of increased vascularisation but this could not be maintained long term 
due to the high instability of the angiogenic growth factor [61].  Promising 
methods to overcome this have used new biomaterial strategies.  One such 
approach uses a polymeric system to localise and control the delivery of 
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VEGF and PDGF from a scaffold [62].  An increase in angiogenic ingrowth 
and formation of mature vessels after implantation has been shown in 
animals but constructs of this type were relatively small and as such 
results may not be reproducible in larger constructs.  Other groups have 
used growth factors to prime the implantation site.  For instance, the pre-
implantation of a bFGF releasing device which is later removed upon 
implantation of a monolayer sheet of hepatic tissue has been shown to 
improve engraftment and function of these cells when compared to HCs 
injected through the portal vein [63].  Although promising the scale up to 
larger functional cell sheets is yet to be shown and so the problem of 
vascularising a large TE liver substitute still remains.  Similar approaches 
of controlled release of growth factors have been studied when trying to 
create TE skin substitutes [64–67] but some argue that the repeated 
administration of such approaches could become a practical issue [68].  As 
a result more sophisticated methods have been investigated, including the 
genetic modification of cells to overexpress important growth factors.  A 
study carried out by Supp et al. describes the use of human keratinocytes 
genetically modified (GM) by transduction with a replication incompetent 
retrovirus to overexpress VEGF [69].  Skin substitutes consisting of a 
collagen-glycosaminoglycan substrate cultured with human fibroblasts and 
the GM keratinocytes were then implanted onto a full thickness wound on 
athymic mice.  Results showed increased numbers of dermal blood vessels 
and decreased time to vascularise when compared with controls [69].  
Whilst this may be an approach to improve vascularisation it is 
challenging to get GM cells approved for clinical use due to the potential 
of random viral integration into the genome, however alternative methods 
are being developed to overexpress genes without the need for random 
integration or integration at all  [68,70].      
 
1.3.3. Harnessing natural vascular architectures   
 
The re-use of biological structures is another approach being used to 
produce TE constructs with intrinsic vasculature.  By decellularising 
mammalian tissues a naturally derived 3D structure containing 
microvascular networks can be obtained.  These matrices can then be 
repopulated with appropriate primary cells to produce perfusable 
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constructs [71].  A benefit of the decellularisation process is the retention 
of natural ECM components, which as described previously, can aid the 
angiogenic process.  Such a technique has been used to produce TE 
bladder constructs [72].  Here, porcine small bowel segments were 
processed to produce acellular matrices which were then repopulated with 
parenchymal cells to restore tissue function and EPCs, due to their ability 
to differentiate into capillary, arterial and venous ECs.  Implantation into 
pigs showed good perfusion with no issue of thrombosis in the short term 
and highlighted the potential of such a method which combines a natural 
vascular architecture with EPCs and perfusion conditions [73].  
Furthermore, this approach has been used to decellularise porcine heart 
tissue with the retention of the natural vascular network and native 
ultrastructural properties.  Recellularisation with human umbilical vein 
endothelial cells (HUVECs) showed the creation of a cell monolayer within 
the vessels with no cell infiltration into the bulk tissue [74].  This initial 
work is promising but it is not yet known whether the vessels can support 
parenchymal cells and whether they form an anti-thrombogenic lining 
when implanted in vivo.  Decellularisation of rat livers to produce 
naturally derived 3D scaffolds with intact vascular trees which were then 
been reseeded with primary rat HCs and ECs via perfusion has also been 
used to produce a TE liver substitute.  Microvascular ECs were used to 
provide vascular function whilst the cells were perfused constantly with 
cell culture media.  Transplantation into rats showed that cell viability 
and function were maintained for 8 hours [75].  Similar work carried out 
by other groups also showed promising results  [76–78].  Overall, such 
methods seem to overcome cell seeding and mass transport issues 
associated with commonly used techniques as the native vasculature 
enables nutrients and cells to be delivered throughout the entire tissue 
construct [77].  However large amounts of cells are required for such a 
method and this may be a limiting factor for its translation.  It is also 
important to note that the majority of positive results obtained to date 
using decellularisation techniques have been related to simple, thin tissues 
such as skin, bladder etc. where it is relatively simple to remove and 
replace cells [79].  More challenging issues arise with increased tissue 
complexity.  For instance when decellularising the heart questions arise 
such as: 
 
Chapter 1: Introduction 
 
19 
 
• What is the most appropriate decellularisation technique to remove 
as many cells as possible from such a thick scaffold without causing 
detrimental effects to the ECM?  
• What are the best type of cells to use when repopulating the 
scaffold? 
• What developmental stage should the cells be at when repopulating 
the scaffold? 
• How do you get the correct cell type back to the correct site within 
the decellularised heart? 
 
All of these questions are yet to be answered and as a result research in 
this area is still active. 
  
1.3.4. Production of a synthetic vascular architecture 
 
Scaffolds should not only promote good cell attachment and allow for the 
storage and release of compounds, but should also be able to promote and 
guide vascularisation.  This has led several groups to look at incorporating 
a vascular network imprint within scaffolds to try and promote 
neovascularisation.  One example is the microelectromechanical systems 
(MEMS) approach whereby polymer moulding using micro-etched silicon is 
used to produce planar 3D channel networks with capillary dimensions 
[80].  These channels act as microfluidic bioreactors and are considered to 
be advantageous primarily because they provide a large surface-area-to-
volume ratio and therefore provide adequate nutrient and oxygen supply 
throughout the construct. These channel networks have been used to 
culture HCs within the channels in vitro [81].  Liver sinusoids have also 
been mimicked using this 3D architecture and fluid perfusion approach, 
with reports stating that cells have maintained elevated liver function in 
vitro [82].  The use of hepatocytes was reported in this study but no 
mention of the use of any type of EC is made for the promotion of 
angiogenesis or even for the eventual prevention of thrombosis.  Research 
is ongoing in this area, specifically in trying to scale the constructs to 
physiologically relevant sizes [80].  An alternative approach to fabricate 
intrinsic vascular channels within scaffolds for myocardial TE has also 
been studied.  Marsano et al. produced an array of cubically packed 
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channels within porous poly(glycerol sebacate) scaffolds, using a laser, that 
were then seeded with rat cardiomyocytes (CMs) and transduced 
myoblasts releasing VEGF.  Ten weeks after implantation into a mouse 
model of myocardial infarction the vascular ingrowth and contractility of 
the patch were greatly improved [83].  Although promising these scaffolds 
were only 1mm thick and the possibility of scale up to physiologically 
relevant sizes remains unknown.  Miller et al. reported the 3D printing of 
filament networks of carbohydrate glass which was used to generate 
cylindrical networks that could be lined with ECs and perfused with blood 
under high pressure [84].  They demonstrated that vascular channels 
sustained the metabolic function of primary hepatocytes in engineered 
tissue constructs in vitro.  This preliminary work seems promising but long 
term studies would be required to determine whether this technique could 
be translated in vivo.             
 
1.3.5. Integrating cellular components   
 
Another way to induce neovascularisation in TE substitutes is to 
incorporate angiogenic cellular components into the matrix material.  
Delivering cells of endothelial origin has been the focus of many studies 
aimed at enhancing neovascularisation since they are directly associated 
with contributing to vessel formation.  Cells ranging from terminally 
differentiated ECs to pluripotent stem cells have been studied to observe 
their vascularisation potential [68].  However, the use of terminally 
differentiated ECs such as human dermal microvascular endothelial cells 
(HDMECs) and HUVECs alone has resulted in poor formation of 
functional vascular development in vivo [85,86] and this has led to the use 
of co-cultures of ECs with different cell types as well as the use of EPCs.  
Lesman et al. carried out a study comparing porous scaffolds seeded with 
only human embryonic stem cell derived cardiomyocytes (hESC-CM) to 
that seeded in combination with HUVECs and mouse embryonic 
fibroblasts.  When implanted into an infarcted heart rat model the tri-
culture scaffold demonstrated increased levels of vascularisation in 
comparison to the scaffold containing only hESC-CMs [87].  Other studies 
have also highlighted the need for ‘helper’ cells which are believed to 
secrete paracrine factors that enhance network morphogenesis [1,88,89].  
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There is evidence that EPCs, which can be derived from bone marrow, fat 
tissue and peripheral blood are potentially useful for tissue engineering 
applications.  The use of EPCs derived from adult blood to vascularise a 
decellularised dermal skin substitute showed inosculation with the 
recipient murine circulation when implanted in vivo [85].  Other studies 
using bone marrow derived mesenchymal stem cells (BMMSCs) seeded in a 
collagen sponge showed increased vascularisation in vivo [90].  There are 
few reports of endothelial differentiation of BMMSCs in vivo [91] and their 
contribution is thought to be related to their trophic effect on host vessels 
[92].  However harvesting bone marrow is painful and not entirely risk free, 
raising questions over the suitability of such a source.  The use of adipose 
derived mesenchymal stem cells (ADMSCs) has also led to increased 
vascularisation in vivo in a murine model [93].  Clinical trials using 
ADMSCs are currently ongoing to demonstrate the safety and feasibility of 
using such cells [94,95].  The use of pluripotent progenitor cells such as 
embryonic stem cells and induced pluripotent stem cells (iPSCs) have also 
been investigated.  In a recent study Takebe et al. reported the generation 
of vascularised and functional human liver from human iPSCs by 
transplantation of liver buds created in vitro.  Briefly, hepatic endoderm 
cells from human iPSCs were combined with HUVECs and MSCs in vitro 
to form liver buds.  These were then transplanted into mice where human 
vasculature in the constructs became connected to the hosts within 48 
hours.  By using a combination of these three cell types the vasculature 
was reported to be similar to that of an adult liver, whereas transplants of 
only HUVECs and human MSCs showed much less dense vascular 
infiltration [96].  This proof of concept demonstration of organ bud 
transplantation appears promising but in order to determine the optimal 
cell type to use in patients further direct comparative and long term 
studies are required.   
 
It is clear that vascularisation plays a vital role in the survival of TE 
constructs.  The most promising ways to circumvent slow revascularisation 
have used scaffolds with vascular architectures, perfusion conditions and 
relevant cell types, whether this be through the use of the omentum, AV 
or a combination of an acellular natural scaffold with EPCs under 
perfusion.  Although it is recognised that perfusion conditions, the cell 
type and scaffold architecture are important with regards to 
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vascularisation strategies many of the techniques fail to consider them in 
combination.  It is important to take a step back and understand how 
these factors work together to promote angiogenesis in order to advance 
this crucial area. 
 
 
 
Figure 5 - The five main strategies used in an attempt to overcome vascularisation issues 
in tissue engineering.  These include: (A) the use of (i) in vitro and (ii) in vivo 
prevascularisation systems; (B) the use of growth factors to stimulate blood vessel 
ingrowth; (C) the use of natural vascular architectures obtained by decellularisation; (D) 
the production of synthetic vascular architectures; and (E) the integration of cellular 
components to enhance vascularisation. 
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Table 2 - Summary of current tissue engineering approaches and methods that attempt to 
overcome neovascularisation problems. 
Tissue Approaches to 
overcome 
neovascularisation 
issues 
Vascular 
cells? 
Perfusion? Vascular 
architecture? 
Current status 
Bladder Prevascularisation 
systems 
   Omentum: Patients [54] 
Scaffold 
functionalisation: 
applying growth 
factors 
   Animals [58–60] 
Harnessing natural 
vascular architectures 
   Animals [72] 
Liver Production of 
synthetic vascular 
architectures 
   Laboratory [81,82] 
Harnessing natural 
vascular architectures 
   Animals [75–78] 
Scaffold 
functionalisation: 
applying growth 
factors 
   Animals [61,62] 
Myocardium Integrating cellular 
components 
   Animals [1,87] 
Prevascularisation 
systems 
   Omentum: Animals [55] 
Vascular bed/bioreactor: 
laboratory [52] 
Production of 
synthetic vascular 
architectures 
   Animals [83] 
Harnessing natural 
vascular architectures 
   Laboratory [74] 
Skin Scaffold 
functionalisation: 
applying growth 
factors 
   Animals [64–69] 
Integrating cellular 
components 
   EPCs: Animals [85] 
BMMSCs: Animals [90]  
ADMSCs: Patients [93] 
Prevascularisation 
systems 
   Animals [56] 
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1.4. Established angiogenesis assays 
 
As mentioned in the previous section blood vessel formation is a complex 
process that is controlled by a large number of inter-related factors and it 
is therefore not surprising that this remains a challenge in the tissue 
engineering field.  To induce vascularisation within TE substitutes these 
same processes will need to occur and therefore an understanding of the 
basic principles and factors affecting angiogenesis is needed.  Since the 
study of angiogenesis has increased rapidly over the last 40 years as a 
result of its connection with a number of pathologies including cancer, 
rheumatoid arthritis and retinopathies to name but a few  [4], assays have 
been developed in an attempt to study the process.  Ideally these would 
enable the assessment of multiple factors, providing reliable and 
reproducible results directly relating to those found in the clinic [97].  
From the observations gleaned from tissue engineering strategies this 
would include the combination of a relevant vascular architecture, ability 
to incorporate the relevant cell combinations along with flow conditions 
and an appropriate ECM component.  However, despite the increase in 
development of angiogenesis assays there is currently no single ‘gold 
standard' assay.  This section aims to provide an overview of the main 
assays that are presently available, with the advantages and disadvantages 
of each summarised in Table 3. 
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1.4.1. In vitro assays 
 
Endothelial cell migration assays 
 
During angiogenesis ECs are stimulated by a gradient of angiogenic factors 
to produce MMPs which subsequently break down the basement 
membrane and allow ECs to migrate into the surrounding matrix. 
 
Transfilter assays are widely used in vitro to quantify EC migration.  
These are 3D assays consisting of a filter containing 8 µm diameter pores 
upon which ECs are seeded and can travel through.  An attractant is 
placed in the lower chamber and EC migration is observed [98].  The filter 
can be coated with ECM proteins or more complex materials such as 
Matrigel in order to more closely mimic the in vivo microenvironment [99].  
The advantages of this assay are that it is highly sensitive to changes in 
concentration of attractant, is readily reproducible and takes a relatively 
short amount of time to observe quantifiable effects [97,100].  However it 
has been noted to be difficult to set up, to maintain gradients for long 
time periods (as this reaches equilibrium throughout the chamber over 
time) and the user is unable to observe cell movement during the 
experiment [97,101,102].   
 
Other migration assays, known as scratch assays, have been developed and 
use scraping tools to remove an area of confluent ECs from a surface 
before allowing peripheral ECs to migrate and refill the naked area [103].  
The migratory response of the ECs can then be monitored using 
microscopy at different time points to determine the rate and extent of 
migration [104].  However it has been noted that identical confluence of 
ECs between experiments can be difficult to replicate and results may vary 
depending on the size of the denuded area [105,106].  In an attempt to 
overcome this issue the addition of a teflon ‘fence' can be introduced 
whereby, upon removal, ECs grow into the area covered by the fence [106].  
However, this design feature in itself introduces added complexity in the 
setup of this assay whilst discrimination between net migration and 
proliferation can be difficult after 24 hours [97] but nevertheless can be 
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overcome in part with the use of mitomycin C which inhibits cellular 
proliferation [107]. 
For the direct measurement of cell motility which in turn can be an 
indication of angiogenesis, phagokinetic track methods are often used.  
These involve depositing a monolayer of polystyrene beads onto the base 
of a 96-well plate prior to seeding with ECs.  The cells then generate 
tracks that can be measured for directional properties and total distance 
traversed [108].  This method allows for the accurate measurement of cell 
motility [109].  However, the analysis of such an assay can be time 
consuming to process, requiring complex software to track cell paths.  In 
addition, only small numbers of cells can be tracked and there is debate 
over the use of an unnatural substrate to measure realistic cell motility 
[110].                          
      
The type of EC migration assay utilised depends upon the situation being 
investigated.  Whilst the transfilter assays can quantify directional 
migration in response to a chemical stimuli (chemotaxis) and random 
motility (chemokinesis), the relatively simple scratch assay may be useful 
in measuring the response to wound healing since the cells at the border of 
the denuded area are likely to be damaged in the process.  Alternatively 
for direct measurement of cell motility and directional effects on cell 
motion the phagokinetic track method may be the most appropriate [97].   
 
Endothelial cell differentiation assays 
 
Cell differentiation assays aim to simulate the formation of capillary like 
tubes which are representative of the later stages of angiogenesis.  These 
are widely used to assay the pro- and anti-angiogenic effects of various test 
substances.  Basic 2D assays plate ECs onto or into a layer of gel matrix 
(i.e. collagen, fibrin or Matrigel) which stimulates attachment, migration 
and differentiation of ECs) into tubules.  This process can be observed and 
monitored over a period of 4-24 hours via the use of a digital camera [109].   
 
The type of matrix has proven to be important since different matrices can 
result in different rates of differentiation.  For instance the use of collagen 
I and III (interstitial collagens) results in predominantly more cell 
proliferation than tubule formation whereas seeding cells onto a collagen 
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IV and V matrices (basement membrane collagens) results in more 
prevalent tubule formation with a reduced amount of cellular proliferation 
[111].  Matrigel, a complex gelatinous protein mixture derived from mouse 
sarcoma cells, has been found to be the most powerful matrix for tubule 
formation [112].  However there have been disputes over whether the 
tubules formed represent true capillaries due to their lack of lumen.  In 
addition, human fibroblasts have also been shown to form tubules when 
seeded onto Matrigel [113–115].  As a result interpretation of the results 
obtained from using such a method should be made with caution.   
 
Another tube formation assay involves the co-culture of ECs with stromal 
cells, either with or without the use of an ECM.  The stromal cells can be 
fibroblasts, SMCs, or blood vessel explants containing an array of different 
cell types.  Studies looking at the use of fibroblasts as the stromal cell type 
have found that these cells secrete matrix components that go on to act as 
the scaffold upon which ECs form tubules.  These tubules were found to 
more closely resemble those found in vivo.  However this assay is time 
consuming lasting between 12-14 days  and also the matrix components 
secreted by the fibroblasts are not well defined and so this assay is less 
well characterised [97,113].   
 
In addition 3D assays have been developed whereby ECs are sandwiched 
between layers of matrix (Matrigel, collagen or fibrin).  In the initial 7 
days post seeding tubule formation has been observed in the horizontal 
plane, but by day 15 tubules have been found to branch upwards 
penetrating the matrix and forming a 3D network.  However assays such 
as this are difficult to analyse and the matrix must be relatively thin to 
allow for sufficient oxygen and nutrient diffusion to prevent excessive cell 
death [116].   
 
Overall, there are a range of EC differentiation assays to choose from 
depending upon the type of angiogenesis being studied.  Whilst 3D assays 
may be more representative of the in vivo environment there are technical 
challenges associated with their setup and analysis and so in reality many 
groups tend to use 2D assays [97].  Note that most of these measure either 
growth or migration.  They do not measure vascularisation although it is 
one attribute that could be linked to the cell behaviour.        
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Combinatorial cell assays 
 
Once tubules form, mural cells are recruited in order to maintain stability 
of the vessel.  As a result assays have been developed to investigate the 
interaction between ECs and mural cells.  The simplest co-cultures involve 
either seeding both cell types at the same time or initially allowing one cell 
type to adhere followed by subsequent seeding of the other cell type.  
Assays of this type have been used to analyse the effects of ECs on 
mesenchymal cell differentiation and are both useful in obtaining 
information and easy to set up and analyse [117].  However, with assays of 
this nature it is not possible to assess the cell-cell interactions mediated by 
paracrine factors released by one cell type since all cells are evenly 
dispersed [97].   
 
Alternatively, non-contact assays have been developed.  One such method 
involves setting agarose in a well and punching two holes out of it before 
seeding the two cell types into each hole.  The cells attach to the bottom 
of the well and over time the two cell types move towards one another 
under the agarose gel.  Measurement of the soluble diffusible signals can be 
made and if cells are left for between 5-7 days the cell types can come into 
contact and it is possible to monitor the effects of cell-cell interactions on 
the cell phenotype [117].        
 
As with tubule formation assays, 3D EC/mural cell co-culture assays have 
been developed.  One such assay used initially was the spheroid method 
whereby ECs and mural cells are seeded together into non-adherent wells 
and after ~1-4 days they will form spheroids.  However, upon formation 
the mural cells are in the middle whilst the ECs do not form tubules [118].  
An alternative method is similar to that of the 3D tubule formation assay 
where ECs and mural cells are sandwiched between layers of Matrigel and 
subsequently invade the matrix forming tubules resembling those found in 
vivo where the mural cells form a supporting layer [119].  Again, there are 
technical challenges involved in setting up such an assay and unlike the in 
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vivo situation there is no introduction of flow conditions which can alter 
cell phenotype [120]. 
 
Overall, direct cell contact assays can be useful in determining information 
regarding the direct effects of one cell type on another whilst non-contact 
assays can be useful in measuring the diffusible substances released by the 
different cell populations.  Undoubtedly the 3D assay is most 
representative of the in vivo conditions however it can be difficult to both 
set up and analyse fully [97].         
 
1.4.2. Ex vivo assays 
 
Angiogenesis occurring in vivo involves a network of ECs and their 
surrounding cells in constant communication with the surrounding 
environment.  This has led to the development of organ culture methods.  
In essence segments, discs or sections of specific tissue types are cultured 
in a 3D matrix in vitro and microvascular outgrowth is measured over a 
period of around 14 days.  The aortic ring assay is a common method 
whereby a rat aorta is segmented into multiple rings which is then 
embedded in either a matrix of fibrin or collagen and analysed for vessel 
outgrowth.  It has the advantage of including the effects of non-ECs (such 
as SMCs and pericytes) and a supporting matrix.  However, the results are 
often hard to quantify and the model is not seen as wholly representative 
of the microvascular environment due to the use of a large vessel from 
which to observe microvascular outgrowth [121].   
 
A modification of the rat aortic ring assay uses the chick aortic arch [122].  
The ECs found here share characteristics of microvascular cells and this 
assay has the advantage of being rapid and relatively inexpensive.  
However since the explants are taken from growing embryos the ECs are 
proliferative and so are not truly representative of the non-proliferating 
cells that are stimulated to undergo angiogenic sprouting in vivo [97].   
 
The main issue with assays of this type, other than the difficulty involved 
in analysing the results, is that the explants are taken from non-human 
tissue and results obtained may well be species specific.               
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1.4.3. In vivo assays 
 
Chorioallantoic membrane (CAM) assay 
 
The CAM assay is a well-established method that has been in use since the 
1970's.  Test substances or materials are implanted onto the chick 
membrane via a hole that is cut into the egg shell before covering the 
opening and incubating.  The angiogenic response to the substance can 
then be quantified via image analysis techniques [109].  Overall the CAM 
assay is inexpensive and therefore provides the opportunity for relatively 
large scale screening of test substances.  The ease of accessibility of the 
CAM also allows for repeated application of test substances which can be 
applied either directly or via intravenous or intra-allantoic injections.  
However, care must be taken when interpreting the results obtained from 
the CAM since chemical or physical irritation of the membrane can induce 
angiogenesis, disrupting identification of the response from the test 
substance [97,123].  The CAM is also well vascularised and so 
distinguishing between newly formed and existing capillaries can be 
difficult.  In addition, angiogenesis occurs in the CAM up until day 11 post 
fertilisation, and so results obtained from younger embryos have the added 
complication of having unspecified interactions with endogenous factors 
affecting angiogenesis [97].            
 
Corneal angiogenesis assay 
 
The only avascular and transparent tissue in the body is the cornea.  This 
means that any vessels that penetrate into the corneal stroma from the 
limbus are newly formed, which is why there has been development into 
using the cornea as a tool to observe angiogenesis [97,124].  Since almost 
all types of corneal injury can induce neovascularisation, many techniques 
have included either chemical cauterisation, mechanical scraping of the 
limbal epithelium or the implantation of slow release pellets from 
micropockets in the development of such assays [97].  The visualisation of 
vessels is usually achieved by the perfusion of the cornea using a 
fluorescent dye which are then removed from the host and flattened onto 
slides in order to image [125].  Although many of these methods are 
reliable and readily quantifiable, assays of this type are expensive and hard 
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to set up as the size of the eye decreases.  In addition, different angiogenic 
responses have been found depending on the type of injury the cornea is 
subjected to and there is also dispute surrounding the relevance of using a 
naturally avascular tissue to investigate angiogenesis [97,126].                 
 
Zebrafish assay 
 
Zebrafish are tropical freshwater fish that can produce hundreds of 
embryos each time they mate.  Since the embryos can be produced in large 
numbers, are optically transparent, share many genes and mechanisms as 
mammals and their development is very rapid, they make good organisms 
in which to observe the development and function of the vasculature [127].  
To visualise the vessels several techniques are used, for instance injecting 
the embryo with dyes, alkaline phosphatase staining of the ECs and the 
use of confocal microangiography [128–130].  Recently transgenic zebrafish 
with green fluorescent protein (GFP) expressed under the control of 
promoters specific for the developing vasculature have been produced 
including Fli-eGFP [131], mTie-GFP [132] and Flk-GFP [133].  Such 
fluorescent zebrafish have the advantage of enabling high optical resolution 
imaging of the developing vasculature that can be clearly observed over 
time.  This assay has the benefits of being inexpensive and easy to 
maintain.  It is also possible to knockdown specific genes, enabling a quick 
evaluation of gene function in relation to angiogenesis [97,134].  Large 
screen studies can also be undertaken due to the large amounts of embryos 
produced whilst the experiments are relatively short meaning that only 
small amounts of a test substance are needed.  However, as with all of 
these assay there are drawbacks.  The main issue surrounding the use of 
this assay is the relevance of using fish ECs to study the response of 
human tumour xenografts [97].          
          
Chamber assay 
 
Implantation of a transparent chamber in vivo enables the visualisation of 
new blood vessel formation over time [135].  A common example of this 
uses the dorsal skinfold as the chamber implantation site in mice, rats and 
hamsters [136–138].  This method uses two symmetrical frames which are 
implanted into the dorsal skinfold to sandwich an extended double layer of 
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skin.  One layer of skin is then removed to expose the other, which is 
protected by covering with a glass cover slip incorporated into one of the 
frames [139].  It is possible to remove the cover slip for the implantation of 
tumour cells or transplants in order to observe neovascularisation [140].  
The advantages of this assay are that it allows for the determination of 3D 
vessel growth in one animal usually whilst it is conscious over a period of 
1-4 weeks [97].  This means that there is no need for multiple mice for 
each time point, therefore minimising the number of animals required 
[139].  It can also be used to simultaneously study cellular, molecular and 
functional parameters at each time point.  However, the setup of this assay 
is technically demanding and quantification of functional parameters is 
often time consuming, requiring the use of sophisticated image analysis 
systems [97].               
 
Implantation of scaffolds and gels 
 
A range of materials have been implanted into animals (mainly mice) to 
alter the environment in which angiogenesis occurs.  These materials have 
included the use of stainless steel mesh chambers, hollow porous walled 
chambers, synthetic matrices and Matrigel plugs [97,141–143].   
 
As mentioned previously, Matrigel is a complex protein mixture derived 
from mouse sarcoma cells that is a liquid at 4 °C but forms a solid gel at 
37 °C.  Test substances to be investigated can be encapsulated in Matrigel 
and subsequently injected subcutaneously into the animal to form a plug 
which slowly releases the test substance [144].  The angiogenic response 
can then be measured by retrieving and sectioning the gel and looking for 
CD31 positive vessel ingrowth or by measuring the haemoglobin content.  
However, sectioning and immunostaining of gels can be both time 
consuming and costly processes whilst haemorrhaging can lead to spurious 
haemoglobin measurements.  In addition, Matrigel is costly and includes 
the presence of growth factors and cytokines which can have an effect on 
the angiogenic response and thus the results obtained must be interpreted 
with caution [97].  
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An alternative to using Matrigel is to load the test substance onto a 
sponge implant or polymer matrix and then implant this into the animal.  
Sponge implants have been used to observe the formation of fibrovascular 
tissue, neovascularisation, wound healing and cellular proliferation 
[145,146].  However, caution must be taken when drawing conclusions from 
such results since implants become encapsulated upon implantation and 
elicit an immune response which can lead to an angiogenic response in its 
own right thus interfering with the angiogenic response of the test 
substance [97].                
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 Assay Type Advantages Disadvantages 
In
 v
it
ro
 
Cell migration 
Transfilter 
assay 
• High sensitivity to gradient changes 
• Can distinguish between random and 
directional migration 
• High reproducibility 
• Short duration (4-6hrs) 
• Difficult to set up 
• Maintaining transfilter gradients for long periods of 
time is difficult 
• Can’t observe cell motion during experiment 
• Cells migrate through unnatural filter material 
• No flow conditions 
• No ECM component 
Scraping 
assay 
• Good for wound healing studies 
• Can estimate rate of migration 
• Results may vary depending on size of wound 
• Obtaining identical confluence between experiments 
difficult 
• Exact denudation difficult 
• No flow conditions 
• No ECM component 
Phagokinet
ic track 
method 
• Can measure directional effects 
• Accurate measurement of cell 
motility 
• Cells migrating on unnatural substance 
• Only small number of cells can be tracked 
• Time consuming/complex analysis 
• No flow conditions 
• No ECM component 
Cell 
differentiation 
Tube 
formation 
(2D) 
• Short duration (4-24hrs) 
• Relatively simple to analyse 
• Lumen may not be formed 
• Fibroblasts can also form tubes on Matrigel – 
interpret with caution 
• No flow conditions 
Tube 
formation 
(3D) 
• More representative of in vivo 
environment 
• Difficult to analyse 
• Lengthy duration (~15days) 
• Matrices have to be thin to allow for adequate 
diffusion of nutrients/oxygen 
• No flow conditions 
Combinatorial 
cell assay 
Direct 
contact 
(2D) 
• Easy to set up and analyse • Not possible to assess cell-cell interactions mediated 
by factors released by each cell type 
• No flow conditions 
Non-
contact 
(2D) 
• Measurement of soluble factors can 
be made 
• Possible to monitor effects of cell-cell 
interactions on phenotype 
• Time consuming 
• No flow conditions 
• No ECM component 
Spheroid 
method 
(3D) 
• Simple to set up • Mural cells form in centre of spheroid and ECs do not 
form tubules 
• No flow conditions 
• No ECM components 
Matrigel 
(3D) 
• More representative of in vivo 
environment 
• Technically challenging 
• No flow conditions  
E
x 
vi
vo
 Rat aortic ring  - 
• Representative of general in vivo 
environment (inclusion of mural cells 
& ECM) 
• Results hard to quantify 
• Not truly representative of specific microenvironment 
since large vessel used to observe  
• No flow conditions 
Chick aortic 
arch 
 
- 
• ECs similar to microvascular cells 
• Rapid 
• Inexpensive 
• From growing embryos therefore proliferative – not 
representative of non-proliferative ECs found in vivo 
• No flow conditions 
In
 v
iv
o 
CAM - 
• Inexpensive 
• Ease of accessibility allows for 
repeated administration of test 
substances 
• Difficult to distinguish between existing and new 
capillaries 
• Difficult to quantify 
• Chemical/physical irritation of membrane can induce 
angiogenesis 
Corneal 
angiogenesis 
assay 
- 
• Reliable 
• Readily quantifiable 
• Expensive 
• Difficult to set up as eye decreases in size 
• Dispute over relevance of avascular tissue for 
angiogenesis studies 
Zebrafish assay - 
• Inexpensive 
• Easy to maintain 
• Large scale screening studies possible 
• Quick 
• Gene knockdown studies possible 
• Dispute over relevance of fish EC angiogenesis in 
human tumour xenografts 
Implantation of 
sponges and 
polymers  
Matrigel 
plug 
• Not technically difficult 
• Quantification by amount of 
haemoglobin in plug 
• Time consuming analysis 
• Costly analysis 
 
Sponge 
implants 
• Can be used to observe wound 
healing, cellular proliferation, 
fibrovascular tissue formation and 
neovascularisation 
• Implant can become encapsulated inducing angiogenic 
response independently of test substance 
Table 3 - Summary of current angiogenesis assays. 
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Although the development of angiogenesis assays has rapidly advanced 
over recent years, there is currently no ‘gold standard' assay.  Current in 
vitro models concentrate on EC migration, proliferation and differentiation 
in 2D with limited use of additional cell types.  There are no standard 
assays that combine the use of supporting cells (e.g. fibroblasts, SMC, 
pericytes etc.), the ECM and/or basement membrane and fluid flow in 3D 
[97].  Although this complexity exists within in vivo models such assays 
are primarily limited by the species used (e.g. rat, chick etc.), organ sites 
available and complicated analysis techniques (Figure 6).   
 
There is clearly a need for an in vitro model that has the capability of 
combining pro-angiogenic cells with an ECM component that can be 
monitored under flow conditions to learn more about the ‘rules’ of 
angiogenesis.     
 
 
Figure 6 - Deficiencies in current angiogenesis assays 
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1.5. Natural vascular networks and their application as 
angiogenesis models 
 
Several native tissues including; skin, bladder, small intestine, pericardium 
and heart valves have been used in the production of decellularised tissues 
and have been found to promote cell adhesion and migration as well as 
exhibiting low immunogenicity [79,147–149].  These characteristics have 
led to the clinical translation of such tissues with many being available 
commercially (as summarised in Table 4).   
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Table 4 - Examples of clinical products derived from decellularised tissues. Table 
reproduced from Crapo et al. [79]. 
 
Product (Manufacturer) Tissue Source Application Focus 
Alloderm (Lifecell Corp.) Human dermis Soft tissue 
AlloPatch HD, FlexHD 
(Musculoskeletal Transplant 
Foundation) 
Human dermis Tendon, breast 
Neoform (Mentor Worldwide LLC) Human dermis Breast 
GraftKacket (Wright Medical 
Technology Inc.) 
Human dermis Soft tissue, chronic 
wounds 
Strattice (Lifecell Corp.) Porcine dermis Soft tissue 
Zimmer Collagen Repair Patch 
(Zimmer Inc.) 
Porcine dermis Soft tissue 
TissueMend (Stryker Corp.) Bovine dermis Soft tissue 
MatriStem, Acell Vet (Acell Inc.) Porcine urinary 
bladder 
Soft tissue 
Oasis, Surgisis (Cook Biotech Inc.) Porcine small intestine Soft tissue 
Restore (DePuy Orthopaedics) Porcine small intestine Soft tissue 
FortaFlex (Organogenesis Inc.) Porcine small intestine Soft tissue 
CorMatrix ECM (CorMatrix 
Cardiovascular Inc.) 
Porcine small intestine Pericardium, cardiac 
tissue 
Meso BioMatrix (Kensey Nash 
Corp.) 
Porcine mesothelium Soft tissue 
IOPatch (IOP Inc.) Human pericardium Opthalmology 
OrthAdapt, Unite (Synovis 
Orthopaedic and Woundcare Inc.) 
Equine pericardium Soft tissue, chronic 
counds 
CopiOs (Zimmer Inc.) Bovine pericardium Dentistry 
Lyoplant (B. Braun Melsungen AG) Bovine pericardium Dura mater 
Perimount (Edwards Lifesciences 
LLC) 
Bovine pericardium Valve replacement 
Hancock II, Mosaic, Freestyle 
(Medtronic Inc.) 
Porcine heart valve Valve replacement 
Prima Plus (Edwards Lifesciences 
LLC) 
Porcine heart valve Valve replacement 
Epic, SJM Biocor (St. Jude Medical 
Inc.) 
Porcine heart valve Valve replacement 
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Small intestinal submucosa (SIS) is one of the most established and 
broadly used products available on the market [150].  It was first used over 
40 years ago as a vascular substitute.  It has developed over the years and 
nowadays is produced from decellularised small intestine segments applied 
as a sheet of roughly 100 µm thickness [150].  Beyond its use in 
reconstructive surgery in the form of SIS the decellularised small intestine 
has the potential to be used as a test system for both basic and applied 
research.  In 2004 Schultheiss et al. [151] removed part of the small 
intestine whilst retaining the venous and arterial supplies allowing for the 
perfusion of the vascular bed.  They then went on to decellularise the 
tissue producing a perfusable vascular bed that can be recellularised with 
appropriate cell types for a range of applications.  This biological 
vascularised matrix, termed BioVaM, is still quite a new concept and 
therefore there are much fewer studies when compared to the work carried 
out for the SIS matrix.  However studies that have been carried out have 
mainly looked into the following: 
 
1. Re-endothelialising the vascular bed of the BioVaM 
2. Using the BioVaM as a tissue model 
3. Using the BioVaM to vascularise TE constructs in vitro 
 
Initial work on the BioVaM seemed to concentrate on producing an 
endothelial cell lined vascular network.  Different approaches were 
investigated with the first study introducing EPCs derived from peripheral 
blood into the vascular network [151].  This work seemed promising and a 
more detailed follow up study combined this network with SMCs and 
urothelial cells which were seeded into the intestinal lumen to model the 
bladder before implanting into a porcine model.  No thrombosis was 
observed after 3 hours in comparison to that observed when no EC lining 
was present [72].  Another study by the same group looked at using human 
bone marrow derived MSCs, cutaneous microvascular ECs (mECs) and 
peripheral blood mononuclear cells (PBMCs) to repopulate the vascular 
network.  These were shown to differentiate into endothelial like cells.  A 
BioVaM scaffold with autologous PBMCs recellularised into the vascular 
networks and autologous SMCs and fibroblasts on the surface of the 
scaffold was then implanted into the upper arm of one patient for one 
week, forming anastomoses with the host vasculature.  Upon explantation 
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occlusion was found in some microvessels but the main vessels showed 
little evidence of thrombosis [152].  Other studies carried have combined 
the BioVaM with porcine hepatic microvascular ECs and HCs to model 
the liver.  The contruct is shown to be viable for 3 weeks and HCs 
maintained their morphology whilst showing stable metabolic activity.  In 
contrast, HCs in monolayer showed morphological dedifferentiation and an 
unfavourable metabolic state [153].  The use of human mECs and HCs 
have also been used to produce a liver like tissue [154].  Modelling the 
intestine to observe cellular interactions and potential therapies has also 
been investigated.  Human mECs seeded into the vascular bed and the cell 
line Caco-2 (derived from human coxlorectal adenocarcinoma) seeded into 
the lumen has been used to establish such a model [154].  Recently the 
development of an intestinal model based on a rat decellularised small 
intestine segment was reported [155].  The aim of this work was to produce 
an acellular intestinal matrix and only preliminary work regarding 
recellularisation was reported.  This study showed that the ECM was 
preserved without disruption to the mechanical and structural properties 
that it endows.  Amniotic fluid stem cells were repopulated into the lumen 
of the intestine and were shown to be viable.  No re-endothelialisation of 
the vascular bed was undertaken.  Another group has used the porcine 
BioVaM as an in vitro cancer model [156].  It is firstly decellularised and 
then the arterial and vascular pedicles are removed and the tubular SIS 
mucosa is seeded with primary fibroblasts, mECs and cells from the S462 
tumour cell line.  These recellularised flat sheets are then placed between 
metal rings and are cultured either statically or dynamically.  This study 
states that the method is very promising to generate vascularised tumour 
tissues which will allow for the study of angiogenesis and other 
mechanisms relevant to tumour progression however surprisingly does not 
use the vasculature of the scaffold to form re-endothelialised vessels.  
Instead it seeds the mECs onto one side of the tubular SIS mucosa and the 
tumour cells onto the other.  It could be argued that a more accurate 
model would indeed take advantage of this perfusable vascular bed to 
observe vascular sprouting into a tumour placed on top of the matrix.  
This is an approach that was harnessed in later studies in a bid to 
vascularise cardiac TE constructs in vitro.  Nikolic et al. decellularised a 
porcine jejunum to produce the BioVaM before recellularising with a GFP 
and red fluorescent protein (RFP) labelled rat heart EC line (RHE-A) into 
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the venous and arterial pedicles, respectively [157].  A gel based cardiac 
construct (CC) prepared from rat tail type I collagen containing rat 
neonatal cardiomyocytes and ECs was then placed on top of the BioVaM.  
After 10 days under static culture results showed that the GFP and RFP 
labelled RHE-A cells had formed a dense network and were found in close 
proximity to the rat ECs seeded within the CC suggesting a connection 
between the two [157].  This proof of principle study aimed to 
prevascularise the construct in order to supply oxygen and nutrients whilst 
removing waste products from the 3D scaffold with a view to eventually 
translate such scaffolds to the clinic.  This study and all previous work 
leading up to it (i.e. the decellularisation, recellularisation and different 
forms of analyses) has real potential to be used as a test system to 
investigate angiogenesis in more detail.  Overall these approaches have 
utilised a scaffold that overcomes the main deficiencies of current 
angiogenesis models by: 
 
1. Retaining native ECM components 
2. Preserving a vascular architecture and the capacity to be perfused 
3. Having the ability to be recellularised with a range of cell types 
     
Table 5 to Table 7 summarise the studies mentioned above, providing 
more detail about the decellularisation, recellularisation and culture 
conditions.  It can be seen that the majority of studies have used porcine 
jejunal segments with one study using rat.  This has resulted in the need 
to repopulate the decellularised segments with a large number of 
endothelial and parenchymal (where used) cells.  For translational use in 
the clinic this may be necessary but for use as a model the rat jejunum 
may be preferable.  The decellularisation detergent used has been 
predominantly sodium deoxycholate, occasionally combined with sodium 
azide (for use as a lysis buffer) or sodium dodecyl sulphate (SDS).  
Detergents commonly used for decellularisation are either ionic or non-
ionic.  It has been found that in general ionic detergents (such as SDS, 
sodium deoxycholate etc.) are more effective in removing cell nuclei from 
dense tissues but have been found to disrupt the ultrastructure of the 
tissue whilst removing growth factors from the ECM [158–160].  In 
addition it has been shown that it is extremely important that tissues are 
washed thoroughly after decellularisation using ionic detergents, especially 
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SDS.  Reports have indicated that even at low concentrations residual 
detergent has been found to have cytotoxic effects when it comes to 
repopulating the cell free scaffolds [79,161,162].  Conversely, non-ionic 
detergents (such as Triton-X 100) tend to have the opposite effects.  They 
have been found to be less efficient at removing cell nuclei from dense, 
thick tissues but do tend to have less impact on the ultrastructure and 
growth factors contained within the tissues [79,163].  A recent paper that 
looked at detergents used for decellularisation of porcine jejunum for 
production of a BioVaM showed that the ionic detergent, SDS, bound to 
the matrix and even after repeated washing it remained present.  This 
then had a subsequent detrimental effect on the survival rate of porcine 
primary ECs used to repopulate the BioVaM.  In contrast when the milder 
non-ionic detergent, Triton-X 100 was used the same decellularisation 
efficacy was achieved but this time the long term survival and proliferation 
of the ECs was shown [164].  The method of decellularisation in the 
studies used either agitation or perfusion through the vascular bed to 
remove the cells from the tissue, with later studies preferring to use the 
latter method.  The rate at which the vasculature was perfused with 
detergent seemed to be arbitrary with no justifications given in the 
literature.  It varied from between 1.2-2.3 ml/min for porcine tissue and 
the sole study using rat tissue used a rate of 0.01 ml/min.  
Recellularisation of the vasculature used predominantly microvascular ECs 
with the occasional use of EPCs and cell lines whilst the lumen was 
recellularised with parenchymal cells determined by the tissue being 
mimicked.  Culture conditions used in the studies varied.  Some studies 
cultured the constructs under static conditions whilst others perfused the 
vasculature and lumen of the tissue simultaneously.  Culture time ranged 
from 3 hours when implanted into a porcine model to 21 days when 
cultured in vitro and depended very much on the study.   
 
Overall, the concept of using a decellularised vascular matrix derived from 
jejunal segments is relatively new and as a result the methodologies have 
yet to be standardised.  Important questions relating to what 
decellularisation technique to use, what cells to use for recellularisation 
and how to return these cells to the appropriate locations within the 
decellularised tissue are still largely unanswered.  Some view these broad 
issues as the main drawbacks of using such techniques to regenerate tissues 
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in general.  However, initial results from the aforementioned studies 
indicate that the vascular matrix has real potential to be used as a test 
system to investigate a number areas, including angiogenesis.                   
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Table 5 – Summary of studies re-endothelialising the vascular bed of the BioVam. 
 
Table 6 – Summary of studies using the BioVam to vascularise TE constructs in vitro. 
 
 
 
 
Study BioVaM 
Species 
Decellularisation Sterilisation Recellularisation Culture Key Findings 
Detergent Method Vasculature Lumen 
Re-endothelialising 
vascular bed 
Porcine Sodium azide/sodium 
deoxycholate 
Agitation ? 2.5×107 porcine 
peripheral blood 
EPCs 
- Static and in 
vivo (porcine 
model) 
No thrombosis found after 
3hrs in vivo [151]. 
Porcine Sodium deoxycholate Perfusion 
2.3ml/min 
γ 
irradiation 
25kGy 
10.5×106 BM-
MSCs or 4.5×106 
mECs or 15×106 
PBMCs (for HT) 
(all human)  
4×105 
fibroblasts 
(for HT) 
1.26ml/min for 
14 days in vitro 
or 
1 week in vivo 
in human 
Vascular endothelium 
formed in vitro.  Clinical 
transplantation showed 
vessel patency & viability 
after 1 week [152]. 
Study Tissue BioVaM 
Species 
Decellularisation Sterilisation Recellularisation Culture Key Findings 
Detergent Method Vasculature Lumen 
In vitro 
vascularisation 
Cardiac 
patch 
Porcine Sodium 
deoxycholate/
SDS 
Agitation γ 
irradiation 
150Gy 
6×106 GFP RHE-A cells 
venous supply; 6×106 
RFP RHE-A cells 
arterial supply. 
Rat CMs inside lumen; 
CC containing 
4×106 rat neonatal 
heart cells seeded on 
top of lumen 
 
Static  
in vitro 
GFP & RFP 
labelled RHE-A 
cells found to 
have migrated to 
CC and connect 
with rat ECs 
[157]. 
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Table 7 – Summary of studies using the BioVam as a tissue model. 
Study Tissue BioVaM 
Species 
Decellularisation Sterilisati
on 
Recelllularisation Culture Key Findings 
Detergent Method Vasculature Lumen 
Tissue 
Models 
Intestine Porcine Sodium 
deoxycholate 
Perfusion 
2.3ml/min 
γ 
irradiation 
25kGy 
4.5×106 
human 
mECs 
Caco-2 cell line 1.26ml/min 
(vasculature) 
3.8ml/min (lumen); 
14 days in vitro 
Cell adhesion & 3D growth 
enhanced.  HCs express 
important functional proteins 
compared to static culture in 2D 
[154].  
 Rat Sodium 
deoxycholate 
Perfusion 
0.01ml/min 
 - 1×106 AFSCs Static 24hrs in vitro Acelleular ECM with intact 
vascular net formed [155]. 
Liver Porcine Sodium 
deoxycholate 
Perfusion 
1.2ml/min 
γ 
irradiation 
25kGy 
8-15×106 
porcine mEC
s  
Porcine HCs (1 week after 
vascular seeding) 
0.8ml/min for 4 
weeks in vitro 
HCs maintained morphology & 
metabolic activity in BioVaM.  
HCs in monolayer showed 
dedifferentiation/unfavourable 
metabolic state [153]. 
 Porcine Sodium 
deoxycholate 
Perfusion 
2.3ml/min 
γ 
irradiation 
25kGy 
4.5×106 
human 
mECs 
Human HCs 1.26ml/min for 14 
days in vitro 
Cell adhesion & 3D growth 
enhanced.  HCs express 
important functional proteins 
compared to static culture in 2D 
[154]. 
Bladder Porcine Sodium 
azide/sodium 
deoxycholate 
Agitation ? 2.5×107 
porcine 
peripheral 
blood EPCs 
Porcine SMCs & UCs Static 21 days; 3h in 
vivo porcine model 
Re-endothelialisation of vessels 
after 21 days and no thrombosis 
after 3hr in vivo [72]. 
Tumour Porcine Sodium 
deoxycholate 
Perfusion 
80-
100mmHg 
γ 
irradiation 
25kGy 
- Lumen cut open 
8000cells/cm3 (mECs) 
seeded on one side; 
8000cells/cm3 HDFs & 
15000cells/cm3 S462 
tumour cells on other   
Static 14 days 
Dynamic 14 days 
3.8ml/min (shear 
flow) in vitro 
SIS like model leads to tumour 
like tissue formation of cells 
[156]. 
 
 
 
Chapter 1: Introduction 
 
45 
 
1.6. Synthetic vascular networks and their application as 
angiogenesis models 
 
Approaches taken to model angiogenesis in vitro have mainly used natural 
materials, such as collagen I, in various configurations.  Natural scaffolds 
have the advantage of containing intrinsic factors that allow for good cell 
attachment and survival rates as well as having the ability to stimulate 
cells to exhibit EC capillary morphogenesis and sprouting.  However there 
is limited control over the degradation rates of such materials as well as 
their mechanical properties and batch-to-batch variability which could 
lead to irreproducible results [165].  Although the number of studies using 
synthetic materials to investigate angiogenesis is very limited, there has 
been increased interest into the use of synthetic materials.  The benefits of 
using such materials include the ability to regulate the mechanical 
properties of the scaffold, the ease of chemical modification and the control 
of biochemical properties [166].  
 
Chwalek et al. have recently reported the development of a 3D model for 
tumour angiogenesis from semi-synthetic hydrogels [167].  More 
specifically, hydrogels were prepared by cross linking star shaped 
poly(ethylene glycol) (PEG) and glycosaminoglycan heparin.  This not 
only enabled cells to be embedded in 3D but it also provided the capability 
of binding multiple growth factors to the material, mimicking the ECM.  
By varying the ratio of PEG to heparin the mechanical properties of the 
material could be varied and enabling the identification of optimal matrix 
conditions to support vascular network formation.  These matrix 
conditions were then used to determine the 3D interactions between ECs 
and mural cells.  Network formation was observed and stable capillaries 
were maintained for up to 1 month in vitro.  Although this model shows 
extremely promising results and offers a novel platform to test angiogenic 
factors it does not incorporate the ability to be perfused and thus observe 
the effects of fluid flow on vascular net formation. 
 
Jeffries et al. later reported preliminary results using an alternative 
method to develop vascular networks by micropatterning electrospun 
scaffolds [168].  The ultimate goal of this work was to produce a re-
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endothelialised TE vascular network that was capable of direct 
anastomosis to the host vasculature which could be perfused immediately.  
This approach used a combination of fused deposition modelling and 
electrospinning to create the networks.  Fused deposition modelling is a 
rapid prototyping technique that deposits layers of thermoplastic material 
into a desired 3D geometry by extruding it through a heated nozzle [169].  
In this study poly(vinyl alcohol) (PVA) was extruded into a predetermined 
geometry onto a layer of electrospun polydioxanone (PDO).  
Electrospinning is used to produce thin fibres (ranging from nm to µm 
diameters) with a large surface area by applying a potential difference 
between a polymer solution and collector.  It has been used extensively in 
tissue engineering since the degradation rate, fibre diameter, porosity and 
mechanical properties can be easily varied depending on the application 
[170].  After deposition of the PVA onto the electrospun sheet of PDO a 
further layer of PDO was electrospun on top.  The PVA was then removed 
by submerging the scaffold in water to leave a hollow electrospun scaffold 
which was then repopulated with HUVECs.  These cells were shown to 
attach to the electrospun scaffold within the vascular channels, although 
the coverage was uneven.  This represents a novel approach not only for 
the purpose of perfusing TE constructs in vivo (as was the intention of this 
study) but has the potential to be used as a model for angiogenesis, an 
application which has not been studied as yet.  Scaffolds such as this offer 
the ability to be perfused, be recellularised with a variety of cells (either 
individually or in co-culture) and have ECM components placed onto them 
or deposited by the cells.  This novel approach could offer not only the 
tissue engineering community but also those involved in cancer research an 
advanced 3D in vitro model to study angiogenesis.                                                          
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1.7. Project aims and objectives   
 
The aim of this project is to develop in vitro models for angiogenesis that 
have the capability of combining pro-angiogenic cells with an ECM 
component that can be monitored under flow conditions to learn more 
about the ‘rules’ of angiogenesis.  In order to satisfy this aim, the 
objectives of the project are to: 
 
1. Produce vascular networks for experimentation by decellularising 
animal tissue to retain the ECM components and vascular 
architecture. 
 
2. Produce vascular networks for experimentation by electrospinning 
and robocasting to produce a synthetic vascular network.  
 
3. Design a bioreactor for perfusion of vascular networks. 
 
4. Investigate the optimal cell combinations to functionalise the 
vascular networks and recellularise these networks under both static 
and perfused culture. 
 
5. Investigate the effect of flow rate on angiogenic sprouting. 
 
6. Investigate the effect of pro-angiogenic stimuli on angiogenic 
sprouting. 
 
7. Investigate the effects of pro-angiogenic stimuli and flow rate in 
combination to observe the collective effect on angiogenic sprouting.   
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Chapter 2 
 
Materials and Methods 
 
Please refer to Appendix A and B for a list of materials and preparation of 
general reagents, respectively.   
 
2.1. Bioscaffold preparation 
 
Preparation of solutions 
 
Heparin solution 
 
Heparin solution was prepared to a final concentration of 100 U/ml by 
dissolving 153 mg of heparin sodium salt (from porcine intestinal mucosa) 
in 150 ml of PBS.  The solution was then sterilised by passing it through a 
syringe filter into a sample container.   
 
Tissue retrieval 
 
All surgical procedures and animal husbandry were carried out in 
accordance with the UK Home Office guidelines under the Animals 
(Scientific Procedures) Act 1986 and the local ethics committee.  Fifteen 
adult DBIX rats were sacrificed by isoflurane inhalation and cervical 
dislocation.  Once sacrificed a longitudinal abdominal incision was made to 
expose the abdominal cavity.  The inferior vena cava was cannulated using 
a 24 G cannula and flushed with approximately 10 ml of heparin solution 
to prevent blood clot formation.  An 8-10 cm long segment of jejunum was 
then isolated and ligations of vessels at the peripheries of the segment were 
made using suture thread before the intestinal lumen was transected at 
these locations and the jejunum was explanted.  The intestinal lumen was 
flushed with supplemented PBS solution immediately after explantation.  
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The jejunum was then stored, submerged in supplemented PBS, in a 
container at -80 °C until required.   
 
2.2. Decellularisation  
 
Preparation of solutions 
 
Non-ionic detergent 
 
To decellularise each jejunum 2 litres of detergent was required.  The 
detergent was prepared by adding 1% (v/v) Triton-X 100 and 0.1% (v/v) 
ammonium hydroxide to distilled water in a 1L Duran bottle.  A 
magnetic stir bar was placed into the bottle and the solution was 
subsequently mixed on a magnetic stirrer until the Triton-X 100 had 
completely dissolved.     
 
Decellularisation 
 
Decellularisation was performed to remove native cells and retain the ECM 
components.  This method was adapted from work published by Baptista 
et al. [77].  Firstly, the jejunum was removed from the -80 °C freezer and 
thawed at 4 °C prior to transferring to a petri dish.  This step contributes 
towards the decellularisation process since the freeze/thaw cycle assists in 
cell lysis.  The superior mesenteric artery (SMA) was then cannulated 
using a 24 G cannula and suture thread under a dissection microscope.  
Approximately 1ml of blue food colouring was then perfused through the 
cannula to determine whether all of the jejunum would be equally supplied 
with detergent.  Upon successful cannulation of the jejunum, the SMA was 
attached to a peristaltic pump via a luer barb adapter which in turn was 
attached to a 1 meter length of tubing.  The tissue was then submerged 
completely in 2 L of distilled water (in a tall glass beaker), along with the 
opposite end of the tubing to form a closed circuit (Figure 7).   Distilled 
water was then continuously perfused and recirculated through the vessels 
at a rate of 2.7 ml/min for 3 hours.  Subsequently the jejunum was 
removed from the beaker and its contents was replaced with 2 L of non-
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ionic detergent.  The tissue was then re-submerged in the beaker and 
detergent was perfused and recirculated continuously overnight.  Finally 
the beaker was filled with distilled water and this was circulated for a 
further 3 hours to remove any residual detergent from the tissue.  Please 
note that buffers were not replenished/changed during the individual 
steps.  Upon completion of the final distilled water wash the jejunum was 
transferred to a petri dish containing PBS and was stored at 4 °C until 
required.  Please refer to Appendix C (Figure 72) for the calibration curve 
showing flow rate vs revolutions per minute (RPM) for this setup.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Bioscaffold sterilisation 
 
To sterilise the decellularised jejunum approximately 5 ml of 0.1% (v/v) 
PA was flushed through the vasculature before being completely 
submerged in PA for 3 hours at 4°C.  Sterile PBS was then flushed 
through the vasculature of the matrix three times to remove any residual 
acid.  Once this process was complete the matrix was handled in sterile 
conditions in a class II laminar flow hood (Walker Safety Cabinets, 
Glossop, UK), unless otherwise stated.  
 
Peristaltic pump 
Figure 7 – Schematic outlining the decellularisation setup. 
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2.4. Bioscaffold characterisation 
  
Samples were fixed for 24 hours at 4 °C in 3.7% (w/v) neutral buffered 
formalin solution in PBS.  They were dehydrated using graded alcohol 
washes before embedding in paraffin wax.  Sections of 6 µm were taken for 
each sample using a microtome (Leica, Germany) and slides were stained 
appropriately as outlined.  
 
2.4.1. Vascular patency  
 
Preparation of solutions 
 
FITC-Dextran 
 
FITC-Dextran (250 kDa) was dissolved in PBS to a final concentration of 
100 µg/ml.  
 
Vascular patency 
 
After decellularisation 1 ml of blue food colouring was injected through the 
SMA of the jejunum to determine the patency of the vessels.  The vessels 
were macroscopically visualised and imaged under a dissection microscope.     
 
To observe the patency of the vessels microscopically, approximately 1 ml 
FITC-Dextran was infused into the SMA of the jejunum and imaged 
immediately using a confocal microscope at wavelengths of between 492 
nm λex and 520 nm λem. 
  
2.4.2. Preparation of histological slides 
 
Samples were washed with PBS and then fixed in 3.7% (w/v) 
formaldehyde for at least 24 hours at 4 °C.  Samples were then processed 
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overnight in a benchtop tissue processor, undergoing the steps outlined in 
Table 8.   
Table 8 – Summary of steps taken to prepare histology samples 
Step Solution Immersion Time (hours) 
1 70% IMS 1 
2 70% IMS 1 
3 80% IMS 1.5 
4 85% IMS 1.5 
5 90% IMS 1.5 
6 95% IMS 1.5 
7 100% IMS 1.5 
8 100% IMS 1.5 
9 Xylene 1.5 
10 Xylene 1.5 
11 Paraffin wax 2 
12 Paraffin wax 2 
  
 
Samples were then embedded in molten paraffin wax using the embedding 
centre, dispenser and hot plate.  The wax blocks were then allowed to cool 
and solidify on ice blocks for at least 1 hour prior to sectioning using the 
microtome.  Blocks were trimmed at an initial thickness of 15 µm until the 
surface of the sample within the block was reached.  Sections were then 
sliced at 6 µm and immediately transferred to a water bath set to 38 °C.  
This allowed the sections to flatten out before being mounted onto the 
surface of the SuperFrost Plus slides.  Slides were then placed on top of 
the hot plate, set to 37 °C, to allow them to dry and stored at room 
temperature until required.          
 
2.4.3. Hematoxylin and Eosin (H&E) staining 
 
H&E staining was performed to compare samples and determine whether 
cells had been removed via the decellularisation process.  Slides were 
placed into a holder and the following steps were carried out (Table 9).  
Using a pasteur pipette, DPX mountant was placed onto the samples 
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which were then covered with a coverslip and allowed to dry before 
imaging using a light microscope.      
 
Table 9 – Summary of processing steps carried out for H&E staining. 
Step Process Solution Immersion time 
(mins) 
1 Dewaxing Xylene 3 
2 Dewaxing Xylene 3 
3 Re-hydration 100% IMS 1 
4 Re-hydration 70% IMS 0.5 
5 Re-hydration Distilled water 1 
6 Staining (cell nuclei) Hematoxylin 1.5 
7 Staining Tap water (running) 4 
8 Staining  
(intra/extracellular proteins) 
Eosin 5 
9 Staining Tap water 0.5 
10 Dehydration 70% IMS 0.5 
11 Dehydration 100% IMS 0.5 
12 Dehydration Xylene 0.5 
13 Mounting DPX mountant - 
 
2.4.4. Glycosaminoglycan (GAG) staining 
 
Preparation of solutions 
 
Alcian blue solution  
 
Alcian blue solution was prepared by mixing 1 g of alcian blue 8GX into 
100 ml of 3% (v/v) acetic acid solution in distilled water and adjusting the 
pH to 2.5 using acetic acid.         
 
GAG Staining 
 
GAGs are an important component of the ECM.  They play key roles in 
binding growth factors, cytokines and water within the ECM [171].  To 
visually determine whether GAGs had been retained, staining using the 
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alcian blue stain was used.  Freshly cut sections (within two days of 
sectioning) were placed into a holder and processed according to the 
processes in Table 10.  It is important to use fresh sections as old slides 
can give inconsistent staining of GAGs with alcian blue.  Using a pasteur 
pipette, DPX mountant was placed onto the samples which were then 
covered with a coverslip and allowed to dry before imaging using a light 
microscope.     
 
Table 10 – Summary of processing steps for GAG staining of samples. 
Step Process Solution Immersion time (mins) 
1 Dewaxing Xylene 10 
2 Dewaxing Xylene 10 
3 Re-hydration 100% IMS 3 
4 Re-hydration 100% IMS 2 
5 Re-hydration 100% IMS 2 
6 Re-hydration 70% ethanol 2 
7 Re-hydration Running tap water 3 
8 Staining 1% (w/v) Alcian blue 15 
9 Staining Running tap water 1 
10 Staining Distilled water 0.5 
11 Staining Periodic acid 5 
12 Staining Distilled water 1 
13 Staining Schiffs reagent 15 
14 Staining Running tap water 5 
15 Staining Gills no. 3 hematoxylin 1.5 
16 Staining Running tap water Until water runs clear 
17 Dehydration 70% ethanol 0.25 
18 Dehydration 100% IMS 1 
19 Dehydration 100% IMS 2 
20 Dehydration 100% IMS 3 
21 Dehydration Xylene 10 
22 Dehydration Xylene 10 
23 Mounting DPX mountant - 
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2.4.5. Collagen staining 
 
Preparation of solutions 
 
Picosirius red solution 
 
Picosirius red solution was prepared by adding 0.1 g of direct red 80 to 100 
ml of saturated aqueous solution of picric acid (1.3% v/v in distilled 
water).   
 
Acidified water 
 
Acidified water was prepared by adding 5 ml of glacial acetic acid to 1 
litre of distilled water.  
 
Collagen Staining 
 
Collagen is the main contributor to the mechanical and physical properties 
of the ECM, especially collagen type I.  Sirius red staining was used to 
visualise the collagen content of the decellularised jejunum.  Slides were 
placed into a holder and processed according to the steps in Table 11.  
Once stained DPX mountant was placed onto the samples and a coverslip 
was placed on top.  Slides were allowed to dry before imaging using both 
light and polarised light microscopy.     
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Table 11 – Summary of steps taken for collagen staining of samples. 
Step Process Solution Immersion time (mins) 
1 Dewaxing Xylene 10 
2 Dewaxing Xylene 10 
3 Re-hydration 100% IMS 3 
4 Re-hydration 100% IMS 2 
5 Re-hydration 100% IMS 2 
6 Re-hydration 70% ethanol 2 
7 Re-hydration Tap water 1 
8 Staining Weigert’s hematoxylin 5 
9 Staining Running tap water 4 
10 Staining Picosirius red 60 
11 Staining Acidified water 0.25 
12 Staining Acidified water 0.25 
13 Dehydration 70% ethanol 0.25 
14 Dehydration 100% IMS 1 
15 Dehydration 100% IMS 2 
16 Dehydration 100% IMS 3 
17 Dehydration Xylene  10 
18 Dehydration Xylene 10 
19 Mounting DPX mountant - 
 
2.4.6. Elastin staining 
 
Preparation of solutions 
 
Working elastic stain solution 
 
The solution was prepared on the day of use by adding the following 
reagents, in the order indicated, into a glass container. 
 
• Hematoxylin Solution  20 ml  
• Ferric Chloride Solution   3 ml  
• Weigert’s Iodine Solution   8 ml  
• Deionized Water    5 ml  
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Working ferric chloride solution 
 
The working ferric chloride solution (for differentiation) was prepared on 
the day of use by adding 3 ml of ferric chloride solution and 37 ml 
deionized water to a glass container.  
 
Elastin staining 
 
Elastin is a structural protein found in tissues that are required to stretch, 
such as skin, blood vessels etc.  To determine whether elastin had been 
retained samples were stained with elastic stain and ferric chloride 
solution.  Sections were placed into a slide holder and subjected to the 
protocol outlined in Table 12.  Coverslips were then mounted to the slides 
by adding DPX mountant media and were allowed to dry before imaging 
using a light microscope.    
 
Table 12 – Summary of processing steps taken to stain for elastin. 
Step Process Solution Immersion time (mins) 
1 Dewaxing Xylene 10 
2 Dewaxing Xylene 10 
3 Re-hydration 100% IMS 5 
4 Re-hydration 100% IMS 5 
5 Re-hydration 95% IMS 1 
6 Re-hydration 70% ethanol 1 
7 Re-hydration Distilled water 1 
8 Staining Elastic stain 10 
9 Staining Distilled water 1 
10 Staining Ferric chloride 1-2 
11 Staining Tap water 1 
12 Staining 95% IMS 0.5 
13 Dehydration Distilled water 0.5 
14 Dehydration Van Gieson stain 1-3 
15 Dehydration 95% IMS 0.5 
16 Dehydration Xylene 5 
17 Dehydration DPX mountant  - 
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2.4.7. Masson-Goldner trichrome staining 
 
Preparation of solutions 
 
Glacial acetic acid 
 
A working solution of 1% (v/v) acetic acid was prepared by diluting the 
stock solution in the ratio of 1:100 in distilled water.  
 
Weigert’s iron hematoxylin 
 
Weigert’s solution A and Weigert’s solution B (from catalogue number 
115973) were mixed in the ratio 1:1 and used within one week of 
preparation. 
 
Masson-Goldner trichrome staining 
 
Masson-Goldner trichrome staining is a 3 colour staining protocol used in 
histology and is well suited for distinguishing cells from surrounding 
connective tissue.  This stain was used for analysing CAM samples.  Slides 
were placed into a holder and the steps were performed according to Table 
13.  Once stained DPX mountant was placed onto the samples and a 
coverslip was placed on top.  Slides were allowed to dry before imaging 
using a light microscope.       
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Table 13 – Summary of processing steps to carry out Masson-Goldner trichrome staining. 
Step Process Solution Immersion time (mins) 
1 Dewaxing Xylene 5 
2 Dewaxing Xylene 5 
3 Re-hydration 100% IMS 1 
4 Re-hydration 70% IMS 0.5 
5 Rinse Distilled water 1 
6 Staining Weigert’s hematoxylin  5 
7 Staining Running tap water  5 
8 Staining 1% acetic acid 0.5 
9 Staining Azophloxine solution 10 
10 Staining 1% acetic acid 0.5 
11 Staining Tungstophosphoric acid 
orange G solution 
1 
12 Staining 1% acetic acid 0.5 
13 Staining Light green SF solution 2 
14 Staining 1% acetic acid 0.5 
15 Dehydration 70% ethanol 0.5 
16 Dehydration 96% ethanol 0.5 
17 Dehydration 100% ethanol 0.5 
18 Dehydration 100% ethanol 0.5 
19 Dehydration 100% ethanol 2 
20 Dehydration Xylene 5 
21 Dehydration Xylene 5 
22 Mounting DPX mountant - 
 
2.4.8. Staining of cell nuclei 
   
Preparation of solutions  
 
DAPI 
 
A working DAPI solution containing 1 µg/ml was prepared by diluting 
DAPI in the ratio of 1:1000 in PBS.  
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Staining of cell nuclei 
 
DAPI is a fluorescent stain that binds strongly to A-T rich regions in 
DNA.  It is used widely in fluorescence microscopy to determine the 
presence of cell nuclei.  To determine the effectiveness of the 
decellularisation protocol in removing cells, samples were stained using 
DAPI to identify the presence of DNA.  Slides were placed into a holder 
and de-waxed by submerging sequentially in xylene (2×3 minutes), 100% 
IMS (1×1.5 minutes), 70% IMS (1×1 minute) and distilled water (3×1 
minute).   A PAP pen was used to draw circles around each sample on the 
slide, forming a water repellent barrier that enabled staining reagents to 
remain localised on the tissue sections.  The working DAPI solution was 
then pipetted over each sample before covering the samples with tin foil 
and leaving them at room temperature for 10 minutes.  The samples were 
then washed three times with PBS and coverslips were affixed to the slides 
using DPX mountant media.  The stained samples were imaged using a 
confocal microscope at a wavelength range of between 365 nm λex and 460 
nm λem. 
 
2.4.9. Immunolabeling of laminin and fibronectin 
 
Preparation of solutions 
 
BSA 
 
To prepare the blocking serum 0.75 g of BSA was measured and dissolved 
completely in 10 ml of PBS to give a final concentration of 7.5% (w/v). 
 
Similarly 1% (w/v) BSA was produced by dissolving 0.1 g of BSA in 10 ml 
of PBS.      
 
Primary antibodies 
 
Polyclonal rabbit anti-fibronectin primary antibody was diluted in the 
ratio of 1:1500 in 1% (w/v) BSA. 
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Polyclonal rabbit anti-laminin primary antibody was diluted in the ratio of 
1:100 in 1% (w/v) BSA. 
 
Secondary antibodies 
 
FITC anti-rabbit secondary antibody was diluted in the ratio of 1:500 in 
1% (w/v) BSA. 
 
Triton-X 100 
 
Triton-X 100 was prepared to a final concentration of 0.1% (v/v) in PBS 
by dissolving 10 µl in 10 ml of PBS.   
 
Immunolabeling of laminin and fibronectin 
 
Laminin is an adhesion protein found in the ECM, especially the basement 
membrane.  It has been shown to play an important role in vascular 
formation and maintenance and is thought to be a key component to EC 
friendly scaffold materials [171].  Fibronectin is the next most abundant 
protein found in the ECM.  It is a glycoprotein found in submucosal and 
basement membrane structures and is responsible for cell adhesion [172–
174].  Immunolabeling of both proteins was performed to determine 
whether they had been retained post decellularisation.  Slides were placed 
into holders, de-waxed and rehydrated by submerging sequentially in 
xylene (2×3 minutes), 100% IMS (1×1.5 minutes), 70% IMS (1×1 minute) 
and distilled water (3×1 minute).  A PAP pen was used to draw circles 
around each sample on the slide, forming a water repellent barrier that 
enabled reagents to remain localised on the tissue sections.  Cells were 
then permeabilised using 0.1% (v/v) Triton-X 100 for 20 minutes.  
Samples were subsequently incubated in 7.5% (w/v) BSA at room 
temperature for 60 minutes, followed by washing once with 1% (w/v) BSA 
in PBS.  Samples were incubated with either anti-laminin primary 
antibody produced in rabbit or anti-fibronectin antibody produced in 
rabbit at 4 °C overnight.  Samples were washed 3 times in PBS before 
incubating with FITC anti-rabbit secondary antibody at room temperature 
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for 60 minutes before washing a further 3 times with PBS.  Nuclear 
counterstaining was then performed using DAPI by incubating at room 
temperature for 20 minutes and then washing a further three times with 
PBS.  Coverslips were then fixed onto the slides using DPX mountant 
media.  Samples were imaged using a confocal microscope set to 495 nm 
λex, 515 nm λem (FITC) and 358 nm λex, 461 nm λem (DAPI).            
 
2.4.10. Contact cytotoxicity assay 
 
Preparation of solutions 
 
Culture medium (DMEM, 10% FCS (v/v)) 
 
Human dermal fibroblasts (HDFs and RN22 (rat Schwann cell line) cells 
were cultured in DMEM, 10% FCS (v/v) (Table 14).    
  
Table 14 – Components of DMEM, 10% FCS (v/v) culture medium. 
Component Volume (ml) Final concentration  
DMEM 439 88% (v/v) 
FCS 50 10% (v/v) 
Penicillin/streptomycin 5 100 IU/ml / 0.1 mg/ml 
Amphotericin B 1.25 0.625 µg/ml 
L-glutamine 5 2 mM 
 
 
Contact cytotoxicity assay 
 
To determine whether potentially cytotoxic detergents were effectively 
removed after decellularisation, a contact cytotoxicity assay was 
performed.  Samples of sterile decellularised jejunum were cut into 
approximately 5 mm2 sections.  Cyanoacrylate contact adhesive (15 µl) 
was then placed into the centre of 1 well of a 6 well plate to serve as a 
positive control (i.e. cells will not grow on this).  Subsequently 15 µl of 
type I rat tail collagen (handled on ice) was added to the centre of the 
adjacent well of the 6 well plate and was neutralised using 7.5 µl of sterile 
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1M sodium hydroxide.  The pH of the collagen gel was tested using pH 
indicator test strips with the ideal pH being 7.4 upon neutralisation.  The 
plate was placed in a 37 °C incubator for 15 minutes to allow the gel to 
set.  This served as a negative control (i.e. cell will grow on this).  Samples 
of decellularised jejunum (5 mm2) were attached to the bottom of the 
remaining wells using collagen gel and sterile sodium hydroxide (again in 
the ratio 2:1) and were allowed to set in the incubator.  The number of 
plates prepared corresponded to the number of cell types being tested (in 
this case two).  Wells were washed three times with PBS for 10 minutes 
each.  Whilst washing, HDFs and RN22 cells were passaged and counted 
(for more details on passaging and counting cells please see section 2.6).  
Please note that HDFs were used at passage 8 and RN22 cells were used 
at passage 12.  Each cell type was resuspended in DMEM, 10% FCS (v/v) 
to a concentration of approximately 250,000 cells/ml.  A total of 2 ml of 
cell suspension was added to each test and control well.  Plates were 
incubated for 48 hours at 37 °C in a 5% CO2 atmosphere.  Media was then 
aspirated and the wells were washed gently with PBS.  Samples were then 
fixed with 3.7% (w/v) formaldehyde for 10 minutes.  After removing the 
formaldehyde, Giemsa stain was added to cover each cell layer and was 
incubated for 5 minutes.  Each well was then rinsed using tap water until 
it ran clear and the plates were allowed to air dry.  Plates were examined 
microscopically using bright field microscopy and changes in morphology, 
vacuolisation, detachment and cell lysis were recorded and imaged in order 
to determine whether cells had been adversely affected by the presence of 
the decellularised jejunum and potential residual cytotoxic detergents.                  
 
2.5. Quantitative analysis 
 
2.5.1. DNA quantification 
 
Preparation of solutions 
 
Buffer ATL & buffer AL 
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Both of these buffers may form precipitates upon storage.  When 
necessary, the buffered were warmed to 56 °C until the precipitates had 
fully dissolved.   
 
 
Buffer AW1 & buffer AW2 
 
Both of these buffers are supplied a concentrates.  Prior to use, the 
appropriate amount of ethanol was added as indicated on the bottle to 
obtain the working solution.    
 
Digestion buffer 
 
This digestion buffer was prepared by adding the following reagents to a 
glass container, stirring continuously using a magnetic stirrer. 
 
• L-Cysteine hydrochloride     0.394 g 
• Di-sodium ethylenediaminetetraacetic acid 0.931 g 
• PBS containing calcium and magnesium  500 ml 
 
The pH was then adjusted to 6.0 ± 0.1 by adding 6 M hydrochloric acid or 
6 M sodium hydroxide.  This solution was stored at room temperature for 
a maximum of 6 months.  
 
DNA standard solutions 
 
Stock solution was prepared by adding 5ml of nuclease free water to 5 mg 
of calf thymus DNA and dissolving by inversion.  This was stored at -20 
°C for a maximum of 6 months.   
 
A primary standard was prepared by adding 200 µl of DNA stock solution 
to 1.8 ml of digestion buffer (100 µg/ml).   
 
To prepare the DNA standard, reagents were combined according to Table 
15. 
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Table 15 – Summary of DNA standard preparation. 
Standard concentration 
(µg/ml) 
Volume of primary 
standard (µl) 
Volume of digestion 
buffer (µl) 
50 200 200 
45 180 220 
40 160 240 
35 140 260 
30 120 280 
25 100 300 
20 80 320 
15 60 340 
10 40 360 
5 20 380 
0 0 400 
 
 
DNA quantification 
 
In order to determine the effectiveness of the decellularisation protocol, 
quantification of the DNA present in samples pre- and post-
decellularisation was performed.  DNA was isolated and quantified from 
fresh (n=3) and decellularised (n=3) rat jejunums using the DNeasy Blood 
and Tissue kit according to the manufacturer’s (Qiagen) instructions.  
Firstly, around 100 mg of fresh and decellularised tissue was macerated, 
placed in a sterile 1.5 ml micro centrifuge tube and lyophilised to a 
constant weight.  Samples were digested by adding 360 µl of buffer ATL 
and 40 µl of proteinase K which was mixed thoroughly by vortexing and 
then samples were incubated overnight at 56 °C.  After this 400 µl of 
buffer AL and 400 µl ethanol were added to each digest and mixed 
thoroughly by vortexing.  Each sample was transferred to a DNeasy mini 
spin column placed in a collection tube and centrifuged at 6000 g for one 
minute before discarding the flow-through.  Buffer AW1 (500 µl) was 
added and centrifuged again for one minute at 6000 g discarding any flow-
through.  To dry the DNeasy membrane 500 µl of buffer AW2 was added 
and centrifuged for three minutes at 20,000 g.  This stage is important 
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since any residual ethanol can potentially interfere with subsequent 
reactions.  The DNeasy mini spin columns were then transferred to 1.5 ml 
centrifuge tubes before adding 200 µl of buffer AE to the DNeasy 
membrane and incubating for 1 minute at room temperature.  DNA was 
then eluted by centrifuging for one minute at 6000 g.  For maximum DNA 
yield this step was repeated (i.e. adding buffer AE).  The amount of DNA 
present in each sample was measured by determining the absorbance at 
260 nm through the use of a NanoDrop 1000 (Thermo Scientific).  A DNA 
standard was also tested to ensure the accuracy of the readings.  Samples 
were stored at 4 °C for short periods or -20 °C for long term storage.   
 
2.5.2. Collagen quantification 
 
Preparation of solutions 
 
Assay buffer 
 
The assay buffer was prepared by adding the following reagents, in the 
order indicated, into a glass container. 
 
• Citric acid (monohydrate)   6.65 g    
• Glacial acetic acid     1.6 ml 
• Sodium acetate (trihydrate)  16 g  
• Sodium hydroxide    4.55 g 
• Propan-1-ol     40 ml 
 
The volume of solution was then made up to 150 ml using distilled water.  
The pH was adjusted to 6.0-6.5 using 6 M hydrochloric acid whilst stirring 
using a magnetic stirrer.  The volume was then adjusted to 200 ml using 
distilled water.  This solution will remain stable for up to 2 months if kept 
in a dark bottle at 4 °C.   
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Chloramine T 
    
Chloramine T (1.41 g) was dissolved in 100 ml of distilled water using a 
magnetic stirrer.  This was prepared fresh immediately prior to use. 
 
Ehrlich’s reagent 
 
This solution was prepared by adding the following reagents to a glass 
container, stirring continuously using a magnetic stirrer. 
 
• P-dimethylaminobenzaldehyde  1.88 g 
• Propan-1-ol     7.5 ml 
• Perchloric acid    3.35 ml 
• Distilled water    1.65 ml 
 
Once prepared the solution was used within 1 hour. 
 
 Assay standards 
 
To make the primary standard the following reagents were combined. 
• Trans-4-hydroxy-L-proline   25 mg 
• Assay buffer     25 ml 
 
To make the secondary standard the following reagents were combined 
and then prepared as outlined in Table 16. 
 
• Primary standard     1 ml 
• Assay buffer     9 ml  
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Table 16 – Secondary standard preparation for collagen quantification.  
Standard concentration 
(µg.ml-1) 
Volume of secondary 
standard (µl) 
Volume of buffer  
(µl) 
30 750 1750 
25 625 1875 
20 500 2000 
15 375 2125 
10 250 2250 
8 200 2300 
6 150 2350 
4 100 2400 
2 50 2450 
0 0 2500 
 
 
Collagen quantification 
 
To determine whether collagen had been retained post-decellularisation a 
quantitative analysis was performed.  Hydroxyproline is an amino acid 
found almost exclusively in the protein collagen.  This assay uses a 
chloramine T mixture to convert hydroxyproline in the digested samples to 
a pyrrole. Ehrlich’s reagent is then added to react with the pyrrole to 
produce a chromophore and the absorbance of the plate is read. The 
content of hydroxyproline in the unknown samples is determined by 
comparison with a predetermined hydroxyproline standard curve.   
 
To perform the assay approximately 100 mg of fresh and decellularised 
tissue was macerated and placed into 1.5 ml micro-centrifuge tubes.  The 
mass of the centrifuge tubes was measured before and after the addition of 
tissue samples to determine the mass of tissue.  The samples were then 
transferred to a freeze dryer and were lyophilised at -50 °C to a constant 
mass.  The mass of the tubes was measured after 12 hr of lyophilisation 
and again at intervals of 4 hr or until the mass of the tubes was constant.  
Lyophilised tissue samples were then digested using 6 M hydrochloric acid 
to break down proteins to their component amino acids at 121 °C in an 
oven overnight in polypropylene universal containers.  Sodium hydroxide 
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(6 M) was added to neutralise each sample and the final volume was 
noted.  Collagen content was measured indirectly through measurement of 
the hydroxyproline content according to Reddy et al. [175].  Briefly, 50 µl 
of each sample was added to a clear flat bottomed 96 well plate and 
oxidised by adding 100 µl of chloramine T solution.  The plate was gently 
shaken at 60 rpm for 5 minutes using a table shaker before adding 100 µl 
of Ehrlich’s reagent to each well.  The plate was then incubated at 60 °C 
for 45 minutes.  Absorbance was read at 562 nm.  Blank values (i.e. assay 
buffer) were then subtracted from all of the standards and unknown 
samples.  A standard curve of hydroxyproline concentration against 
absorbance was plotted (Appendix C, Figure 68) and unknown values were 
interpolated using a linear regression of the standard curve.               
 
2.5.3. GAG quantification 
 
Preparation of solutions 
 
Papain digestion solution 
 
1250 units of papain were dissolved in 25 ml of digestion buffer using a 
magnetic stirrer to give a final concentration of 50 U/ml.  This solution 
was used immediately.    
 
0.1 M sodium di-hydrogen orthophosphate 
 
3.45 g of sodium di-hydrogen orthophosphate was added to 250 ml of 
distilled water and mixed thoroughly using a magnetic stirrer.  This 
solution was stored for up to 3 months at room temperature.    
 
0.1 M di-sodium hydrogen orthophosphate 
 
3.55 g of di-sodium hydrogen orthophosphate was added to 250 ml of 
distilled water and mixed thoroughly using a magnetic stirrer.  This 
solution was stored for up to 3 months at room temperature.    
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Assay buffer 
 
The assay buffer was prepared by adding the following reagents to a glass 
container and stirring continuously using a magnetic stirrer. 
 
• 0.1M sodium di-hydrogen orthophosphate 137 ml 
• 0.1M di-sodium hydrogen orthophosphate 63 ml 
 
The pH was adjusted to 6.8 using 6 M hydrochloric acid or 6 M sodium 
hydroxide.  The assay was stored for a maximum of 3 months at room 
temperature.    
 
1,9 Dimethylmethylene blue (DMB) dye solution 
 
The DMB dye solution was prepared by adding the following reagents to a 
glass container and stirring continuously using a magnetic stirrer. 
 
• 1,9 dimethylene blue  8 mg 
• Ethanol    2.5 ml 
• Formic acid    1 ml 
• Sodium formate   1 g 
 
The volume was then increased to 500 ml using distilled water and the pH 
was adjusted to 3.0 using formic acid.  The dye was stored for a maximum 
of 3 months at room temperature. 
 
Assay standards 
 
To make the primary standard the following reagents were combined and 
then prepared according to Table 17. 
 
• Chondroitin sulphate B    10 mg 
• Assay buffer     10 ml 
 
 
Chapter 2: Materials and Methods 
 
71 
 
Table 17 – Preparation of the GAG assay standard. 
Standard concentration 
(µg.ml-1) 
Volume of primary 
standard (µl) 
Volume of buffer  
(µl) 
200 40 160 
150 30 170 
100 20 180 
50 10 190 
25 5 195 
12.5 5 395 
6.25 5 795 
3.125 5 1595 
0 0 250 
 
 
GAG quantification 
 
GAG content was analysed to determine quantitatively how much had 
been preserved post decellularisation using the dimethylmethylene blue 
(DMB) assay first described by Farndale et al. [176].  The assay uses the 
metachromatic dye 1,9 dimethylmethylene blue to quantify the amount of 
GAGs in the standard and test samples.  The binding of the GAGs to the 
dye induces a shift in the absorption spectrum which is directly 
proportional to the amount of GAGs.  The sample values of GAGs are 
determined by the standard curve.   
 
Briefly, fresh and decellularised tissues (100 mg) were macerated and 
lyophilised.  Samples were digested by adding 5 ml of papain digestion 
solution and incubating for 48 hours at 60 °C before transferring 40 µl of 
each test solution into a clear flat bottomed 96 well plate.  DMB dye 
solution (250 µl) was added to each well and the plate was shaken for two 
minutes on a plate shaker.  The optical densities were measured using a 
micro plate spectrophotometer at 520 nm.  Blank values (i.e. assay buffer) 
were subtracted from all of the standards and unknown samples.  A 
standard curve of chondroitin sulphate B concentration vs absorbance 
(Appendix C, Figure 67) was plotted and unknown values were 
interpolated using a linear regression of the standard curve.               
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2.6. General cell culture 
  
All cell culture work was carried out in a class II biological safety cabinet 
(Walker Safety Cabinets, Derbyshire, UK).  Prior to commencing work the 
safety cabinet was sterilised using 70% IMS (Fisher Scientific UK, 
Loghborough, UK) and all equipment to be used within it was either 
sterilised using 70% IMS or autoclaved.  Sterile cell culture plasticware 
(Costar, Buckinghamshire, UK) was used and liquids were either 
purchased sterile or were filter sterilised.  All cells were incubated under 
humidified conditions at 37 °C containing 5% CO2.                     
2.6.1. Human dermal fibroblast culture 
 
Preparation of solutions 
 
‘Difco-trypsin’ 
 
‘Difco-trypsin’ was prepared to a final concentration of 0.1% (w/v) by 
combining the following reagents. 
 
• Difco-trypsin powder 0.5 g 
• D-glucose   0.5 g 
• Phenol red   0.5 ml 
• PBS    500 ml 
 
The pH was adjusted to 7.4 using 2 M sodium hydroxide solution and was 
filter sterilised.  Aliquots were prepared (10 ml) and frozen at -20 °C until 
required.    
 
Collagenase A solution 
 
Collagenase A powder was dissolved in serum free culture media (see 
above) to a final concentration of 0.05% (w/v).  The solution was filter 
sterilised and stored in 10 ml aliquots at -20 °C until required.   
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Cryopreservation medium 
 
Cryopreservation medium was prepared to the required volume by using 
90% (v/v) FCS and 10% (v/v) DMSO. 
 
 
Cell isolation 
 
Skin samples were taken from consenting patients undergoing elective 
abdominoplasty or breast reduction surgery.  Tissues were collected and 
used under the requirements stipulated by Research Tissue Bank Licence 
12179.  Tissue samples (0.5 x 0.5 cm) were incubated in 10 ml of ‘Difco-
trypsin’ for between 12-18 hours at 4 °C.  Enzymatic action was stopped 
by adding 5 ml of FCS.  The epidermis was separated from the dermis 
using sterile forceps before mincing the dermis finely and incubating with 
10ml of collagenase solution at 37 °C overnight.  The action of the 
collagenase solution was stopped with the addition of 10 ml of culture 
medium (DMEM, 10% FCS (v/v)).  Following centrifugation of the 
resulting cell suspension (400 g for 10 minutes), pelleted cells were cultured 
in a T25 flask containing DMEM, 10% FCS (v/v).  The medium was 
changed after 24 hours and then every 3-4 days until ~80% confluent.          
 
Passaging cells 
 
Once cells had reached ~80% confluence they were transferred into new 
flasks in order to continue cellular proliferation and ultimately increase the 
total number of cells available for experiments.  To passage cells, cell 
culture medium in the flask was removed and the cell layer was washed 
with 10ml PBS to remove any excess serum proteins left from the medium 
(this would inhibit subsequent enzyme action).  The cells were then 
incubated with 2.5 ml trypsin/EDTA solution and incubated at 37 °C for 
5 minutes or until the cells had detached from the flask (this was 
confirmed using phase microscopy).  The trypsin/EDTA was then 
neutralised using 7.5 ml of culture medium and the cell suspension was 
transferred to a universal container before centrifuging at 200 g for 5 
minutes.  The supernatant was then removed before gently tapping the 
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cell pellet to break it up.  The cells were then resuspended in culture 
medium and approximately 1 × 105 cells were seeded into each T75 flask 
before incubating at 37 °C in a 5% CO2 environment.  Again, the medium 
was changed after 24 hours and then every 3 days until ~80% confluent.    
 
Counting cells 
 
In order to count the number of cells in a cell suspension, a 
haemocytometer was used.  After thoroughly resuspending cells in a known 
volume of culture medium 10 µl of the suspension was pipetted into the 
haemocytometer by placing the pipette tip at the edge of the chambers 
and allowing capillary action to draw the suspension from the pipette.  
Care was taken not to overfill the chamber.  The grid lines of the 
haemocytometer were focussed upon using the 10x objective of an inverted 
microscope and phase contrast was used to visualise cells.  A hand tally 
counter was then used to count the total number of cells present in a set of 
16 squares (as indicated in Figure 8) which occupies a volume of 1 × 10-
4 ml.  At least 2 sets of 16 squares were counted to obtain an average 
number of cells.  The calculation below was used to calculate the total 
number of cells present per milliliter of cell suspension.  
 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝐶𝐶𝑐𝑐 𝑚𝑚𝐶𝐶 = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑛𝑛𝑛𝑛.𝑛𝑛𝑜𝑜 𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑛𝑛𝑐𝑐𝑛𝑛𝑐𝑐𝐴𝐴𝑐𝑐  𝑥𝑥  𝑐𝑐𝑑𝑑𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑑𝑛𝑛𝑛𝑛 𝑜𝑜𝐴𝐴𝑐𝑐𝑐𝑐𝑛𝑛𝐴𝐴
1 𝑥𝑥 10−4    
      
 
 
     
 
 
 
 
 
 
 
 
 
 
Figure 8 – Haemocytometer showing 9 squares comprised of 16 individual squares 
each (blue).      
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Cryopreservation of cells 
 
Cells were treated as if passaging but instead of resuspending in DMEM, 
10% FCS (v/v) culture medium after centrifuging, cells were instead 
resuspended in cryopreservation medium to a concentration of 1 × 106 
cells/ml.  This cell suspension was then added to 1 ml cryovials which 
were transferred to a Mr Frosty freezing container that enables cells to be 
cooled at a rate of -1 °C per minute.  The container was placed into a -80 
°C freezer for at least 4 hours before transferring the cryovials to a liquid 
nitrogen dewar (~ -196 °C).       
 
Thawing cells  
 
Cryovials were removed from the liquid nitrogen Dewar using necessary 
safety precautions and were immediately thawed in a water bath set to 37 
°C.  When the cell suspension had just thawed it was transferred to a 
universal container filled with 10 ml of culture medium before centrifuging 
at 200 g for 5 minutes.  The cell pellet was then resuspended in culture 
medium, transferred to a T75 flask and incubated at 37 °C in a 5% CO2 
environment.  The culture medium was replaced after 24 hours and then 
every 3 days thereafter until ~80% confluent.    
 
2.6.2. Human dermal microvascular endothelial cell culture 
 
Preparation of solutions 
 
Pig skin gelatin (0.1%) solution 
 
Pig skin gelatin solution was prepared by dissolving 0.1 g of pig skin 
gelatin in 100 ml of PBS.  The solution was then sterile filter, aliquoted 
and stored at -20 °C until required.   
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HDMEC growth medium  
 
HDMEC growth medium was bought from PromoCell as a kit, containing 
the basal medium and supplement mix.  To prepare the culture medium 
the contents of the supplement mix was added to 500 ml of basal medium 
in a class II cell culture cabinet.  In addition, 5 ml of 
penicillin/streptomycin and 1.25 ml of amphotericin B were added.  The 
final concentrations of the components used in the HDMEC growth 
medium are shown in Table 18. 
 
Table 18 – Summary of the composition of HDMEC growth medium. 
Component Final concentration  
FCS 0.05 ml/ml 
EC growth supplement 0.004 ml/ml 
Epidermal growth factor (recombinant human) 10 ng/ml 
Heparin 90 µg/ml 
Hydrocortisone 1 µg/ml 
Penicillin 100 U/ml 
Streptomycin 0.1 mg/ml 
Amphotericin B 0.25 µg/ml 
  
 
Passaging cells 
 
Proliferating HDMECs derived from human juvenile foreskin were 
purchased from PromoCell.  Prior to passaging cells T25 flasks were 
coated with 5 ml pig skin gelatin solution and incubated at 37 °C in a 5% 
CO2 atmosphere overnight.  The gelatin solution was then aspirated off 
and the flask was washed 3 times with sterile PBS.  To passage cells, 
media was first aspirated from the T25 flask before washing with 2.5mls of 
hepesBSS to remove any residual serum proteins.  After removal of the 
hepesBSS solution, pre-warmed trypsin EDTA (2.5 ml) was then added 
and flasks were incubated at room temperature for 2-3 minutes, 
monitoring cell detachment continuously using phase contrast microscopy.  
To quench the action of the trypsin EDTA, 2.5 ml of trypsin neutralising 
solution was added and the cell suspension was collected in a sterile 
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universal container.  Cells were centrifuged at 200 g for 5 minutes before 
resuspending in culture medium and splitting in the ratio 1:3 into T25 
flasks.  HDMECs were used at passage 5 in this study.                        
 
Cryopreservation of cells 
 
Please refer to section 2.6.1.  Please note that cells were resuspended in 
Cryo-SFM bought from PromoCell instead of cryopreservation medium 
(90% FCS/10% DMSO).    
 
Thawing cells 
 
Please refer to section 2.6.1.  Note that cells were transferred to a T25 
flask. 
 
2.7. Melanin infusion of dermal fibroblasts 
 
Preparation of solutions 
 
Melanin supplemented culture medium  
 
Culture medium was prepared as outlined in section 2.6.1.  To 10 ml of 
culture medium, 10 mg of melanin was added to give a concentration of 1 
mg/ml.  This was then sonicated for 15 minutes.   
 
Melanin infusion of dermal fibroblasts  
 
To macroscopically determine the distribution of cells when infused into 
the decellularised jejunum, fibroblasts were infused with melanin so that 
they were visible.  To do this 5 ml of melanin supplemented culture 
medium was added to T75 flasks containing HDF cells that were at least 
70% confluent.  Cells were incubated for 24 hours before removing the 
melanin solution and were then used for recellularisation.      
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2.8. Bioscaffold recellularisation 
  
Bioscaffold recellularisation    
 
HDMECs inside vascular channels only 
 
Re-endothelialisation of the jejunum was performed by perfusing HDMECs 
into the vascular channels.  A sterile decellularised jejunum was placed 
into a sterile petri dish in a class II biological safety cabinet.  Using a 5 ml 
syringe and forceps, HDMEC culture medium was perfused through the 
cannula and thus the bioscaffold.  The jejunum was then immersed in 
culture medium and placed in an incubator set at 37 °C in a 5% CO2 
atmosphere.  HDMECs were then passaged and counted as described in 
section 2.6.1 and 2.6.2.  1.5 × 106 cells were resuspended in 1ml of HDMEC 
growth medium and then perfused through the vasculature of the pre-
warmed decellularised jejunum using a 1 ml syringe.  This was incubated 
at 37 °C in a 5% CO2 atmosphere overnight.           
 
HDMECs and HDFs inside vascular channels 
 
HDMECs were recellularised into the decellularised jejunum as described 
above.  This was incubated for at least 3 hours at 37°C in a 5% CO2 
atmosphere.  HDFs were then passaged and counted as described in 
section 2.6.1.  1.5 x 106 HDFs were then resuspended in 1ml of HDMEC 
medium and perfused through the vasculature of the decellularised 
jejunum using a 1ml syringe.  This was incubated at 37°C in a 5% CO2 
atmosphere overnight.              
 
HDMECs inside vascular channels and HDFs inside lumen 
 
A sterile decellularised jejunum was preconditioned with media and 
warmed as described above.  HDFs were passaged and counted as 
described in section 2.6.1.  0.75 x 106 HDFs were resuspended in 5 ml of 
HDMEC medium and perfused through the lumen of the intestine.  This 
was incubated (fully submerged in HDMEC medium) for at least 3 hours 
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at 37 °C in a 5% CO2 atmosphere.  This process was repeated but this 
time the jejunum was flipped onto the reverse side so that the HDFs were 
perfused onto the opposite surface of the lumen.  Again the jejunum was 
incubated for at least 3 hours at 37 °C in a 5% CO2 atmosphere.  
HDMECs were then passaged and counted as described in section 2.6.1 
and 2.6.2.  1.5 × 106 cells were resuspended in 1 ml of HDMEC growth 
medium and then perfused through the vasculature of the decellularised 
jejunum using a 1 ml syringe.  This was then incubated at 37 °C in a 5% 
CO2 atmosphere overnight.              
 
2.9. Bioreactor design and preparation 
 
Bioreactor design and production 
 
The bioreactor was designed using the 3D CAD design software, 
SolidWorks.  The drawings produced by this program are provided in 
Appendix C (Figure 69 - Figure 71).  The base and lid of the bioreactor 
chamber were made from Lexan medical grade polycarbonate due to its 
optical clarity, durability and known biocompatibility [177].     
 
Gasket production 
 
Gaskets were manufactured to produce a seal between the lid and base of 
the bioreactor.  Silicon gaskets were produced by adding 50 ml of silicone 
elastomer and 5 ml of curing agent to a straight sample container and 
stirring thoroughly.  This was then transferred to a square petri dish and 
baked in an oven for 60 minutes at 60 °C.  The flat silicon sheet was then 
cooled and transferred to a laser cutter.  The silicon gasket was drawn on 
the package Inkscape and this file was loaded onto the laser cutting 
software.  The gaskets were then cut out of the silicon.             
 
Bioreactor preparation  
 
Base and lid 
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Prior to use, the base of the bioreactor had a barbed to threaded adapter 
screwed into the inner aspect of inlet port.  A 2 cm long piece of tubing 
was then attached to the adapter which in turn had a male luer lock 
adapter attached to the end as illustrated in Figure 9.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The lid of the bioreactor had barded to threaded adapters screwed into 
one pair of adjacent holes with 1 cm long tubing attached whilst the other 
pair of holes were blocked by screwing in plugs (Figure 10). 
 
 
 
 
 
 
 
 
Barbed to threaded adapter 
Male luer lock adapter  
Tubing  Bioreactor base 
Figure 9 – Image showing the configuration of the base of the bioreactor prior to 
sterilisation  
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Both the base and lid of the bioreactor were placed into a tall 2 L capacity 
glass beaker inside a class II biological safety cabinet.  This was then filled 
with 2 L of 0.1% PA and incubated at room temperature for up to 5 
hours.  The PA was then removed and replaced with sterile distilled water.  
This was then left overnight to wash the bioreactor base and lid to remove 
any residual acid.     
  
Tubing 
 
Pharmed BPT was used for the section of tubing to be placed over the 
peristaltic pump rollers since it is more durable than conventional silicon 
tubing when used in such circumstances.  Due to the increased cost of such 
tubing the rest of the system consisted of cheaper Versilic silicon tubing.  
Both types of tubing were connected to one another using straight barbed 
tubing connectors (Figure 11).     
 
Plugs  
Barbed to threaded adapters 
with tubing attached 
Figure 10 – Image showing the configuration of the lid of the bioreactor prior to 
sterilisation   
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Barbed to threaded adapters were placed at the ends of the lengths of 
Versilic silicon tubing (so that it could be connected to the base of the 
bioreactor – Figure 12).    
 
 
Pharmed tubing  
Straight barbed tubing connector  
Versilic 
silicon 
tubing  
Figure 11 – Image showing the configuration of the central section of 
the tubing 
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Prior to use the tubing was sterilised by autoclaving.    
 
Gasket, stainless steel grid and screws 
 
Prior to use, the gasket, stainless steel grid and screws were all sterilised 
by autoclaving.   
 
2.10. Perfusion of recellularised bioscaffold  
 
Perfusion of recellularised bioscaffold 
 
Assembly of the bioreactor took place in a sterile class II biological safety 
cabinet.  The base was firstly removed and the barbed to threaded 
adapters at the end of the tubing were screwed into the inlet and outlet 
ports using sterile forceps.  The silicon gasket was then positioned in place 
before placing the stainless steel grid into the base chamber (Figure 13).  
The chamber was then filled with ~70 ml of HDMEC growth medium.  
The tubing was attached to the peristaltic pump and the medium was 
perfused through the tubing.  The recellularised jejunum was then 
Barbed to threaded adapter 
Versilic silicon tubing 
Figure 12 - Image showing the configuration of the end section of the 
tubing  
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removed from the incubator and the cannula was attached to the male luer 
lock adapter.  The lid was placed on top of the base and secured into place 
using 8 socket head cap screws.  Sterile syringe filters were then attached 
to the tubing on the lid to allow for gas exchange (Figure 14).  The 
bioreactor was then transferred to an incubator with the peristaltic pump 
positioned outside and perfused continuously with medium (Figure 15).             
 
 
 
 
 
 
Silicon 
gasket 
Stainless steel grid Tubing connected to inlet 
Tubing connected 
to outlet 
Figure 13 - Image showing the configuration of the base of the 
bioreactor for perfusion of the recellularised jejunum  
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Syringe filter 
Socket head cap screw 
Cannula attached to 
male luer lock adapter 
Figure 14 – Image showing the assembled bioreactor used to perfuse the 
recellularised jejunum 
Figure 15 – Image showing the bioreactor 
perfusion setup  
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2.11. LIVE/DEAD Cell Staining  
 
Preparation of solutions 
 
LIVE/DEAD cell staining solution 
 
Propidium iodide and Syto 9 were diluted in pre-warmed DMEM in the 
ratio 1:3000 under sterile conditions.   
 
LIVE/DEAD cell staining 
 
LIVE/DEAD staining was performed to determine whether cells perfused 
throughout the samples had survived.  The staining procedure employs 
two nucleic acid stains — the green-fluorescent Syto 9 stain and the red-
fluorescent propidium iodide stain.  These stains differ in their ability to 
penetrate healthy cells.  When used alone, Syto 9 stain labels both live 
and dead cells.  In contrast, propidium iodide penetrates only cells with 
damaged membranes, reducing Syto 9 fluorescence when both dyes are 
present. Thus, live cells with intact membranes fluoresce green, while dead 
cells with damaged membranes fluoresce red.  Sections were taken, 
transferred to a 6 well plate and incubated at 37 °C at 5% CO2 for 20 
minutes.  Samples were then imaged using a confocal microscope.   
 
2.12. Collagen gel preparation 
 
Preparation of solutions 
 
VEGF 165 solution 
 
A stock solution of VEGF 165 (10 ng/µl) was diluted to a concentration of 
1 ng/µl by adding sterile PBS.   
 
Collagen gel preparation 
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Working on ice, VEGF loaded and ‘plain’ collagen gels were prepared 
using the reagents outlined in Table 19. 
 
Table 19 – Components of the plain and VEGF loaded collagen type I gels. 
Component ‘Plain’ gel VEGF loaded gel 
Rat tail collagen type I 0.2 ml 0.2 ml 
HDMEC culture medium 0.1 ml 0.1 ml 
VEGF - 3 µl 
Sodium hydroxide Added drop-wise  Added drop-wise 
 
 
Firstly the rat tail collagen (type I) and HDMEC culture medium were 
combined with or without the addition of VEGF 165.  The final 
concentration of VEGF 165 within the gels was 10 ng/ml.  Sterile 1 M 
sodium hydroxide was added drop-wise to neutralise the pH before 
allowing to set in a 37 °C incubator for 15 min.    
 
 
2.13. Production of natural angiogenesis model 
 
Angiogenesis models consisted of the recellularised jejunum containing 
varying cell combinations with VEGF loaded gels placed on top.  The aim 
of such combinations was to induce EC outgrowth into the gels.   
 
Recellularised natural scaffolds were placed into the bioreactor as 
explained in section 2.10.  Stainless steel rings were then placed on top of 
the recellularised jejunum as shown in Figure 16.  Collagen was prepared 
as described in section 2.12 and 100 µl was pipetted into each metal ring.  
The bioreactor was then sealed and transferred to an incubator where the 
gels were allowed to set at 37 °C for 15 min.  The scaffold was then 
perfused.  
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2.14. Chick CAM assay 
 
To assess the angiogenic properties of decellularised jejunum in vivo the 
CAM assay was used.  Fertilised chick eggs were incubated at a constant 
temperature of 37 °C and humidity of 40% in a chick egg incubator.  
Seven days post fertilisation, a small window was dissected into the chick 
egg using a sterile blade and forceps.  Small segments (~1 cm in length) of 
sterilised decellularised jejunum were placed onto the CAM.  This was 
repeated with a collagen gel (please refer to section 2.12 for preparation 
details) as a negative control.  The window was sealed by covering with 
parafilm (sterilised by submerging in 70% IMS) and securing with masking 
tape and returned to the incubator for a further 7 days.  Samples were 
then exposed by removing the surrounding egg shell and imaged using a 
digital microscope.   
 
2.15. Synthetic scaffold production 
  
Synthetic vascular nets were made via a multi-step process as illustrated 
by Figure 17.  Firstly a thin layer of poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) was electrospun onto a flat metal sheet 
Figure 16 – Image showing the placement of collagen gels onto 
the recellularised jejunum 
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collector.  Alginate was then printed onto the electrospun sheet before 
spinning another layer of PHBV on top.  Alginate was then removed using 
ethylenediaminetetraacetic acid (EDTA) solution.  Each step is described 
below. 
 
 
 
2.15.1. Electrospinning PHBV 
 
Preparation of solutions 
 
PHBV polymer solution 
 
Working in a fume hood, 3 g of PHBV pellets, 3 g methanol and 24 g of 
DCM were added to a clean 30 ml glass container.  This mixture was 
magnetically stirred overnight to dissolve the bulk polymer. 
 
Electrospinning PHBV 
 
Figure 17 – Schematic showing the production of the synthetic vascular 
networks 
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Once fully dissolved, 2.2 ml of the polymer solution was transferred into 
4x5ml syringes with 0.6 mm ID blunt tip needles placed onto the ends.  
These were then placed onto a single syringe pump, set to deliver 40 
µl/min per syringe.  A flat metal sheet was placed onto a mandrel at a 
distance of 17 cm from the needle tip.  A potential difference of 17 kV was 
applied to the needles using a high voltage power pack until all of the 
polymer had been electrospun.    
             
2.15.2. Alginate printing 
 
Preparation of solutions  
 
Alginate paste 
 
Alginate paste was produced by firstly adding 36.35 g of distilled water 
and 0.1 g of calcium chloride dihydrate to a glass beaker and stirring 
magnetically until dissolved.  The solution was heated to approximately 60 
°C before adding 0.75 g of alginic acid sodium salt from brown algae whilst 
constantly stirring.  Finally, 12.125 g of glycerol was added and stirred 
until the alginic acid sodium salt was homogeneously distributed and 
resembled a smooth paste.  To test the ultimate removal of alginate the 
paste was supplemented with 0.25 g of fluorescent Eosin Y.   
 
Alginate printing 
  
Once cool, the alginate paste was transferred into a 3 cm3 syringe barrel 
with a 0.6 mm ID blunt dispensing tip attached.  The syringe barrel was 
attached to a positive displacement dispensing system that controlled the 
extrusion rate of the alginate.  A 3D printer was used to hold the positive 
displacement dispensing arm and thus print the alginate.  The design to be 
printed was controlled through the use of custom built g-code software 
(Vascular Pattern Path Generator (VPPG)) where the geometry, feed rate 
of the printer and number of iterations could all be controlled.  For each 
design a separate g-code file was produced with the given parameters and 
then loaded into the Pronterface software used to control the printer.  The 
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flat metal sheet containing the electrospun layer was placed onto the 
RepRap stage and the blunt dispensing tip attached to the syringe barrel 
was positioned just above it.  To print the design alginate was discharged 
from the syringe barrel by pressing down the foot pedal that controls the 
positive displacement dispensing system whilst simultaneously pressing the 
'print' button on the Pronterface software.  Previous work carried out by 
Adam Kelly had determined that the optimum extrusion rate of alginate 
was 0.025 cm3/min and feed rate of the printer is 5000 mm/min and these 
values were used for all printed designs.  Once the alginate design had 
been printed onto the electrospun mat, the electropinning process was 
repeated in order to cover the alginate with a further layer of electrospun 
PHBV.    
 
2.15.3. Alginate removal 
  
Preparation of solutions 
 
EDTA (0.5 M) solution  
 
EDTA (0.5 M) was prepared by adding 73.02 g of anhydrous acid free 
EDTA (MW 292.24) to 400 ml of distilled water and stirring continuously.  
The pH was adjusted to 8.0 by adding sodium hydroxide pellets 
(approximately 32.5 g) to ensure that the EDTA would dissolve.  The final 
volume was then adjusted to 500 ml by adding distilled water.    
 
Alginate removal 
 
To remove the alginate and leave a hollow void between the two 
electrospun sheets, the vascular nets were removed from the flat sheet 
using a scalpel blade and placed into a 100 ml plastic tub and submerged 
in 0.5 M EDTA solution overnight on a see-saw rocker set to 70 
oscillations/min.   
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2.16. Scanning electron microscopy (SEM) 
 
Preparation of solutions 
 
Ethanol solutions 
 
Graded ethanol solutions were prepared as indicated in Table 20.  
 
Table 20 – Preparation of graded ethanol solutions for preparation of samples for SEM.  
Absolute ethanol 
(ml) 
Distilled water 
(ml) 
Final volume 
(ml) 
Final concentration 
(%) 
9 1 10 90 
8 2 10 80 
6 4 10 60 
3.5 6.5 10 35 
  
 
Ethanol/HMDS solution  
 
Ethanol and HMDS were combined in the ratio 1:1 to give 10 ml of 
solution.  
 
SEM – Samples with cells 
 
To image samples containing cells the steps indicated in Table 21 were 
carried out. 
 
 
 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
 
93 
 
Table 21 – Preparation of samples containing cells for SEM. 
Step Solution Immersion time (mins) 
1 2.5% gluteraldehyde 60 mins 
2 PBS 15 
3 PBS 15 
4 PBS 15 
5 Distilled water 5 
6 35% ethanol 15 
7 60% ethanol 15 
8 80% ethanol 15 
9 90% ethanol 15 
10 100% ethanol 15 
11 Ethanol/HMDS (1:1) 60 
12 100% HMDS 5 
 
Samples were then allowed to dry completely in air.  Samples were then 
covered in a thin layer of gold coating using a sputter coater and imaged 
using a SEM with an accelerating voltage of 10 kV and a spot size of 3.   
 
SEM – Samples without cells  
 
Samples were covered in a thin layer of gold coating using an Emscope 
SC500 sputter coater and then imaged using an Inspect F SEM with an 
accelerating voltage of 10 kV and a spot size of 3.   
 
2.17. Synthetic scaffold sterilisation 
 
Prior to sterilisation each scaffold was cannulated with a 24 G cannula 
under a dissection microscope.  Scaffolds were then transferred to a petri 
dish and sterilised by submerging in 30 ml of 70% ethanol for 45 minutes.  
Scaffolds were then washed 3 times with sterile PBS.      
 
 
Chapter 2: Materials and Methods 
 
94 
 
2.18. Mechanical testing 
 
Tensile mechanical testing was conducted for the synthetic scaffolds using 
a uniaxial load test machine fitted with a 4.5 N load cell.  To test the bulk 
material the dimensions of strips of scaffold sheets were measured using a 
pair of digital callipers before being fixed to the clamps of the machine 
positioned 10 mm apart.  Each sample was then pulled at a rate of 0.1 mm 
per minute and elongated to failure (n = 4).  Data of the force and 
extension were logged before being converted into stress-strain curves 
using the following equations: 
 
𝑆𝑆𝑐𝑐𝑐𝑐𝐶𝐶𝑆𝑆𝑆𝑆 =  𝐹𝐹𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 
𝐴𝐴𝑐𝑐𝐶𝐶𝑐𝑐
 
 
𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =  𝐸𝐸𝐸𝐸𝑐𝑐𝐶𝐶𝑐𝑐𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐
𝑂𝑂𝑐𝑐𝑐𝑐𝑂𝑂𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝐶𝐶𝐶𝐶𝑐𝑐𝑂𝑂𝑐𝑐ℎ 
 
The following parameters were calculated using the stress-strain curve (as 
indicated in Figure 18): 
 
1. Ultimate tensile stress (UTS) – this is the maximum stress that a 
material can withstand prior to failure and is the maximum stress 
on the stress vs. strain curve. 
2. Yield stress – this is the point at which a material deforms 
plastically i.e. it will not return to its original shape. 
3. Young’s modulus – this is a measure of the stiffness of a material 
and is the gradient of the stress vs. strain curve within the elastic 
region. 
4. Ultimate strain – this is the strain measured at the point of failure. 
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To obtain the suture retention strength both ends of the scaffold sheet 
were sutured 3 mm from the end of the sample before being clamped in 
place within the uniaxial load test machine (as shown in Figure 19).  The 
distance between the clamps was measured and each sample was then 
pulled at a rate of 0.1 mm per minute and elongated to failure (n = 6). 
Suture retention strength was calculated as the following equation: 
 
𝑆𝑆𝑆𝑆𝑐𝑐𝑆𝑆𝑐𝑐𝐶𝐶 𝑐𝑐𝐶𝐶𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑆𝑆𝑐𝑐𝑐𝑐𝐶𝐶𝑐𝑐𝑂𝑂𝑐𝑐ℎ =  𝐿𝐿𝑐𝑐𝑐𝑐𝐿𝐿
𝑆𝑆𝑆𝑆𝑐𝑐𝑆𝑆𝑐𝑐𝐶𝐶 𝐿𝐿𝑐𝑐𝑐𝑐𝑚𝑚𝐶𝐶𝑐𝑐𝐶𝐶𝑐𝑐 𝐸𝐸 𝑚𝑚𝑐𝑐𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝑐𝑐ℎ𝑐𝑐𝑐𝑐𝑖𝑖𝑐𝑐𝐶𝐶𝑆𝑆𝑆𝑆 
 
 
Figure 18 – Stress vs strain curve showing relevant parameters 
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2.19. Synthetic scaffold recellularisation 
 
HDMECs only 
 
To endothelialise the synthetic vascular channels HDMECs were perfused 
into the scaffolds.  A sterile synthetic scaffold was placed into a sterile 
petri dish in a class II biological safety cabinet.  HDMECs were passaged 
and counted as described in section 2.6.1 and 2.6.2.  0.5 × 106 cells were 
resuspended in 1 ml of HDMEC growth medium and then perfused 
through the synthetic net using a 1 ml syringe.  This was incubated at 37 
°C in a 5% CO2 atmosphere overnight (Figure 20).  The following day the 
synthetic scaffold was flipped over and the same process was repeated.            
 
HDMECs and HDFs inside vascular channels 
Figure 19 – Images showing the placement of scaffolds in the tensile test machine for 
determination of the suture retention strength 
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A sterile synthetic scaffold was placed into a sterile petri dish in a class II 
biological safety cabinet.  HDMECs were passaged and counted as 
described in section 2.6.1 and 2.6.2.  0.5 × 106 cells were resuspended in 
1ml of HDMEC growth medium and perfused through the synthetic net 
using a 1ml syringe.  This was incubated for at least 3 hours at 37 °C in a 
5% CO2 atmosphere.  HDFs were then passaged and counted as described 
in section 2.6.1.  0.5 x 106 HDFs were resuspended in 1 ml of HDMEC 
growth medium and perfused through the synthetic net.  This was 
incubated at 37 °C in a 5% CO2 atmosphere overnight (Figure 21).  The 
following day the synthetic scaffold was flipped over and the same process 
was repeated.                           
 
HDMECs inside vascular channels and HDFs on outer surface of scaffold 
 
A sterile synthetic net was placed into a sterile petri dish in a class II 
biological safety cabinet.  HDMECs were passaged and counted as 
described in section 2.6.1 and 2.6.2.  0.5 × 106 cells were resuspended in 1 
ml of HDMEC growth medium and perfused through the synthetic net 
using a 1 ml syringe.  This was submerged in HDMEC medium and 
incubated at 37 °C in a 5% CO2 atmosphere.  HDFs were then passaged 
and counted as described in section 2.6.1.  The scaffold was removed from 
the incubator and placed in a sterile petri dish.  0.5 x 106 HDFs were 
resuspended in 200 µl of HDMEC growth medium and pipetted over the 
outer surface of the scaffold.  This was then returned to the incubator for 
up to 2 hours to allow the HDFs to attach to the surface.  The scaffold 
was then submerged in HDMEC growth medium and incubated overnight 
(Figure 22).  The following day the synthetic scaffold was flipped over and 
the same process was repeated.                                
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Figure 20 – Schematic showing the steps taken to recellularise the synthetic scaffolds with 
HDMECs only  
Figure 21 – Schematic showing the steps taken to recellularise the synthetic scaffolds with HDMECs 
and HDFs within the channels  
Figure 22 - Schematic showing the steps taken to recellularise the synthetic scaffolds with HDMECs within the 
channels and HDFs on the outer surface of the scaffolds  
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2.20. Production of synthetic angiogenesis model 
 
Synthetic angiogenesis models consisted of the recellularised synthetic 
scaffolds combined with VEGF loaded collagen gels.  The aim of the 
models was to observe the outgrowth of ECs into gels.    
 
Recellularised synthetic scaffolds were incubated for 7 days and then 
placed in a sterile petri dish in a class II biological safety cabinet.  Using 
the sterile needle from a 24 G cannula, holes were pierced in the channels 
of the synthetic scaffolds.  Collagen was then prepared as described in 
section 2.12 and 100 µl was pipetted into each hexagonal well formed by 
the channels.  The gels were allowed to set in a 37 °C incubator for 15 min.  
The scaffolds were then re-submerged in HDMEC growth medium (Figure 
23) and cultured for 7 days.        
 
 
 
 
 
 
 
 
 
Figure 23 – Schematic showing the production of the angiogenesis model using the synthetic 
pseudo-vascular networks.   
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2.21. Immunohistochemistry 
 
Preparation of solutions 
 
BSA 
 
To prepare the blocking serum 0.75 g of BSA was measured and dissolved 
completely in 10 ml of PBS to give a final concentration of 7.5% (w/v). 
 
Similarly 1% (w/v) BSA was produced by dissolving 0.1 g of BSA in 10 ml 
of PBS.      
 
Primary antibodies 
 
Antigen Host Dilution  
Fibronectin Rabbit 1:1500 
Laminin Rabbit 1:100 
CD31 Mouse 1:20 
CD144 Mouse 1:50 
αSMA Rabbit 1:200 
DLL4 Rabbit 1:200 
Collagen IV Goat 1:100 
 
Secondary antibodies 
 
All secondary antibodies were diluted in the ratio 1:500 in 1% BSA. 
Triton-X 100 
 
Triton-X 100 was prepared to a final concentration of 0.1% (v/v) in PBS 
by dissolving 10 µl in 10 ml of PBS.   
 
PFA (4%) 
 
20 g of PFA was added to 500 ml of HBSS containing calcium and 
magnesium (in a fumehood).  The solution was then heated to 60 °C 
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before adding 1 M sodium hydroxide solution drop-wise until the PFA had 
gone into solution.  This was then cooled to room temperature before use.        
 
BSA/Tween 20 solution 
 
100µl of Tween20 was pipetted into 10 ml 1% (v/v) BSA to produce a 
1% BSA/1% Tween 20 (v/v). 
 
10µl of Tween20 was pipetted into 10 ml 1% (v/v) BSA to produce a 1% 
BSA/0.1% Tween 20 (v/v). 
 
Glycine (100mM) solution 
 
0.75 g of glycine was dissolved to 100 ml of PBS to give a 100 mM 
solution. 
 
Immunohistochemistry (slides) 
 
Slides were prepared as described in section 2.4.2.  They were then placed 
into a holder and were processed using the steps outlined in Table 22 
below.       
 
Table 22 – Outline of immunohistochemistry steps. 
Step Process Solution Immersion time 
(mins) 
1 Dewaxing Xylene 3 
2 Dewaxing Xylene 3 
3 Re-hydration 100% IMS 1 
4 Re-hydration 70% IMS 0.5 
5 Re-hydration Distilled water 1 
 
 
A PAP pen was used to draw circles around each sample on the slide, 
forming a water repellent barrier that enabled staining reagents to remain 
localised on the tissue sections.  Cells were then permeabilised by 
submerging in 0.1% Triton-X 100 for 20 minutes.  Samples were incubated 
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in 7.5% BSA at room temperature for 1 hour, followed by washing once 
with 1% BSA.  Samples were incubated with the appropriate primary 
antibodies diluted in 1% BSA at 4 °C overnight.  Samples were washed 3 
times in PBS before incubating with the appropriate secondary antibodies 
diluted in 1% BSA  at RT for 1 hour and washing a further 3 times with 
PBS.  Samples were counterstained with DAPI solution by incubating at 
RT for 20 minutes and washing a further three times with PBS.  Slides 
were imaged using a confocal microscope.  
 
Immunohistochemistry (3D cultures)  
 
Many of the synthetic and bioscaffold samples were immunostained intact 
(i.e. without processing and producing slides) since many structures and 
cell distribution patterns are not readily appreciated in 2D.  Samples were 
fixed in 4% PFA for 20 minutes at RT.  Samples were then quenched with 
100 mM glycine, followed by one wash with PBS, and were then blocked 
for 1 hour with 1% BSA at RT.  Primary antibodies were added at the 
appropriate dilutions in 1% BSA and incubated at RT overnight.  The 
samples were subsequently washed for 2 hours in 1% BSA/0.1% Tween 20 
(v/v), followed by incubation with the appropriate secondary antibodies 
for 2 hours at RT.  Once the secondary antibody had been added all 
subsequent processes were carried out in the dark (by covering in 
aluminium foil).   Finally the samples were washed again with 1% 
BSA/1% Tween20 for at least 8 hours with hourly changes of the 
BSA/Tween20 solution, after which the samples were stored in PBS at 4 
°C in the dark before imaging using a confocal microscope. 
 
2.22. FITC-lectin perfusion 
 
Preparation of solutions 
 
FITC-lectin solution 
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FITC conjugated lectin from Lycopersicon esculentum was diluted in 
HBSS with calcium and magnesium in the ratio 1:20 under sterile 
conditions.    
 
 
FITC-lectin perfusion 
 
Lectins are proteins that have been found to specifically bind to sugar 
complexes attached to lipids and proteins [178,179] and have been found to 
be extremely useful for microvascular labelling [180–182].  When 
conjugated with a fluorescent dye (FITC), any lectin that binds to the 
vascular endothelium can be visualised using fluorescence microscopy.  To 
visualise potential vessel formation in the synthetic angiogenesis model, the 
scaffolds were perfused with 100 µl of FITC-lectin solution at a rate of 40 
µl/min, controlled using a syringe pump.  The scaffolds were then fixed in 
4% PFA in HBSS with Ca2+ and Mg2+ for 30 minutes and subsequently 
immunostained for CD31 as described above. 
 
2.23. Statistical analysis 
 
Statistics were performed using an unpaired Student's t-test.  The 
significance of the results are denoted by a * symbol (* p < 0.05, **** p < 
0.0001). 
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Chapter 3 
 
Use of natural vasculature to study 
angiogenesis 
 
3.1. Aims and objectives 
 
The aim of this chapter is to develop a naturally derived in vitro model for 
studying angiogenesis by: 
 
1. Producing vascular networks via decellularising animal tissue to 
retain the ECM components and vascular architecture. 
 
2. Designing a bioreactor for perfusion of these vascular networks. 
 
3. Investigating the optimal cell combinations to functionalise the 
vascular networks and recellularise these networks. 
 
4. Investigate the effects of pro-angiogenic stimuli on angiogenic 
sprouting.   
 
3.2. Introduction 
 
Vascularisation plays a vital role in the survival of TE constructs. Several 
groups have investigated different methods to overcome the issue of 
constructs failing because of slow neovascularisation but as yet none have 
succeeded in developing an adaptable solution.  Although it is recognised 
that: 
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• Perfusion conditions  
• The cell type 
• Scaffold architecture  
 
are all important with respect to vascularisation strategies many of the 
studies used fail to consider them in combination.  It is therefore 
important to take a step back and understand how these factors work 
together to promote angiogenesis in order to advance this crucial area.  
This lack of understanding may be due to the deficiencies of current 
angiogenesis models which in turn fail to combine: 
 
• Supporting cells  
• An ECM and/or basement membrane and 
• Perfusion in 3D   
 
Recently, in an attempt to vascularise TE constructs in vitro for 
subsequent translation to the clinic, Schultheiss et al. developed a 
perfusable 3D vascular net by decellularising porcine jejunum [151].  Not 
only can this construct be recellularised with porcine peripheral blood 
EPCs but it is also composed of predominantly ECM components and can 
be perfused through the arterial and venous pedicles.  This technique 
therefore offers real potential for use as a model to investigate angiogenesis 
in vitro.   
 
In this chapter an angiogenesis model derived from a decellularised rat 
jejunum is presented.  It is characterised to determine the ECM 
components present after decellularisation prior to recellularising with a 
combination of HDMECs and HDFs.  A custom built bioreactor is then 
used to perfuse the vascular network to establish the effects of perfusion on 
re-endothelialisation.  A VEGF loaded gel is then placed onto the scaffold 
to observe the effects of this pro-angiogenic stimulator. 
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3.3. Results 
 
3.3.1. Decellularisation 
 
To decellularise the jejunum the vasculature was used as a transport 
network to continuously perfuse the non-ionic detergent solution 
containing Triton-X 100 and ammonium hydroxide for ~16 hours.  
Macroscopically, decellularisation appeared to have occurred since the 
intestine turned increasingly translucent compared to its intact 
counterpart as indicated in Figure 24 (A&B).  Histological staining was 
carried out to characterise the microscopic composition of the intact and 
decellularised jejunum.  H&E staining (Figure 24 (C&D)) showed that the 
process removed almost all cells since there is little to no basophilic 
staining typical of nuclear material.  It also showed the retention of the 
pink eosinophilic staining associated with collagen suggesting that this is 
retained post decellularisation.     
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3.3.2. Bioscaffold characterisation 
 
Once decellularised, it was important to characterise the jejunum in order 
to determine whether this would be a suitable biomaterial to use as a 
potential vascular network for subsequent use as an angiogenesis model.  
Key questions to answer included: 
 
1. Are the decellularised vessels patent? 
2. What are the components of the ECM and how do these 
compare to the fresh jejunum? 
3. Is the resultant biomaterial cytotoxic? 
4. Is the bioscaffold inherently angiogenic? 
 
This section outlines the key findings to the questions listed above. 
A B 
C D 
Figure 24 - Macroscopic view of intact jejunum (A) and translucent decellularised 
jejunum after treatment with detergent (B).  H&E staining of the intact jejunum 
shows the presence of cells (C) but the almost complete removal of cells post 
decellularisation (D).     
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3.3.2.1 Vascular patency 
     
The vessels of the decellularised jejunum were easily seen macroscopically 
(greater than ~300 µm) by placing the sample above a light source (Figure 
25A).  To test the patency of the vessels blue dye was injected into the 
scaffold, highlighting the intact vascular structures (Figure 25B).  To 
further confirm vascular patency, FITC-Dextran (250 kDa) containing 
solution was injected via the SMA and viewed using a confocal microscope.  
Fine branching of the vasculature was observed (Figure 25C) however 
after ~5-10 minutes the fluorescent dye had leaked into the tissue 
parenchyma.      
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2.2 DNA content  
 
To investigate whether nuclear material had been retained after 
decellularisation, DAPI staining was carried out.  Figure 26A shows the 
presence of DNA in the intact jejunum section but very little in the 
decellularised section (Figure 26B).  Quantification of DNA (n=3) found 
that ~97% of DNA is removed after the decellularisation process, 
illustrating its efficacy (Figure 26C).   
 
 
 
 
 
A B C 
Figure 25 – Macrocopic view of the vessels of the decellularised jejunum placed over a light 
source (A) and via the injection of blue dye (B).  FITC-Dextran injection shows 
microscopic patency (C).  
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3.3.2.3 Collagen content  
Figure 26 – DAPI staining of intact jejunum (A) and decellularised jejunum (B).  
Quantitative analysis of the DNA content shows a 97% reduction post 
decellularisation n=3 (P < 0.0001) (C).  
A B 
C **** 
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Collagen content was investigated by firstly staining with Picosirius red 
and imaging the samples using bright field microscopy.  Using this method 
collagen is stained red and appears to be retained when comparing the 
intact (Figure 27A) and decellularised (Figure 27B) jejunum.  When 
examined under circularly polarised light, larger collagen fibres tend to 
appear bright orange or red whilst smaller reticular fibres appear green in 
colour [183,184].  From Figure 27 (C&D) it can be seen that the majority 
of fibres appear to be bright orange/red indicating the presence and 
retention of larger collagen fibres after decellularisation.  Quantification of 
collagen (n=3) measured per mg of dry tissue mass indicates a 30% 
increase in its proportion of the total mass of tissue after decellularisation 
A B 
C D 
E * 
Figure 27 – Bright field microscopy images of Pico-Sirius red staining of intact 
(A) and decellularised jejunum (B).  Circularly polarised light microscopy images 
of intact (C) and decellularised jejunum (D) showing larger collagen fibers (bright 
orange/red) and smaller reticular fibers (green).  Quantification of collagen 
content shows a 30% increase post decellularisation n=3 (P < 0.05) (E).       
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(Figure 27E) and may be explained by the removal of other components 
such as cellular proteins.     
                     
3.3.2.4 GAG content  
 
Alcian blue staining of the fresh and decellularised jejunum (Figure 28 
(A&B)) shows little difference in terms of colouration.  Further analysis 
via GAG quantification (n=3) showed that there was no significant 
difference in GAG content before and after the decellularisation process 
(Figure 28C).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
Figure 28 – Alcian blue staining for GAGs shows little difference in colouration between 
the intact (A) and decellularised jejunum (B).  Quantification confirms that there is no 
significant difference between GAG content before or after decellularisation n=3 (C).  
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3.3.2.5 Elastin content  
 
 
The Accustain elastic staining protocol was carried out on both intact and 
decellularised jejunum sections.  The presence of elastic fibres is indicated 
by the presence of a blue black to black colour, collagen by a red colour 
and muscle or other tissue elements by a yellow colour.  Figure 29 shows 
the complete removal of any blue black to black staining and hence elastic 
fibres after decellularisation but does show the retention of collagen 
confirming previous results.  As a result of this staining, quantification of 
elastin was deemed unnecessary.  Elastin content is important in larger 
vessels that require elastic recoil but less important in smaller vessels such 
as capillaries which consist of only the tunica intima [1].  Since this study 
aims to induce angiogenic sprouting from microvasculature, the loss of 
elastin was not deemed a significant enough reason to optimise the 
decellularisation protocol in an attempt to retain this protein.           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2.6 Laminin and Fibronectin content 
 
Immunostaining for the ECM proteins laminin and fibronectin was 
undertaken for sections of intact and decellularised jejunum.  Figure 30A 
A B 
Figure 29 – Elastic staining of the intact (A) and decellularised (B) jejunum shows almost 
complete removal of any elastic fibers indicated by the blue/black to black colour.  Collagen 
fibers are shown in red confirming the retention of collagen post decellularisation.    
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and Figure 30B show sections of intact and decellularised jejunum 
immunostained for laminin (red) and counterstained with the nuclear stain 
DAPI (blue), respectively.  These images show that laminin is preserved 
after the decellularisation process whilst removing the majority of the 
nuclear material.  Immunostaining for fibronectin on sections of both 
intact (Figure 30C) and decellularised (Figure 30D) jejunum shows the 
almost complete removal of the protein and nuclear material after the 
decellularisation process.           
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3.3.2.7 Cytotoxicity 
  
To determine whether the decellularised jejunum would be cytotoxic to 
cells, rat Schwann cells (derived from the RN22 cell line) and HDFs were 
cultured in the presence of decellularised jejunum segments and then 
stained using the Giemsa stain.  Rat tail collagen type I was used as a 
negative control since it is well know that cells will grow in its presence 
Figure 30 – Immunostaining for laminin (red) on intact (A) and decellularised (B) 
sections of jejunum shows the retention of the ECM protein post decellularisation.  
Immunostaining for fibronectin (red) on intact (C) and decellularised (D) sections of 
jejunum shows the complete removal of the protein post decellularisation.  
Counterstaining with DAPI (blue) shows the almost complete removal of nuclear material 
post decellularisation in both instances.          
A B 
C D 
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[185,186] whilst cyanoacrylate glue was used as a positive control due to 
its potent cytotoxic nature [187,188].  Figure 31 (A-E) and Figure 32 (A-
E) shows macroscopically that both cell types grow up to and around the 
decellularised jejunal segments and the collagen type I gels, whilst almost 
all cells died in the presence of cyanoacrylate (Figure 31F and Figure 32F).  
This is confirmed microscopically as shown in Figure 33.  This illustrated 
that the decellularised jejunum is not cytotoxic to cells.  This assay could 
have also been used to determine the quantitative viability of cells in the 
presence of the jejunum samples and would have given more definitive 
results but as a crude assay to determine cytotoxicity, this assay was 
deemed sufficient.      
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D E F 
Figure 31 – HDF cytotoxicity tests using Giemsa staining.  HDFs were cultured 
in the presence of type I rat tail collagen as a negative control (A-B) and 
decellularised jejunum (C-E) and show growth up to and in contact with the 
biomaterials.  HDFs cultured in the presence of cyanoacrylate glue did not survive 
due to its cytotoxic nature (F).   
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Figure 32 – RN22 cytotoxicity tests using Giemsa staining.  RN22 cells were 
cultured in the presence of type I rat tail collagen as a negative control (A-B) 
and decellularised jejunum (C-E) and show growth up to and in contact with 
the biomaterials.  RN22 cells cultured in the presence of cyanoacrylate glue did 
not survive due to its cytotoxic nature (F).   
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Figure 33 – Light microscopy images of HDF and RN22 cell cytotoxicity 
tests using Giemsa stain.  HDFs and RN22 cells cultured in the presence of 
type I rat tail collagen as a negative control (A&B respectively) and 
decellularised jejunum (C&D respectively) show growth up to and in 
contact with the biomaterials.  HDFs and RN22 cells cultured in the 
presence of cyanoacrylate glue did not survive due to its cytotoxic nature 
(E&F respectively).      
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3.3.2.8 Angiogenic potential  
 
To assess the inherent angiogenic properties of the decellularised scaffold 
via the presence of growth factors, the CAM assay was used.  Sections of 
decellularised intestine were placed onto chick membranes along with 
negative collagen gel controls at seven days post fertilisation and incubated 
in place for a further 7 days.  Samples were then exposed by removing the 
surrounding egg shell and imaged using a digital microscope.  A 15mm 
diameter circle was then drawn around each sample and vessels crossing 
the circle were counted as indicated in Figure 34.  If vessels entered and 
exited the circle without branching they were counted only once (Figure 34 
(left)).  However if vessels entered the circle and then branched before 
exiting, they were counted as separate vessels (Figure 34 (right)).  Only 
vessels of approximately 50µm in diameter (Figure 35) or greater were 
counted.  Figure 36(A,C,E) and Figure 36(B,D,F) show representative 
images of blood vessel development around and towards the decellularised 
jejunum sections and negative collagen gel control, respectively.  
Macroscopic quantification (n=3) measured blindly by assessors showed a 
significant increase (P < 0.0001) in the number of vessels growing towards 
the decellularised intestine sections compared to the collagen gel control 
(Figure 36G).  This suggests that the decellularised scaffold has a certain 
degree of angiogenic capability.  However caution should be taken when 
interpreting results from the CAM assay since chemical or physical 
irritation of the membrane can induce angiogenesis, disrupting 
identification of the response from the test substance, as discussed in 
section 1.4.3 [97,123].  Staining sections of the samples using the Masson-
Goldner trichrome stain showed that blood vessels infiltrated the 
decellularised scaffolds as indicated by the black arrows (Figure 37(A-B)).  
Red blood cells are highlighted by the orange/red colour whilst the 
collagen component of the ECM is shown by the green/blue colour.  
Staining of the collagen gel controls (Figure 37(C-D)) showed a lack of 
cellular and blood vessel infiltration.  This further indicates the angiogenic 
nature of the decellularised intestinal scaffolds.  It would be interesting to 
identify and quantify the growth factors that may be present within the 
scaffolds.  To do so a commercial multiplex angiogenesis ELISA could be 
used.  
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Figure 34 – Schematic illustrating how the blood vessels were counted for each sample.  If 
vessels entered and exited the circle without branching they were counted only once (left).  
However if vessels entered the circle and then branched before exiting, they were counted as 
separate vessels (right).       
Figure 35 – CAM assay image showing 
representative minimum vessel size.  Only 
vessels of approximately 50 µm or above 
(arrow) were counted. 
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Figure 36 – Representative CAM assay images of blood vessel development around and towards the 
decellularised jejunum sections (A, C, E) and negative collagen gel control (B, D, F).  Macroscopic 
quantification measured blindly by assessors showed a significant increase (P < 0.0001) in the 
number of vessels growing towards the decellularised intestine sections compared to the collagen gel 
control n=3 (G).   
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3.3.3. Recellularisation 
 
3.3.2.9 Distribution of cells 
 
To determine the macroscopic distribution of cells throughout the 
decellularised jejunum once recellularised, HDFs were cultured in the 
presence of melanin to allow for its endocytosis and subsequent 
visualisation of the cells.  Viability of the melanin infused HDFs was 
assessed visually by inspecting the morphology of the cells under a light 
microscope.  Inspection showed the typical elongated shape associated with 
HDFs with attachment to the T75 plastic substrate.   Figure 38A shows 
A B 
C D 
Figure 37 – Images showing sections of decellularised jejunum and collagen gels placed on 
the CAM assay and subsequently stained using Masson-Goldner trichrome stain.  Images 
showed that blood vessels infiltrated the decellularised scaffolds as indicated by the black 
arrows (A).  A magnified view of the area indicated by the black box in (B) shows cellular 
infiltration and blood vessels occupied by RBCs.  The same staining of the collagen gel 
controls shows a distinct lack of cellular and blood vessel infiltration (C, D).  Please note 
that RBCs are highlighted by the orange/red colour whilst the collagen component of the 
ECM is shown by the green/blue colour.   
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the visible monolayer of HDFs on the surface of a T75 flask after a 24 hour 
incubation with melanin.  When centrifuged a dark brown cell pellet could 
also be seen (Figure 38B) showing that melanin had been endocytosed.  
Bright field microscopy images show that HDFs appear brown after 
incubation with melanin after 24 hours (Figure 38 (C, D)).  After cells 
were infused into the decellularised jejunum it could be seen that they had 
distributed evenly throughout the entire vascular network (Figure 39 (A, 
B)).  As a result, sections of jejunum could subsequently be taken and 
analysed with increased confidence that they would be representative of 
the entire jejunum.        
 
 
 
 
 
Figure 38 – Melanin endocytosis in HDFs.  A macroscopically visible cell monolayer can 
be seen in a T75 flask after 24 hours of incubation with melanin (A) and a brown cell 
pellet is visible after centrifugation (B).  Bright field microscopy images show the uptake 
of melanin into HDFs (C, D).      
A B 
C D 
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3.3.2.10 Re-endothelialisation of vessels 
 
To assess the ability of the decellularised jejunum to act as a scaffold for 
vessel reconstruction and development, HDMECs were infused and allowed 
to attach to the matrix for at least 24 hours.  After this time 
LIVE/DEAD staining was performed on segments of the jejunum and 
imaged using confocal microscopy to assess whether the HDMECs were 
able to attach and survive.  Figure 40A shows that the majority of cells 
are live (green) with a very small proportion of dead (red) cells.  
Immunostaining of the samples to detect CD31+ cells shows that the ECs 
had attached to the vessels seemingly forming an interconnected layer 
(Figure 40B).     
 
 
 
Figure 39 – Recellularisation of jejunum with HDFs containing melanin.  An even distribution of cells 
can be seen throughout the jejunum (A).  A magnified section shows that the HDFs occupy the 
vessels within the jejunum (B).    
A B 
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3.3.4. Perfusion flow vs. static culture 
 
Static culture of HDMECs within the decellularised jejunum for 24 hours 
showed that the cells were alive and seemed to occupy the vascular spaces 
(Figure 40).  For longer periods of culture samples were either perfused 
using a bioreactor or cultured under static conditions.  Previous research 
by other groups has shown that perfusion allows for nutrient supply to the 
ECs whilst the shear stress on the cells lining the vessels can stimulate EC 
differentiation and function, suggesting that perfusion is better than static 
culture [154].  However there is very little, if any, literature looking at 
which flow rates are best to use to promote differentiation and function of 
HDMECs when recellularised in a rat jejunum.  Several flow rates were 
therefore investigated when perfusing the bioscaffolds.  Recellularised 
jejunum sections were cultured and sections were taken after 24 hours of 
static culture and 3 days of either static or perfused culture to be analysed 
using the LIVE/DEAD stain and for immunohistochemical analysis.  
Figure 41 shows the results of the LIVE/DEAD staining.  After 24 hours 
in static culture cells appear to be alive with the majority staining green 
(Figure 41 (A, D, G)), as shown previously.  Sections were then taken and 
cultured under static conditions whilst the rest of the bioscaffold was 
Figure 40 – Images of representative jejunum segments after recellularisation 
with HDMECs after 24 hours.  LIVE/DEAD staining shows mostly live 
cells (green) with a small proportion of dead (red) cells occupying the vessels 
(A).  CD31+ staining (red) shows the HDMECs lining the vessels with 
DAPI counterstaining highlighting the cell nuclei (blue) (B).     
A B 
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attached to the bioreactor and perfused.  Figure 41 (B, E, H) shows the 
LIVE/DEAD staining of the sections cultured for 3 days under static 
conditions.  In all cases there are few cells and those that are present in 
the vasculature appear to be dead (red).  Figure 41 (C, F, I) shows 
LIVE/DEAD staining of the sections cultured for 3 days at 2.7 ml/min, 
0.5 ml/min and 0.025 ml/min respectively.  The initial flow rate of 2.7 
ml/min was determined by researching the physiological measurements of 
blood flow through first order mesenteric artery branches of rats which has 
been shown to be 0.3 ml/min [189].  To determine the flow to be applied 
through the SMA the number of branches for each jejunal segment (in this 
study, 9) was multiplied by this flow rate since the total flow rate through 
the SMA is equal to the sum of the flow rates through the first order 
branches.  Using this physical law of continuity the flow rate of detergent 
perfused through the vasculature was 2.7 ml/min.  Values of 0.5 ml/min 
and 0.025 ml/min were chosen arbitrarily to be one and two orders of 
magnitude smaller than the initial 2.7 ml/min flow rate.  Results showed 
that at the higher flow rate there are fewer cells present occupying the 
vessels suggesting that this flow rate is too high and may be detaching the 
cells from the vessel wall.  At the lower flow rates more cells appear to be 
present and in addition these cells are alive.   
 
Figure 42 shows the results of immunostaining for the endothelial cell 
marker CD31 (red).  After 24 hours in static culture the vessels were 
occupied with HDMECs that appeared to have formed a uniform layer 
(Figure 42 (A, D, G)).  Immunostaining of sections cultured for 3 days 
under static conditions confirmed what was seen using the LIVE/DEAD 
stain as HDMEC coverage was sparse (Figure 42 (B, E, H)).  Figure 42 
(C, F, I) shows immunostaining of the sections cultured for 3 days at 2.7 
ml/min, 0.5 ml/min and 0.025 ml/min respectively.  Again, at the highest 
flow rate CD31+ staining showed an uneven coverage of HDMEC cells 
throughout the vascular spaces.  At 0.5 ml/min HDMECs were present in 
the vessels which appeared to be more populated when comparing to the 
sections that were perfused at 2.7 ml/min.  However the coverage was still 
discontinuous in parts.  At the lowest flow rate (0.025 ml/min) there 
appeared to be more HDMEC cells present in the vessels that showed a 
more uniform coverage.  All of these experiments were repeated twice and 
at least three sections of recellularised jejunum were analysed per 
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experiment.  At least 5 images of each section were taken.  Future analysis 
should aim to quantify the differences in cell distribution, survival etc. 
between each flow rate.  This could be achieved by quantifying the level of 
fluorescence in each image taken from the samples.           
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Figure 41 – LIVE/DEAD staining of sections of jejunum recellularised with HDMECs and cultured under static 
and perfused conditions.  Staining after 24 hours in static culture showed well populated vascular spaces with live 
cells (A, D, G).  After 3 days in static culture sections show the presence of very few live cells (B, E, H).  
Staining of sections perfused for 3 days at 2.7 ml/min (C) shows few HDMECs occupying the vessels suggesting 
that this flow rate is too high and may be detaching the cells from the vessel wall.  Lowering the flow rate to 0.5 
ml/min (F) and 0.025 ml/min (I) shows an increased number of HDMECs present.        
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Figure 42 - Immunostaining of sections of recellularised jejunum cultured under static and perfused 
conditions.  CD31+ staining (red) and counterstaining with DAPI (blue) shows well distributed HDMECs 
throughout the vascular spaces after 24 hours in static culture (A, D, G).  After 3 days in static culture 
sections showed sparse population with HDMECs (B, E, H).  Staining of sections perfused for 3 days at 2.7 
ml/min (C) shows few HDMECs occupying the vessels suggesting that this flow rate is too high and may be 
detaching the cells from the vessel wall.  Lowering the flow rate to 0.5 ml/min (F) showed an increased 
number of HDMECs, although the coverage was discontinuous in parts.  At the lowest flow rate (0.025 
ml/min) there appeared to be more HDMEC cells present in the vessels that showed a more uniform 
coverage (I).    
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3.3.5. Incorporation of HDFs and their effects on re-endothelialisation 
 
Interactions between endothelial and stromal cells are important for 
vascularisation of regenerating tissue and it has been shown that 
fibroblasts play a key role by acting as a ‘helper’ cell modulating EC 
migration, viability and network formation in a 3D tissue like environment 
and also during the angiogenic process [88,190–192].  HDFs were therefore 
co-cultured with HDMECs to investigate whether they had an effect on 
the re-endothelialisation of the jejunum vessels.   
 
HDFs were perfused:- 
 
1. Into the vessels along with HDMECs 
2. Into the lumen of the intestine to surround the vessels          
 
The recellularised jejunum was then cultured under either static conditions 
or perfused at a rate of 0.025 ml/min.   
 
Figure 43 shows LIVE/DEAD staining and immunostaining of sections 
that had HDFs perfused into the vessels along with the HDMECs.  After 
24 hours in static culture the majority of the cells were alive (Figure 43A).  
Immunostaining for CD31 after 24 hours showed the presence of HDMECs 
in what appeared to be distinct locations throughout the vessels with other 
areas stained only with DAPI, showing the locations of the HDFs (Figure 
43D).  After 3 days in static culture LIVE/DEAD staining (Figure 43B) 
shows a lack of cells which was confirmed by immunostaining (Figure 
43E).  Perfusion of the bioscaffold at a rate of 0.025 ml/min shows an 
improvement in the presence of cells after 3 days when compared to static 
culture.  LIVE/DEAD staining (Figure 43C) shows that the cells are 
alive but does not distinguish between HDFs and HDMECs.  
Immunostaining for CD31 (Figure 43F)   shows distinct areas occupied by 
HDMECs (red/blue) and HDFs (blue).  This suggests that the different 
cell types are competing for space within the vascular channels and which 
actually inhibits HDMECs from forming a continuous monolayer.                  
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Figure 44 shows LIVE/DEAD staining and immunostaining of sections 
that had HDFs perfused into the lumen of the jejunum and HDMECs 
perfused into the vasculature.  After 24 hours in static culture the majority 
of the cells were alive (Figure 44A).  Immunostaining for CD31 after 24 
hours showed the presence of HDMECs in what appeared to be a uniform 
distribution throughout the vessels (Figure 44D).  After 3 days in static 
Figure 43 - LIVE/DEAD staining and immunostaining of sections that had HDFs perfused into 
the vessels along with the HDMECs.  LIVE/DEAD staining after 24 hours (A) shows the 
presence of mainly live cells.  After 3 days of static culture (B) there are very few cells when 
compared to those present after 3 days of perfused culture at 0.025 ml/min (C).  Immunostaining 
for CD31 (red) and counterstaining with DAPI (blue) shows the presence of HDMECs in distinct 
locations throughout the vessels with other areas stained only with DAPI, showing the locations 
of the HDFs after 24 hours in static culture (D).  After 3 days in static culture there are very few 
cells (E).  Perfusion of the bioscaffold at a rate of 0.025 ml/min shows an improvement in the 
presence of cells after 3 days when compared to static culture whilst showing distinct areas 
occupied by HDMECs and HDFs (F).         
A B 
D E 
C 
F 
24 hours 
STATIC 
3 days 
PERFUSED 
3 days 
STATIC 
Chapter 3: Use of natural vasculature to study angiogenesis 
 
131 
 
culture LIVE/DEAD staining (Figure 44B) shows a lack of cells which 
was confirmed by immunostaining (Figure 44E).  Perfusion of the 
bioscaffold at a rate of 0.025 ml/min showed an improvement in the 
presence of cells after 3 days when compared to static culture.  
LIVE/DEAD staining (Figure 44C) shows that the cells are alive within 
the vessels.  Immunostaining for CD31 and counterstaining with DAPI 
(Figure 44F) shows an almost uniform distribution of HDMECs within the 
vascular channels with the presence of HDFs (only stained with DAPI) 
outside the channels.  In all cases it has been shown that perfusion at a 
low flow rate is better than static culture.    Figure 45 shows a comparison 
Figure 44 - LIVE/DEAD staining and immunostaining of sections that had HDFs perfused into 
the lumen of the jejunum and HDMECs perfused into the vasculature.  LIVE/DEAD staining 
after 24 hours (A) shows the presence of mainly live cells.  After 3 days of static culture (B) there 
are very few cells when compared to those present after 3 days of perfused culture at 0.025 ml/min 
(C).  Immunostaining for CD31 (red) and counterstaining with DAPI (blue) shows the uniform 
distribution of HDMECs throughout the vascular channels (D).  After 3 days in static culture 
there are very few cells (E).  Perfusion of the bioscaffold at a rate of 0.025 ml/min shows an 
improvement in the presence of cells after 3 days when compared to static culture whilst showing 
an almost uniform distribution of HDMECs (F).           
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between the three perfused (0.025ml/min) cell combinations: 
 
1. HDMECs only (Figure 45A) 
2. HDMECs and HDFs inside the vessels (Figure 45B) 
3. HDMECs within the vessels and HDFs within the intestinal lumen 
(Figure 45C) 
 
Perfusing HDMECs within the vessels and HDFs within the intestinal 
lumen appears to give the most uniform distribution of HDMECs within 
the vascular channels after 3 days in culture.  Figure 46 shows a higher 
magnification view of the immunostained segment of jejunum infused with 
HDMECs within the vessels and HDFs within the intestinal lumen.  It 
shows a continuous layer of HDMECs within the vascular structures.  All 
of these experiments were repeated twice and at least three sections of 
recellularised jejunum were analysed per experiment.   
         
 
 
 
 
 
 
 
 
Figure 45 – Immunostained sections of perfused jejunum (0.025 ml/min) which had HDMECs infused through 
the vasculature only (A), HDMECs and HDFs infused through the vasculature (B) and HDMECs infused 
through the vasculature with HDFs infused through the intestinal lumen (C).  CD31 staining is shown in red 
and nuclear staining is shown in blue.         
A C B 
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3.3.6. Use of the recellularised natural vascular net as an angiogenesis 
model 
 
Experiments showed that infusing HDMECs within the vascular channels 
with HDFs infused through the intestinal lumen and then perfusing this at 
a rate of 0.025 ml/min for 3 days gave the most uniform distribution of 
HDMECs within the vascular channels.  This cell combination and flow 
rate were therefore taken forward and used in the development of the 
angiogenesis model.  
 
VEGF is a potent and well known stimulator of angiogenesis.  To test 
whether HDMECs could be stimulated into sprouting, VEGF (10 ng/ml) 
and non-VEGF loaded collagen gels were placed on top of the 
recellularised intestine and the intestines perfused for 3 days.  Gels and 
segments of recellularised jejunum were then immunostained for CD31 
(HDMEC marker) and delta like ligand 4 (DLL4) (tip cell marker) and are 
shown in Figure 47.  HDMECs present in the sections of jejunum that had 
VEGF loaded gels placed on top expressed DLL4 (shown in green) 
A B 
Figure 46 – Immunostained section of jejunum with HDMECs infused through the vasculature 
and HDFs infused through the intestinal lumen (A).  A magnified view of the sample 
indicated by the white box shows a uniform and continuous distribution of HDMECs within 
the vascular channels (B).  CD31 staining is shown in red and nuclear staining is shown in 
blue.              
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indicating that HDMECs had become specialised endothelial tip cells 
capable of leading the outgrowth of blood vessel sprouts towards gradients 
of VEGF (Figure 47 (A-C)).  Analysis of the VEGF loaded collagen gel 
shows that HDMECs had migrated into the gel and some expressed DLL4 
but they had not organised themselves into vessel like structures (Figure 
47D).  Analysis of sections of jejunum that had non-VEGF loaded gels 
placed onto them showed the presence of HDMECs within the vessels but 
did not show expression of the DLL4 marker (Figure 47 (E, F)).  This 
experiment was repeated twice and at least three sections of recellularised 
jejunum were analysed per experiment.   
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Figure 47 – Immunostained segments of recellularised jejunum (HDMECs within the 
vascular channels and HDFs within the intestinal lumen) and VEGF/non-VEGF loaded gels 
for CD31 (red) and DLL4 (green).  HDMECs present in the sections of jejunum that had 
VEGF loaded gels placed on top expressed DLL4 indicating that they had become 
specialised endothelial tip cells (A-C).  VEGF loaded collagen gel sections showed that 
HDMECs had migrated into the gel and some expressed DLL4 but they had not organised 
themselves into vessel like structures (D).  Sections of jejunum that had non-VEGF loaded 
gels placed onto them showed the presence of HDMECs within the vessels but did not show 
expression of the DLL4 marker (E, F).    
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3.4. Discussion 
 
Advances in the field of tissue engineering have shown promising steps 
towards the regeneration of vital tissues and organs including skin [193], 
bladder [54], urethra [194] and  trachea [195].  However one of the main 
challenges in almost all cases is the lack of rapid vascularisation upon 
transplantation which leads to early graft failure.  Without an 
understanding of the factors that affect blood vessel formation and 
sprouting it is unlikely that this problem will be solved.  Many in vitro 
angiogenesis assays are available but none combine the ability to include 
supporting cells (e.g. SMCs, pericytes or fibroblasts or other stromal cells), 
the ECM and perfusion [97].  In the present study we aimed to develop a 
model that will allow all three components to be combined for 
investigation of the sprouting angiogenesis process.   
 
3.4.1. Bioscaffold characterisation 
 
As discussed in Chapter 1 (section 1.5), using rat jejunal segments reduces 
the number of cells required to repopulate the scaffold and is the reason 
for the use of this species in this study.  Since the rat jejunum is relatively 
thin it was decided to use Triton-X 100 as the decellularisation detergent 
because it has been shown to cause less damage to the ultrastructure of 
the tissue when compared to ionic detergents [79,163].  The protocol was 
modified from that published by Baptista et al. [77].  Physiological 
measurements of blood flow through first order mesenteric artery branches 
(indicated in Figure 48) has been shown to be 0.3 ml/min [189].  To 
determine the flow to be applied through the SMA the number of branches 
for each jejunal segment (in this study, 9) was multiplied by this flow rate 
since the total flow rate through the SMA is equal to the sum of the flow 
rates through the first order branches.  Using this physical law of 
continuity the flow rate of detergent perfused through the vasculature was 
2.7 ml/min.                                
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Continuous perfusion of detergent via the vascular tree of the rat intestine 
allowed for the production of a natural acellular matrix after ~18 hours.  
Initial H&E staining showed the removal of the majority of cellular 
material from the fresh jejunum after which was further confirmed via 
DAPI staining which highlighted the almost complete removal of cellular 
material from the jejunum.  Quantification of the DNA in both the intact 
and decellularised samples showed a 97% removal of cellular material.  
Vascular patency was then tested by infusing blue food dye through the 
vascular net.  This was shown to fill acellular vascular architecture 
showing the preservation of the native vascular network after 
decellularisation.  Further confirmation was made by injecting FITC-
Dextran into the vasculature, and again this filled the acellular vascular 
architecture. However in both instances the injected liquid diffused into 
the tissue parenchyma after a period of around 5-10 minutes and is most 
likely due to the leakiness of the acellular vascular structures as a result of 
the removal of the EC lining.   
 
Figure 48 – Schematic showing the mesenteric branched 
circulation of a rat.  Reproduced from the study by Pourageaud 
et al. [189] 
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Histology and quantitative assays were then used to investigate the 
composition of the ECM after decellularisation.  The ECM has been shown 
to be a collection of proteins, glycoproteins and proteoglycans produced by 
cells not only to structurally support the surrounding tissue but also to 
provide important functional biochemical cues.  It has been shown to be 
responsible for a range of processes such as angiogenesis, vasculogenesis, 
inflammation, cell proliferation, migration and more [171].  The main 
component of the ECM is the protein, collagen with more than 20 different 
types identified.  Collagen is the main contributor to the mechanical and 
physical properties of the ECM, especially collagen type I.  Sirius red 
staining was used to visualise the collagen content of the decellularised 
jejunum.  Staining showed little difference in the presence of collagen 
(stained red) when comparing the intact and decellularised jejunum 
sections.  When Sirius red stained sections are examined under circularly 
polarised light, larger collagen fibres (indicative of type I collagen) tend to 
appear bright orange or red whilst smaller reticular fibres (indicative of 
type III collagen) appear green in colour [183,184].  Comparing the intact 
and decellularised sections it can be seen that the majority of fibres appear 
to be bright orange/red indicating the presence and retention of larger 
collagen type I fibres.  Quantification showed that the proportion of 
collagen increased by 30% after the process and could be as a result of the 
removal of other cellular proteins within the matrix increasing the 
proportion of collagen with respect to the dry weight after processing.  
Fibronectin is the next most abundant protein found in the ECM.  It is a 
glycoprotein found in submucosal and basement membrane structures and 
is responsible for cell adhesion [173,174,196].  Immunostaining for this 
protein showed that it was almost completely removed after 
decellularisation.  To discover the affect that this has on recellularisation 
experiments, the bioscaffold could be perfused with fibronectin prior to 
reseeding the vascular structures with cells in future experiments.  Laminin 
is another adhesion protein found in the ECM, especially the basement 
membrane [173].  It has been show to play an important role in vascular 
formation and maintenance and is thought to be a key component to EC 
friendly scaffold materials [171].  Fortunately laminin was found to be 
preserved after the decellularisation process as identified through the use of 
immunohistochemistry.  GAGs are another important component of the 
ECM.  They play key roles in binding growth factors, cytokines and water 
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within the ECM.  The heparin rich GAGs do this by taking advantage of 
the heparin binding capabilities of many cell surface receptors and growth 
factors such as VEGF [171].  This makes their presence desirable in tissue 
engineering scaffolds due to their angiogenic potential.  The presence of 
GAGs was visualised by using the alcian blue stain.  This showed little 
difference between the intact and decellularised samples.  Quantification 
confirmed that there was no significant difference between the two 
samples.  Finally the Accustain elastic staining kit was used to stain for 
the presence of elastin (black colour).  Elastin is another structural protein 
found in tissues that are required to stretch, such as skin, blood vessels 
etc.  This was found to be completely removed in sections of decellularised 
jejunum and so no formal quantification was performed.  These findings 
are similar to those published in related literature [77,155].  Baptista et al. 
report findings from the decellularisation of rat livers using the same 
detergents as used in this study (the decellularisation protocol in this 
study was derived from this paper).  They report similar trends as found 
in this study with the removal of 97% of DNA, an increase in the 
proportion of collagen (10%) in relation to the dry weight of tissue, the 
retention of GAGs, slight reduction in elastin but they do show the 
retention of both laminin and fibronectin [77].  This slight difference may 
be due to difference in the tissue that was being decellularised.  To the 
best of my knowledge Totonelli et al. are the only group that have 
reported on the decellularisation of rat jejunum.  They use the detergent 
sodium deoxycholate and again report similar trends to those observed in 
this study.  They showed the removal of 99% of DNA, the retention of 
GAGs, removal of elastin and an increased proportion of collagen [155].                 
 
To investigate whether or not the scaffold would be cytotoxic to cells after 
the decellularisation process, RN22 cells and HDFs were cultured in the 
presence of decellularised jejunum segments.  Rat tail collagen type I was 
used as a negative control since it is well know that cells will grow in its 
presence [185,186] whilst cyanoacrylate glue was used as a positive control 
due to its potent cytotoxic nature [187,188].  Giemsa staining, used to 
impart colour to cells to aid microscopic identification, showed that cells 
grew up to and around the decellularised jejunum segments in the same 
way as they did in the presence of the collagen gel.  However all cells died 
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in the presence of the cyanoacrylate glue.  This confirmed that the 
decellularised jejunum was not cytotoxic to cells.  
 
To examine the retention of angiogenic growth factors by the presence of 
GAGs, sections of decellularised jejunum were loaded onto the CAM assay.  
As a control, collagen I gels were used containing no growth factors.  
Macroscopic quantification measured blindly by assessors showed a 
significant increase (P < 0.0001) in the number of vessels growing towards 
the decellularised intestine sections compared to the collagen gel control 
showing the inherent angiogenic effect of the decellularised jejunum.  This 
response argues for the preservation of key growth factors or GAGs that 
have bound chick growth factors that will ultimately affect cell response 
upon reseeding.  Masson-Goldner trichrome staining showed that there had 
been a high level of cellular infiltration into the decellularised jejunum 
segments in comparison to the collagen gel control.  This confirms the 
cytotoxicity results that showed that the scaffold is cell friendly.  In 
addition blood vessels had infiltrated the decellularised jejunum further 
confirming its angiogenic potential.  
  
3.4.2.  Recellularisation of the vascular network 
 
In order to produce a model to investigate angiogenesis, cells were infused 
through the vasculature to repopulate the acellular matrix.  To 
macroscopically observe the distribution of cells within the matrix to 
ensure even dispersal, advantage was taken of the process of phagocytosis 
of synthetic melanin by HDFs to allow for their pigmentation and 
visualisation.  HDFs were used not only for their ability to phagocytose 
melanin but also because fibroblasts have been reported to act as helper 
cells in neovascularisation [192,197,198] and were investigated for this 
purpose in this study.  The results highlighted that the cells could indeed 
phagocytose melanin and appeared as a brown sheet in a T75 flask.  After 
infusion into the decellularised jejunum they had distributed evenly 
throughout the bioscaffold, occupying the vascular structures.  This gave 
confidence that when a section was taken from the recellularised jejunum 
it would be representative of the whole sample.   
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Delivering cells of endothelial origin has been the focus of many studies 
aimed at investigating angiogenesis since they are directly associated with 
contributing to vessel formation.  Until recently the most commonly used 
human ECs used for in vitro angiogenesis assays have been HUVECs.  
However since angiogenesis involves the microvasculature there has now 
been a shift towards the use of microvascular ECs [97] with many studies 
using  HDMECs to study angiogenesis [199–203].  HDMECs were therefore 
used initially to recellularise the decelluarised jejunum.  After 24 hours in 
static culture LIVE/DEAD staining showed that the cells had occupied 
the vascular structures and the majority were live.  Immunostaining for 
the EC marker CD31 confirmed that the cells had attached to the vascular 
channels and they had formed an evenly distributed layer.   
 
Although the recellularised jejunal segments were cultured under static 
conditions it is widely acknowledged that fluid flow and shear stress 
associated with it plays a role in determining the structure and function of 
ECs in vivo [204].  The exact mechanism by which the endothelium 
experiences shear stress remains unclear since every mechanosensing 
molecule in the process is not known [205].  However the activation of ion 
[206–208], cation [209] and stretch sensitive channels [210] have been 
observed immediately after exposure to shear stress.  An increase in 
intracellular calcium and a considerable increase in NO production has also 
been noted.  An increase in the levels of NO due to the action of shear 
stress is known to be caused by the activation of the enzyme eNOS.  Upon 
activation eNOS catalyses L-arginine to L-citrulline and nitric oxide (NO) 
[15].  These factors play a key role in signalling to the EC that it is under 
shear, which in turn elicits an angiogenic response depending on the level 
of shear stress encountered [205].  NO has also been shown to play a key 
role in regulating vessel tone (vessel wall tension), acting as a powerful 
vasodilator.   Briefly, it stimulates soluble guanylyl cyclase in the vascular 
SMCs to induce formation of cyclic guanosine monophosphate.  This in 
turn activates protein kinase G which promotes the reuptake of cytosolic 
calcium into the sarcoplasmic reticulum, the expulsion of calcium out of 
the cell and the opening of calcium activated potassium channels.  The 
calcium concentration then decreases in the cell and SMC relaxation 
ensues [211].  Due to the link between behaviour of the endothelium and 
fluid forces it was decided to investigate the effects of perfusion on the re-
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endothelialisation of the vascular structures.  Previous studies (summarised 
in Table 5 and Table 7 in Chapter 1) that have perfused the recellularised 
jejunum have used flow rates ranging from 0.8 ml/min to 3.8 ml/min.  
None of the studies have provided justification for this choice or 
observations using different flow rates.  It was therefore decided to trial 
several flow rates to see what effects this would have on the re-
endothialisation of the vessels.  An initial flow rate of 2.7 ml/min was used 
to perfuse the network.  This was the same flow rate used to decellularise 
the jejunum and was chosen due to its relation to the physiological fluid 
flow found in the small jejunum of rats [189].  After 24 hours after the 
infusion of HDMECs the scaffold was constantly perfused at this rate for 3 
days.    
 
LIVE/DEAD analysis and immunostaining for CD31 showed the presence 
of very few cells suggesting that this flow rate is too high and may be 
detaching the cells from the vessel wall.  Flow rates of approximately one 
and two orders of magnitude smaller were then used (0.5 ml/min and 
0.025 ml/min respectively).  In both instances there were more live 
HDMECs present after 3 days under constant perfusion than when 
cultured under static conditions.  Also when the lower flow rate of 0.025 
ml/min was used there appeared to be more live cells occupying the 
vascular channels with a more uniform distribution when compared to 
using a flow rate of 0.5 ml/min.  This suggests that HDMECs need a low 
flow rate (but not static) to attach and distribute throughout the vascular 
network.   
 
Having identified a suitable flow rate, the HDMECs were then co-cultured 
with HDFs in an attempt to improve the re-endothelialisation of the 
vessels.  Studies have shown that using mature HDMECs in a monoclonal 
culture have shown relatively poor results when seeded onto biomaterial 
scaffolds due to their inability to survive, proliferate over long periods and 
most importantly to self-assemble into tube like structures [192].  However, 
improved results have been noted by using a co-culture of HDMECs and 
fibroblasts [192,197,198].  Cell proliferation and cell signalling have been 
improved through the use of such co-cultures and it is believed that this is 
as a result of paracrine signalling mechanisms that promote production of 
VEGF from fibroblasts and the upregulation of VEGF receptors on 
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HDMECs [192].  To determine whether the HDFs had to be in direct 
contact with the HDMECs to could accomplish this ‘helper’ cell status, 
they were either seeded within the vascular channels along with the 
HDMECs or they were seeded into the lumen of the jejunum so that they 
were not in direct contact with the HDMECs.  The co-culture of cells into 
the decellularised intestinal scaffold was again maintained under both 
static and perfusion cultures to determine whether perfusion enhanced re-
endothelialisation with the inclusion of HDFs.  Results clearly indicated 
the necessity for a low rate of perfusion since there were very few cells 
present in both instances when the scaffolds were cultured statically.  
When perfused different results were obtained when HDFs were infused 
into the vasculature of the jejunum along with the HDMECs compared to 
when they were seeded within the lumen.    Immunostaining for CD31 
showed distinct areas occupied by HDMECs and HDFs when they were 
both infused into the vascular channels.  This suggests that the different 
cell types are competing for space within the vascular channels which 
actually inhibits HDMECs from forming a continuous monolayer.  
However, when the HDFs were seeded within the lumen results showed an 
almost uniform distribution of HDMECs within the vascular channels, 
showing a similar distribution to that obtained after 24 hours in static 
culture.  This implies that HDFs and HDMECs do not need to be in direct 
contact for the HDFs to act as ‘helper’ cells and that they communicate 
via soluble mediators that can penetrate through the bioscaffold.  These 
could be cytokines such as VEGF, FGF etc.  The most uniform 
distribution of HDMECs was therefore obtained by infusing HDMECs into 
the vascular channels and seeding HDFs into the lumen of the jejunum 
and then perfusing continuously for 3 days at a rate of 0.025 ml/min.     
    
3.4.3. The use of the recellularised vascular network as an angiogenesis 
model 
 
The aforementioned cell combination and flow rate that gave the most 
uniform distribution of HDMECs within the vascular channels was taken 
forward and used in the development of the angiogenesis model, with 
particular focus placed on investigating sprouting angiogenesis.   
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It is well documented that VEGF is a potent pro-angiogenic molecule 
[22,212–214].  As discussed in Chapter 1 it is not the only pro-angiogenic 
growth factor associated with angiogenesis and in fact it is the interplay 
between a variety of factors (chemical and mechanical) that ultimately 
promotes angiogenesis [4].  However, for the preliminary development of 
the angiogenesis model it was decided to initially focus solely on the use of 
VEGF before adding other growth factors which could potentially 
complicate the analysis and potential troubleshooting.  The concentration 
of VEGF to use in angiogenesis assay has been investigated by many 
groups.  In many instances a concentration of 10 ng/ml was found to be 
optimal [215–218] and so was used in this study.  In order to immobilise 
and set up a VEGF concentration gradient the growth factor was added to 
a collagen gel.  Type I collagen from rat tails has also been used widely in 
angiogenesis assays since ECs have been shown to penetrate into the 
collagen gels to a depth of ~200 µm in a 24 h period [219–221].  It was 
decided not to use matrices such as Matrigel since this is not completely 
defined, containing multiple ECM proteins and growth factors [222].  
Furthermore, fibroblasts have been shown to act like ECs when seeded 
onto Matrigel [113–115] and this could have potentially interfered with the 
interpretation of results obtained when using HDFs.  Collagen was 
therefore used in order to immobilise the VEGF.  The final concentration 
of the VEGF in the gels was 10 ng/ml since this had been used in previous 
studies whereby ECs had been found to infiltrate and form capillary like 
structures [44,223–225].  The collagen gels (with and without VEGF) were 
loaded into metal rings that had been placed onto the recellularised 
jejunum in order to fix the gel in place and identify their location at the 
end of the experiments since both the recellularised jejunum and gels were 
translucent.  The recellularised jejunum was then continuously perfused for 
3 days before staining sections for the CD31 and DLL4 markers.  A period 
of 3 days was chosen to reduce the likelihood of infections whilst using the 
bioreactor system, however it would be possible to run the system for 
longer (order of weeks) if the system was housed in a clean room.  Results 
showed that HDMECs present in the sections of jejunum that had VEGF 
loaded gels placed on top expressed DLL4 indicating that HDMECs had 
become specialised endothelial tip cells capable of leading the outgrowth of 
blood vessel sprouts towards a VEGF signal.  Analysis of the VEGF 
Chapter 3: Use of natural vasculature to study angiogenesis 
 
145 
 
loaded collagen gel showed that HDMECs had migrated into the gel and 
some expressed DLL4 but they had not organised themselves into vessel 
like structures.  Future experiments would aim to extend the culture time 
to see if the ECs reorganised into capillary like structures with further 
perfusion.  Analysis of sections of jejunum that had non-VEGF loaded gels 
placed onto them showed the presence of HDMECs within the vessels but 
did not show expression of the DLL4 marker.  These observations are 
validated by what has been reported in the literature where VEGF has 
been shown to regulate tip cell migration [226–228].  These preliminary 
results indicate that this technique offers real potential for use as a model 
to investigate angiogenesis in vitro.          
 
                    
3.4.4. Limitations  
 
Although this technique combines an ECM component, the ability to add 
a variety of supporting cells and the capacity to be perfused there are 
some limitations.  Firstly, since it is a natural scaffold there is inevitable 
batch-to-batch variability amongst the resected jejunal sections.  In 
addition the process of cannulating the SMA, recellularising the jejunum 
and setting up the bioreactor system is quite intricate and therefore 
requires a lot of practise to become efficient and so it is difficult to 
efficiently scale up experiments to gain rapid outputs.  
 
3.5. Summary  
 
In this chapter an angiogenesis model derived from a decellularised rat 
jejunum was presented.  After decellularisation ~97% of the DNA content 
was removed whilst preserving the vascular network.  Analysis of the ECM 
components showed an increase in the proportion of collagen with respect 
to the dry weight (~30%), the retention of GAGs and laminin but did 
show the removal of elastin and fibronectin.  Recellularisation showed that 
the vascular network could be evenly re-endothelialised with HDMECs 
when HDFs were seeded into the lumen and the jejunum was perfused at a 
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rate of 0.025 ml/min for 3 days, continuously recirculating the medium 
(without replenishment).  Higher flow rates resulted in the loss and 
subsequent uneven coverage of HDMECs within the channels.  Placing 
VEGF loaded gels onto the recellularised jejunum led to the expression of 
DLL4 by HDMECs indicating their transformation into tip cells.  Tip cells 
are synonymous with sprouting angiogenesis since they allow for the 
exploration of the surrounding environment to sense chemoattractants, 
such as VEGF, emitted as a result of hypoxia.  Please note that the 
culture medium was not supplemented with VEGF.  These results indicate 
the potential of this technique to model angiogenesis and overcome the 
shortcomings of current angiogenesis assays by allowing the inclusion of 
supporting cells, an ECM component and the ability to perfuse the whole 
scaffold.    
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Chapter 4 
 
Synthetic vasculature to study 
angiogenesis 
 
4.1. Aims 
 
The aim of this chapter is to develop a synthetically derived in vitro model 
in which to study angiogenesis by: 
 
1. Producing vascular networks for experimentation by electrospinning 
and robocasting to produce a synthetic vascular network.  
 
2. Investigating the optimal cell combinations to functionalise the 
vascular networks and recellularise these networks. 
 
3. Investigating the effects of pro-angiogenic stimuli on angiogenic 
sprouting.   
 
4.2. Introduction 
 
Over the years many assays have been developed and are now used 
extensively to investigate the process of angiogenesis, as discussed in 
Chapter 1.  The vast majority of the knowledge gained about angiogenesis 
has been gained from the use of static 2D cell culture systems.  Although 
helpful, the use of very simplified systems using flat, stiff substrates to 
culture cells does not capture the highly complex tissue environment in 
which angiogenesis naturally takes place.  It is therefore suspected that 
cells will behave differently in such simple systems and are 
misrepresentative, potentially giving erroneous results.  The development 
Chapter 4: Synthetic vasculature to study angiogenesis 
 
148 
 
of 3D assays has therefore been undertaken by various groups [165].  These 
have mostly used natural materials such as collagen I, fibrin or Matrigel 
because they have intrinsic properties that enable good cell attachment, 
proliferation and EC sprouting [165].  However it has been identified that 
when using natural materials there is limited control over degradability 
and mechanical properties whilst batch-to-batch variability has been 
identified.  Groups have therefore started to look into using synthetic 
materials to model angiogenesis since they can be easily modified both 
chemically and biochemically whilst their mechanical properties can be 
tightly controlled.   
 
As discussed in Chapter 1, Jeffries et al. reported the use of a novel 
technique combining fused deposition modelling and electrospinning to 
form synthetic vascular networks that were then capable of being perfused 
and recellularised with ECs [168].  The purpose of this study was to 
produce a synthetic scaffold to act as a vascular bed to support TE 
constructs.  In this chapter the aforementioned approach is modified and 
used to produce perfusable synthetic networks for use as an angiogenesis 
model.  Instead of using fused deposition modelling of PVA, robocasting of 
alginate is used instead.  Robocasting is also an extrusion based technique 
but unlike fused deposition modelling it does not require a heated nozzle to 
extrude the material [229].  This means that it potentially allows for the 
introduction of biomolecules within the fabrication process increasing the 
functionality without facing the loss of activity or denaturation of proteins 
and it also enables the retention of microstructural integrity of the 
electrospun mats as they will not be altered by the high temperatures.  
The use of alginate is also easy to remove and cell friendly.  
Electrospinning of the vascular network uses the polymer, PHBV since 
previous work carried out in our group has found it to be biocompatible 
and biodegradable [230].  The pseudo-vascular synthetic networks are then 
recellularised with a combination of HDFs and HDMECs and analysed to 
determine the extent of cell attachment.  A VEGF loaded gel is then 
placed onto the scaffold to observe the effects of this pro-angiogenic 
stimulator on blood vessel sprouting.            
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4.3. Results 
4.3.1. Synthetic vascular net production 
  
Through the combination of alginate printing (via the use of a 3D printer) 
and electrospinning it was possible to rapidly produce a number of 
replicate scaffolds.  The geometry of the scaffolds was controlled through 
the use of custom built g-code software, VPPG, and varying sizes of 
scaffolds (Figure 49 (A, B)) made from randomly aligned fibres (Figure 
49C) could be produced.  Removal of the alginate was studied though the 
use of SEM and fluorescence microscopy (Figure 50).  SEM microscopy 
showed that by removing the alginate (Figure 50A) after electrospinning it 
was possible to produce a hollow, interconnected structure (Figure 50B).  
The complete removal of alginate was confirmed using fluorescence 
microscopy by loading Eosin Y into the alginate mixture.  Figure 50C 
shows alginate printed on top of the electrospun mat and Figure 50D 
shows the presence of alginate after electrospinning a further layer on top.  
No fluorescence was visible after adding the electrospun networks into a 
0.5 M solution of EDTA overnight (Figure 50E).  
 
The scaffolds used throughout this study had geometries indicated by 
Figure 49A and Figure 50 (A&B).  These were ~30 mm in length and ~17 
mm wide with the elongated hexagonal shapes in the centre measuring 
~7mm in length and ~4 mm in width.  For each ‘production run’ 36 
scaffolds were produced and around 70% of these were used.  There were 
several reasons for the 30% wastage but the main one was due to the 
printing of the alginate.  Figure 51(A&B) (left) show examples of ‘good’ 
prints where there is not overlap of the alginate but in some cases the 
alginate was completely misprinted as a result of a printer error as 
indicated by Figure 51A (right) and in some cases the alginate would 
merge meaning that the channels were not separate (Figure 51B (right)).  
In these instances the scaffolds were discarded as they were deemed not fit 
for purpose.  Since this was a preliminary study of whether these scaffolds 
would support cell growth and have the potential to be used as an 
angiogenic model, increasing the printing efficiency was not a key focus of 
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the project since enough scaffolds were produced for these purposes via 
this setup.                    
 
 
 
 
 
 
A 
C 
B 
Figure 49 – Synthetic pseudo-vascular nets were produced through a combination of 
robocasting and electrospinning.  The size of the scaffolds could be varied (A, B) and SEM 
imaging showed that they were comprised of randomly aligned fibres (C).  
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Figure 50 – Synthetic pseudo-vascular scaffold prior to the removal of alginate (A) and after removal 
of this sacrificial  substrate by submerging in EDTA solution overnight (B) shown by SEM 
microscopy.  The complete removal of alginate was confirmed through the use of fluorescence 
microscopy.  Alginate loaded with Eosin-Y after printing on top of the electrospun mat (C) and after 
electrospinning on top of the alginate (D).  After submerging the sscaffold in 0.5M EDTA overnight 
the alginate was completely removed (E).         
500 µm 
500 µm 
500 µm 
Alginate 1 mm 
A B 
C D 
500 µm 
E 
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4.3.2. Characterisation of synthetic vascular nets 
 
Prior to cell culture, the fibre diameter and mechanical properties of the 
PHBV scaffolds were tested.  Measurements using Image J software 
showed that the diameter of the fibres was 0.70 ± 0.05 µm.  Previous work 
from our group has shown that PHBV nanofibers such as this are capable 
of allowing the passage of nutrients through the fibres but prevent cells 
from passing through them for a period of up to 6 weeks [230,231].  
Mechanical testing of the bulk PHBV scaffold enabled the UTS, Young’s 
Modulus (E), yield strength and elongation at break to be determined.  A 
typical stress vs. strain graph for such samples is shown in Figure 52.  
Analysis of data from 4 different samples allowed for the average 
properties of the bulk PHBV material to be determined, as summarised in 
Table 23.  The results show that the bulk material has an average UTS of 
0.6 MPa, similar to poly(ether urethane urea) (PEUU) vascular graft 
scaffolds that have been used previously in vivo [232].  Mechanical testing 
of the pseudo-vascular PHBV scaffolds enabled the suture retention 
strength to be determined.  A typical stress vs. strain curve for such 
A B 
Figure 51 – Images of alginate printing onto the electrospun mat.  Examples of good printing 
are shown in (A) and (B) (left).  Examples of alginate printing errors are shown where the 
printer has malfunctioned (A) (right) and where the alginate has merged meaning that the 
channels are not separate (B) (right).  In cases where the alginate had not been printed 
correctly, the scaffolds were discarded.      
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samples is shown in Figure 53.  The suture retention strength of this 
material is also similar to scaffolds that have been used in vivo which have 
a typical range of between 35–59 MPa [233].       
 
UTS 
Young’s Modulus 
Yield Strength 
Elongation at Break 
Suture retention 
 
Figure 53 - Representative stress vs strain curve of the pseudo-vascular scaffolds to 
calculate the suture retention strength. 
Figure 52 – Representative stress vs strain curve for the bulk PHBV material. 
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Table 23 – Summary of the mechanical properties of the bulk PHBV material and 
pseudo-vascular scaffold suture retention strength. 
 Tensile testing (n=4)  
Fibre 
diameter 
(µm) 
UTS 
(MPa) 
Yield 
Strength 
(MPa) 
Young’s 
Modulus 
(MPa) 
Elongation 
at Break 
(%) 
Suture 
Retention 
Strength 
(MPa) (n=6) 
0.70 ± 0.05 0.60 ± 0.08 0.29 ± 0.05 15.00 ± 2.60 36.47 ± 5.03 41.67 ± 5.85 
 
 
4.3.3. Re-endothelialisation of synthetic pseudo-vessels 
 
To determine whether the scaffolds could support cellular attachment, 
growth and survival to form a pseudo-vascular network, HDMECs were 
infused into the scaffolds and cultured under static conditions for 7 days.  
Samples were then analysed for the presence and distribution of cells.  
Figure 54 shows various magnification H&E sections of the scaffolds after 
7 days and shows the distinct lack of HDMEC cells.  SEM analysis of both 
the curved (Figure 55A) and flat (Figure 55B) surfaces shows some cell 
attachment and spreading but it is sporadic.  This was further confirmed 
by immunostaining for CD31 and counterstaining with the nuclear stain 
DAPI on the curved (Figure 55C) and flat (Figure 55D) surfaces where 
HDMEC distribution is patchy.           
 
 
 
 
 
 
Chapter 4: Synthetic vasculature to study angiogenesis 
 
155 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54 – H&E staining of sections of scaffolds recellularised with HDMECs and cultured under 
static conditions for 7 days.  Varying magnifications at 10x (A), 20x (B) and 40x (C) show a lack 
HDMECs present.      
A B C 
Luminal surface 
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Figure 55 – Distribution of HDMECs within the PHBV pseudo-vascular scaffold.  SEM 
images of the curved (A) and flat surface (B) shows the attachment of HDMECs onto the 
scaffold albeit with a sparse distribution.  Fluorescence images stained for CD31+ (red) 
and DAPI (blue) of the curved (C) and flat (D) surfaces again shows the presence of 
HDMECs (red) but with an irregular coverage throughout the scaffold.   
A B 
C D 
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4.3.4. Incorporation of HDFs and their effects on re-
endothelialisation 
 
As mentioned in the previous chapter interactions between endothelial and 
stromal cells are important for vascularisation of regenerating tissue and it 
has been shown that fibroblasts play a key role as acting as a ‘helper’ cell 
modulating EC migration, viability and network formation in a 3D tissue 
like environment and also during the angiogenic process [88,190–192].  As 
with the natural vascular net HDFs were therefore co-cultured with 
HDMECs to investigate whether they had an effect on the re-
endothlialisation of the jejunum vessels.  In the case of the synthetic 
pseudo-vascular scaffolds HDFs were infused either: 
 
3. Into the scaffold along with HDMECs or 
4. Pipetted onto the outer surfaces of the scaffold          
 
Figure 56 shows H&E stained sections of scaffolds recellularised with: 
 
1. HDMECs only (A-C) 
2. HDMECs and HDFs inside the channels (D-F) 
3. HDMECs within the channels and HDFs on the outer surfaces (G-
I)    
 
In both cases where HDFs had been co-cultured with HDMECs there 
appeared to be more cells present on the scaffolds.  Comparing SEM 
images of the different scaffolds shows a uniform coverage of cells when 
HDMECs and HDFs were both seeded inside the channels (Figure 57(C, 
D)) and when HDMECs were within the channels and HDFs were seeded 
on the outer surfaces (Figure 57(E, F)) when compared to recellularising 
with HDMECs alone ((Figure 57(A,B)).  To distinguish between HDMECs 
and HDFs immunohistochemistry was used, where the CD31 marker was 
used to determine the presence of HDMECs and counterstaining with the 
nuclear stain DAPI was used to identify HDFs.  Figure 58(A, B) shows the 
results of recellularising with HDMECs alone where the distribution of 
cells is sporadic.  When adding HDFs into the channels along with 
HDMECs there are distinct areas occupied by both cell type on the curved 
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and flat surfaces (Figure 58(C, D)) although in this case the HDMECs 
seem to attempt to form an interconnected layer.  This suggests that both 
cell types compete for space within the channels preventing a uniform 
monolayer of HDMECs from forming.  However, by adding HDFs to the 
outer surfaces of the channels whilst recellularing the inner surfaces of the 
channels with HDMECs shows a very different result.  Here both the 
curved and flat surfaces show a uniform monolayer of HDMECs (Figure 
58(E, F)).  To confirm that the HDMECs had formed cell-cell junctions 
samples were immunostained for endothelial adherens junction protein VE-
Cadherin (vascular endotheial) also known as CD144.  HDMECs that had 
been seeded into the channels with HDFs on the outer surface of the 
scaffolds exhibited CD144 (Figure 59) indicating that they had formed 
functional intercellular junctions which are a key determinant in the 
cellular permeability and therefore functionality of an endothelium.  To 
test for cellular permeability FITC-Dextran could be perfused through the 
re-endothelialised scaffold and imaged to determine whether the HDMECs 
act as a functional endothelium.      
                   
    
 
Chapter 4: Synthetic vasculature to study angiogenesis 
 
159 
 
 
A B C 
D E F 
G H I 
Figure 56 - H&E staining of sections of scaffolds recellularised with HDMECs only (A-C), 
HDMECs and HDFs both inside the channels (D-F) and HDMECs within the channels and 
HDFs on the outer surfaces (G-I).  All samples were cultured under static conditions for 7 days.  
Note the presence of artefacts on the outer surface of the scaffolds shown in D-F, this could be 
remnants from the H&E sectioning or residual cells that had attached during the scaffold seeding 
process.   
Luminal surface 
Luminal surface 
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A B 
C D 
E F 
Figure 57 – SEM images of the curved and flat inner surfaces of the scaffolds 
recellularised with HDMECs only (A, B), HDMECs and HDFs both inside the channels 
(C, D) and HDMECs within the channels and HDFs on the outer surfaces (E, F).  All 
samples were cultured under static conditions for 7 days.       
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A B 
C D 
E F 
Figure 58 – Immunostained sections of the curved and flat surfaces of the 
scaffolds recellularised with HDMECs only (A, B), HDMECs and HDFs both 
inside the channels (C, D) and HDMECs within the channels and HDFs on 
the outer surfaces (E, F).  All samples were cultured under static conditions 
for 7 days. CD31+ (red) and DAPI (blue). 
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In an attempt to try and understand why adding HDFs resulted in 
HDMECs transforming to produce a monolayer distribution, samples were 
stained for alpha smooth muscle actin (αSMA).  Mature fibroblasts do not 
express this marker, however it is upregulated in myofibroblasts [234–236].  
Myofibroblasts play a key part in tissue remodelling by both exerting and 
responding to mechanical stimuli but also by producing ECM components 
such as collagens, fibronectin and others in response to growth factor 
stimuli [234].  Scaffolds that had HDFs seeded either within the channels 
or on the outer surfaces were sectioned and in both cases showed positive 
staining for αSMA (Figure 60 and Figure 61 respectively).  Interestingly, 
HDMECs also stained positive in certain areas of both scaffolds.  This 
suggests that the HDFs and a proportion of HDMECs differentiate into 
myofibroblasts.  Genetic labelling and RT-PCR may help determine 
whether this is actually the case.  As a control, HDMECs and HDFs 
cultured on TCP were also stained for αSMA and both showed negative 
staining (Figure 63A and Figure 63B respectively).            
 
 
A B 
Figure 59 – Immunostained sections of the curved (A) and flat (B) surfaces of the scaffolds 
for CD144 (red) on samples recellularised with HDMECs within the channels and HDFs on 
the outer surfaces.  All samples were cultured under static conditions for 7 days.  Samples 
were counterstained with DAPI (blue).      
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Figure 60 – Immunostained sections of scaffold recellularised with HDMECS and HDFs
within the channels.  DAPI staining (blue) of cells is shown in (A) with CD31+ 
staining (red) (B) and αSMA staining (green) (C).  A merged image of all three
channels is shown in (D).   
A B 
C D 
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Figure 61 - Immunostained sections of scaffold recellularised with HDMECS within the 
channels and HDFs on the outer surfaces.  DAPI staining (blue) of cells is shown in 
(A) with CD31+ staining (red) (B) and αSMA staining (green) (C).  A merged image 
of all three channels is shown in (D).        
A B 
C D 
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A B 
C D 
Figure 62 - Immunostained sections of scaffold recellularised with HDMECS only shows 
the presence of very few cells.  DAPI staining (blue) of cells is shown in (A) with 
CD31+ staining (red) (B) and αSMA staining (green) (C).  A merged image of all 
three channels is shown in (D).       
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Figure 63 – Immunostaining for αSMA (green) of HDMECs (A) and HDFs (B) cultured 
on TCP.  Counterstained with DAPI (blue) to show cell nuclei.      
A B 
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4.3.5. Use of the recellularised synthetic vascular net as an 
angiogenesis model 
 
Experiments showed that recellularising the scaffolds with HDMECs inside 
the channels and HDFs on the outer surfaces resulted in a monolayer of 
HDMECs evenly distributed on both the curved and flat surfaces.  This 
cell combination was therefore taken forward and used in the development 
of the angiogenesis model.   
 
VEGF is a potent and well known stimulator of angiogenesis.  To test 
whether HDMECs would be stimulated into sprouting, holes were pierced 
into the sides of the recellularised channels (due to the nanofibrous nature 
of the scaffold which prevents migration of cells) after 7 days before 
placing VEGF and non-VEGF loaded collagen gels on top of the scaffolds 
and culturing for a further 7 days, as illustrated in Figure 64.             
 
 
 
 
 
 
After 7 days in culture (after the addition of the gels) the scaffolds were 
fixed and immunostained (as a whole) for CD31.  Confocal microscopy was 
used and images were taken within the collagen gel, close to the edge of 
the channels, as indicated by the schematic shown in Figure 65A.  
HDMECs were found to form interconnected networks branching outwards 
from the channels of the scaffold and into the VEGF loaded collagen gel 
(Figure 65 (B, C)).  A z-stack from this area showed that the HDMECs 
Figure 64 – Schematic showing addition of VEGF and non-VEGF loaded gels onto the 
surface of the recellularised pseudo-vascular scaffolds. 
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had in fact formed 3D capillary like structures (Figure 65D).  No such 
structures were formed when the gel was not loaded with VEGF (Figure 
65E).  To determine whether these capillary like structures could be 
perfused FITC-lectin was injected through the scaffolds.  Figure 66 shows 
that the FITC-lectin (green) co-localises with the CD31 staining (red) 
indicating that the solution has passed through the structures.  Some 
FITC-lectin can be seen to be dispersed through the gel implying that the 
capillary like structures are leaky and have not developed a fully 
impermeable layer of HDMECs.  To confirm that this is indeed the case, 
FITC-BSA or FITC-Dextran could also be perfused.   Please note that 
these experiments were repeated 5 times with at least 6 replicates per 
experiment.  However vascular network formation such as this was 
witnessed in the range of 25-50% of samples per experiment (i.e. 25% in 
experiment 1, 33% in experiment 2 etc.).                                
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Figure 65 – Immunostained recellularised scaffolds cultured for 7 days with VEGF 
loaded gels placed on top.  Images were taken near the boundaries between the 
channels and the gels as indicated by the arrows in the schematic (A).  CD31 
staining (red) shows the formation of an interconnected network of HDMECs (B, 
C) whilst a z-stack shows the formation of 3D capillary like structures (D). No 
such structures were formed when the gel was not loaded with VEGF (E).      
VEGF GEL Vascular channels 
Vascular channels 
B C 
D E 
A 
Chapter 4: Synthetic vasculature to study angiogenesis 
 
170 
 
 
Figure 66 – Perfusion of FITC-Lectin through the recellularised (HDMECs within 
scaffold channels and HDMECs on the outer surface) pseudo-vascular scaffold.  DAPI 
staining (blue) of cells is shown in (A) with FITC-Lectin (green) (B) and CD31+ 
staining (red) (C).  A merged image of all three channels is shown in (D).  Note that 
the cells shown in blue that are not co-localised with HDMECs (shown in red) are 
HDFs.        
   
A B 
C D 
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4.4. Discussion 
 
4.4.1. Synthetic pseudo-vascular network production 
 
Both electrospinning and innovative additive manufacturing techniques 
such as robocasting are used regularly for tissue engineering applications 
[237,238]. Combining these two approaches offers a range of advantages for 
future medical device design.  In this study the use of robocasting allows 
us to readily tune the geometrical design of the vascular networks in terms 
of size, thickness and morphology.  In addition, electrospinning allows us 
to create scaffolds with a range of degradation rates, fibre diameters and 
porosity levels [230,231,239].  By combining these approaches the 
production of pseudo-vascular networks such as this can be readily scaled 
up and sterilised for large experiments and even future clinical 
applications.   
 
The polymer chosen to produce the electrospun scaffold layers was PHBV 
since previous work carried out in our group has found it to be 
biocompatible and biodegradable [230].  Not only that but it also forms 
nanofibers with small pore sizes which was a prerequisite of the material 
needed for this application.  Studies have shown that cells cannot 
penetrate nanofibrous scaffolds due to their small fibre thickness and small 
pore size but do allow for the passage of essential nutrients through the 
pores which are necessary for cell survival [230,240,241].  Since the initial 
aim of this study was to form a HDMEC monolayer within the pseudo-
vascular structures it was necessary that the cells did not migrate through 
the thickness of the scaffold.  In addition it has also been shown that 
irrespective of the polymer material, the nanofibrous topography of 
electrospun scaffolds has the ability to modulate cell behaviour in a similar 
way to ECM fibres by guiding cell migration, controlling differentiation, 
aiding in cell attachment etc. [241–243].  Electrospun layers with fibre 
diameters of ~0.7 µm were produced and used in this study.  To create the 
3D pseudo-vascular nets robocasting of alginate was used.  Robocasting is 
a room temperature extrusion based technique [229] and was used instead 
of techniques such as fused deposition modelling because they do not 
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require elevated temperatures which could potentially alter the 
microstructural properties of the electrospun mat.  Alginate, which is a 
natural polysaccharide used widely in the biomedical field due to its 
biocompatibility [244,245], was used as the sacrificial material to form the 
outline of the pseudo-vascular network.  Not only can it form 3D scaffolds 
but it can also be easily removed using EDTA [246].  Using this 
combination of electrospinning and robocasting it was possible to produce 
a nanofibrous synthetic pseudo-vascular network comprised of 
interconnected hollow channels.  This method quickly produced multiple 
scaffolds for experimentation which could easily be scaled up.  However 
printing errors were encountered during the robocasting of the alginate 
paste and as a result the production efficiency was ~70%, with around 10 
scaffolds being wasted for every 36 produced.  Since this was a preliminary 
study that focussed upon the use of these networks as an angiogenesis 
model, the efficiency of the production was deemed satisfactory for our 
purposes.  
 
Prior to cell culture mechanical properties of the PHBV scaffolds were 
tested results show that the bulk material has an average UTS of 0.6 MPa, 
similar to PEUU vascular graft scaffolds that have been used previously in 
vivo [232].  The suture retention strength of this material is also similar to 
scaffolds that have been used in vivo which have a typical range of 
between 35-59 MPa [233].     
                   
4.4.2. Recellularisation of the pseudo-vascular network 
 
In order for the electrospun pseudo-vascular net to act as a model vascular 
structure for angiogenesis and potentially support neovascularisation 
within biological structures, optimisation of seeding and growth of an 
endothelial monolayer within the scaffold lumen was performed.  As was 
the case in the natural angiogenesis model discussed in Chapter 3, 
HDMECs were used due to their microvascular nature.  Initially HDMECs 
were injected at high density within the lumen alone and allowed to 
adhere to the upper and lower surfaces for 7 days.  After this time results 
showed the presence of CD31 and therefore HDMECs but the distribution 
was discontinuous with HDMECs appearing rounded and little evidence of 
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CD31 at cell-cell junctions.  Since HDFs had been used effectively to 
improve the re-endothelialisation of the natural vascular channels, it was 
decided to apply similar techniques to the synthetic pseudo-vascular 
network.  Therefore HDFs were co-cultured with HDMECs both inside the 
vascular channels and on the outer surfaces of the scaffolds.  Results 
echoed those found when analysing the natural vascular networks.  H&E 
staining of scaffold sections indicated that the greatest improvement in 
cellular coverage was observed when HDFs were cultured within the 
channels when compared to seeding HDFs onto the outer surfaces.  In 
order to further characterise the cell coverage to confirm the results 
indicated via H&E staining the vascular nets were peeled apart to reveal 
the upper and lower surfaces of the channels.  Immunostaining of the 
entire scaffold for CD31 was then performed and the samples were 
analysed using confocal microscopy.  These technique, unlike H&E staining 
was able to discern between HDMECs and HDFs and did indeed show 
improved HDMEC coverage when HDFs were seeded within the channels 
of the nets but unlike H&E staining it showed that the coverage was 
patchy with some areas of HDMECs appearing to have detached from the 
pseudo-vascular net.  This suggested poor cell adhesion and a potential 
competition for space within the channels between the two cell types.  
Although not very well identified through H&E staining, possibly due to 
their thin monolayer distribution, HDMEC coverage was vastly improved 
when HDFs were cultured on the outer surface of the scaffolds.  In this 
instance HDMECs formed a continuous endothelial monolayer with a 
characteristic ‘cobblestone’ appearance and exhibited clear cell-cell junction 
staining of CD31, particularly on the curved surface.  Furthermore, 
staining for the endothelial adherens junction protein VE-Cadherin 
confirmed the establishment of a confluent monolayer on the inside of the 
lumen when HDFs were cultured on the outside.  This shows that 
HDMECs had formed funtional intercellular junctions which are a key 
determinant in the cellular permeabiltiy and therefore functionality of an 
endothlium.  As was the case with the results attained from the natural 
vascular network, this implies that HDFs and HDMECs do not need to be 
in direct contact for the HDFs to act as ‘helper’ cells and that they 
communicate via soluble mediators that can penetrate through the 
synthetic scaffold.         
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Even though fibroblasts were described over 100 years ago it is their 
location and ‘what they are not’ that still defines them.  Their lack of 
distinguishable markers means that they are often identified as ‘non-
SMCs’, ‘non-ECs’ etc. [191].  Gene analysis has found that fibroblasts can 
be quite different depending on their location but their main purpose of 
synthesising and maintaining the ECM remains a common property of 
such cells [247].  Research looking into gene expression of fibroblasts in 
tumours and in locations of active wound healing have found that they are 
activated into myofibroblasts [248].  Unlike fibroblasts these cells can be 
recognised by their expression of αSMA [191].  Myofibroblasts play a key 
part in tissue remodelling by both exerting and responding to mechanical 
stimuli but also by producing ECM components such as collagens, 
fibronectin and others in response to growth factor stimuli [234].  Studies 
investigating tumour growth have also shown increased angiogenesis in 
xenograft models when tumour cells were co-cultured with myofibroblasts 
[249,250].  They have been found to enhance angiogenesis by secreting a 
range of growth factors including VEGF, bFGF, TGF-β, PDGFs etc. [251–
255].  In an attempt to try and determine whether HDFs had been 
activated into myofibroblasts, which could have potentially promoted the 
HDMECs into producing an evenly distributed monolayer, samples were 
stained for αSMA.  Scaffolds that had HDFs seeded either within the 
channels or on the outer surfaces were sectioned and in both cases showed 
positive staining for αSMA suggesting that they had indeed been activated 
into myofibroblasts.  Interestingly, HDMECs also stained positive in 
certain areas of both scaffolds.  Several studies have shown that ECs can 
undergo a transition towards myofibroblast like cells and deposit ECM 
components [256–258].  Although HDFs and a proportion of HDMECs 
have expressed αSMA which may indicate that growth factors and ECM 
proteins are being deposited leading to a more even distribution of 
HDMECs, much more work needs to be done to confirm if this is indeed 
the reason and if so what growth factors and mechanisms are involved.     
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4.4.3. The use of the recellularised pseudo-vascular network as an 
angiogenesis model 
 
Since the combination of HDMECs within the channels and HDFs on the 
outer surface of the scaffold resulted in a uniformly distributed monolayer 
of interconnected HDMECs, this cell combination was used when 
developing the angiogenesis model (again with particular focus placed on 
sprouting angiogenesis).  The advantage of using a scaffold such as this is 
that it has two hexagonal wells in the centre that can be used to deposit 
test substances.  For the same reasons as were discussed Chapter 3 when 
developing the angiogenesis model from the natural vascular network, 
collagen loaded with VEGF was used in an attempt to induce the 
outgrowth of HDMECs from the re-endothelialised channels.  Prior to 
loading the gels onto the scaffold, holes had to be pierced into the sides of 
the channels since the scaffold was nanofibrous.  The nanfibrous properties 
are advantageous when initially seeding HDMECs into the channels since 
the small fibre diameters and pore sizes prevents migration of cells.  
However this is a disadvantage when the aim is to allow for the migration 
of cells.  Gels with concentration of 2 mg/ml of collagen containing 10 
ng/ml of VEGF were pipetted into the wells and allowed to set before 
culturing the scaffolds under static conditions for 7 days.  Results showed 
the presence of a CD31 positive network within the collagen I gel with the 
appearance of a simple vascular network.  This network was found in 
locations close to the pierced channels and extended a small way into the 
gel, but not entirely into the centre.  Perhaps if cultured for a longer 
period of time migration throughout the entire gel may have been seen.  
To determine whether the vascular structures had formed patent tubes 
and could be perfused, FITC-lectin was infused through the vascular 
scaffold.  Lectins are proteins that have been found to specifically bind to 
sugar complexes attached to lipids and proteins [178,179] and have been 
found to be extremely useful for microvascular labelling [180–182].  When 
conjugated with a fluorescent dye (FITC), any lectin that binds to the 
vascular endothelium can be visualised using fluorescence microscopy.  In 
this study confocal imaging was used to visualise FITC-lectin and showed 
significant overlap with CD31.  A possible justification for this could be 
that perfusion had occurred through the newly formed vascular network.  
Diffusion of FITC-lectin to areas not stained with CD31 could imply that 
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the vessels are leaky and HDMECs have not formed an impermeable layer.  
To confirm that this is indeed the case FITC-BSA or FITC-Dextran (due 
to their larger molecular weights) could be perfused in a repeat experiment 
to rule out the possibility that FITC-lectin had diffused through the 
scaffold first before binding to the endothelium instead of being perfused 
through the channels.  Nevertheless these observations are validated by 
what has been reported in the literature where VEGF has been shown to 
regulate angiogenic outgrowth of ECs [226–228].  It is important to note 
that these experiments were repeated 5 times with at least 6 replicates per 
experiment and vessel formation was found in around 25-50% of samples.  
This variability indicates that the angiogenesis model as it stands is not 
reliable enough to perform large scale studies to investigate angiogenesis.  
Improving the reproducibility of this assay is paramount before it can be 
developed further.  The reason for this variability could have stemmed 
from a number of factors including the thickness of the collagen gel used.  
Unfortunately the thickness was not very well controlled since the 
dimensions of the hexagonal well of the scaffold varied between samples 
and even though the same volume of collagen gel was used this variation 
in geometry would have resulted in a variation in thickness of the gel from 
sample to sample.  Gel thickness has been shown to lead to the death of 
ECs and fibroblasts in certain studies [97].  The batch of HDMECs may 
have also been a contributing factor to the variations observed.  Half way 
through this study the batch of HDMECs was changed.  Batch-to-batch 
variation has been noted as a cause for irreproducibility in other studies 
that have developed in vitro angiogenesis assays [259].  In addition the 
position of the holes pierced into the channels of the nanofibrous scaffolds 
to allow for cellular migration differed in their position and size for each 
sample.  This was because the holes were pierced manually with a sterile 
needle which did not allow for precision control of such parameters.  This 
could have led to a variation in results if the pierced holes were above the 
level of the collagen gel for instance.  Much more work therefore needs to 
be done to standardise the techniques used to perform this assay and 
ensure that it is reliable.  However, these promising preliminary results 
indicate that through further development this technique offers real 
potential for use as a model to investigate angiogenesis in vitro.                             
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4.4.4. Limitations  
 
The main limitation of this model is the poor reproducibility associated 
with it with respect to the formation of new vessels sprouting from the 
channels. In developing the model re-endothelialisation of the channels was 
reasonably consistent. Probably more work needs to be undertaken in 
relation to the use of flow - certainly it can be perfused but the lack of 
reproducibility in the development of new vessels may relate to the 
response of the cells to flow which may not be optimum in this model as 
yet.  However the fact that some evidence of new vessels was seen in 
approximately 50% of the experiments shows that the potential is there.  
As it can be perfused and can be seeded with a variety of cells which can 
secrete ECM components and subjected to external pro-angiogenic stimuli 
it has considerable potential.  However, to obtain reproducible results 
clearly more work must be done to optimise the current variables to 
achieve more consistent results. 
 
4.5. Summary 
 
In this chapter robocasting and electrospinning were used to produce 
perfusable synthetic networks for use as an angiogenesis model.  Analysis 
showed that nanofibrous scaffolds with hollow channels capable of 
perfusion were produced with similar mechanical properties as those used 
as vascular grafts in vivo.  Recellularisation showed that the vascular 
network could be evenly re-endothelialised with HDMECs when HDFs 
were physically separated by seeding them on the outer surfaces of the 
scaffolds.  Placing VEGF loaded gels onto the scaffolds caused HDMEC 
outgrowth to occur from within the channels into the collagen gel showing 
that the engineered vasculature maintains its capacity for angiogenesis.  
Furthermore the HDMECs appeared to have formed perfusable tubules 
within the gel.  Unfortunately these results were not found in every 
experiment and indicate the need for further work to guarantee 
reproducible results.  However, these results indicate promising steps 
towards the development of an in vitro platform in which to study 
angiogenesis and vascular biology in a tissue engineering context.   
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Conclusions and Future Work 
 
This project reports the development of two in vitro models to study 
sprouting angiogenesis that have the capability of combining pro-
angiogenic cells with ECM components which can be monitored under flow 
conditions to learn more about the ‘rules’ of angiogenesis.  
 
The first model was developed through the decellularisation of a rat 
jejunum.  Initial experiments focussed on characterising the matrix to 
determine what it was composed of and whether the native vasculature 
remained patent for eventual recellularisation.  Results showed that after 
decellularisation ~97% of the DNA content had been removed whilst 
preserving the vascular network.  Analysis of the ECM components 
showed an increase in the proportion of collagen with respect to the dry 
weight (~30%), the retention of GAGs and laminin but did show the 
removal of elastin and fibronectin.  Placing segments of decellularised 
jejunum onto the CAM model showed cell and blood vessel infiltration into 
the matrix indicating that it had inherent angiogenic potential.  Further 
work could be carried out to characterise the matrix in order to determine 
if and what growth factors had been retained in the matrix and their 
quantities using an ELISA.  After characterising the decellularised 
jejunum, experiments were carried out to determine whether the vascular 
network could be re-endothelialised and if so what conditions were 
optimal.  Recellularisation showed that the vascular network could be 
evenly re-endothelialised with HDMECs when HDFs were seeded into the 
lumen and the jejunum was continuously perfused at a rate of 0.025 
ml/min.  Higher flow rates resulted in the loss and subsequent uneven 
coverage of HDMECs within the channels.  Once satisfactory re-
endothelialisation was observed the next step of the project was to 
determine whether the scaffold could be used as a test bed to model 
angiogenesis.  Placing VEGF loaded gels onto the recellularised jejunum 
led to the expression of DLL4 by HDMECs indicating their transformation 
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into tip cells.  Tip cells are synonymous with sprouting angiogenesis since 
they allow for the exploration of the surrounding environment to sense 
chemoattractants, such as VEGF, emitted as a result of hypoxia [226–228].  
These results indicated the potential of this technique to model 
angiogenesis and overcome the shortcomings of current angiogenesis assays 
by allowing the inclusion of supporting cells, an ECM component and the 
ability to perfuse the whole scaffold.  In the future, experiments could be 
carried out for longer time periods to see whether the HDMECs that had 
migrated into the collagen gels would form tubules that could subsequently 
be perfused with FITC-lectin (as used for the synthetic model).  A host of 
other experiments could also be carried out to observe the effects of other 
growth factors (individually or in combination with others), mechanical 
forces (through the variation of flow rates), cellular mechanical forces 
(through the manipulation of Rho/ROCK pathway), tumour samples or 
hypoxic tissue (such as skin taken from biopsies) on the angiogenic 
outgrowth of HDMECs.  Furthermore this model offers the potential to be 
repopulated with a range of other cells such as EPCs, iPSCs, SMCs etc. 
which may or may not show better re-endothelialisation and angiogenic 
outgrowth.   
 
The second model was developed through the combination of 
electrospinning and robocasting to produce a synthetic pseudo-vascular 
network.  Again, initial experiments aimed to characterise the synthetic 
scaffolds.  Analysis showed that nanofibrous PHBV scaffolds with hollow 
channels capable of perfusion were produced with similar mechanical 
properties as those used as vascular grafts in vivo.  After characterising 
the scaffold, experiments were performed to see if HDMECs would attach 
to the scaffold and form an interconnected monolayer.  Recellularisation 
showed that the vascular network could be evenly re-endothelialised with 
HDMECs when HDFs were physically separated by seeding them on the 
outer surfaces of the scaffolds.  This echoed the results obtained from the 
natural model, indicating the necessity for fibroblasts to act as helper cells 
to ECs.  Further experiments showed that HDFs expressed the marker 
αSMA which is known to be upregulated upon transformation to 
myofibroblasts [191].  Myofibroblasts play a key part in tissue remodelling 
by both exerting and responding to mechanical stimuli but also by 
producing ECM components such as collagens, fibronectin and others in 
Chapter 5: Conclusions and Future Work 
 
180 
 
response to growth factor stimuli [234].  They have been found to enhance 
angiogenesis by secreting a range of growth factors including VEGF, 
bFGF, TGF-β, PDGFs [251–255].  This could explain the reason for the 
enhanced HDMEC distribution when co-cultured with HDFs.  Further 
work could be done to truly understand what mechanisms and cross-talk is 
going on between the HDMECs and HDFs to produce this enhanced 
cellular distribution.  Once a uniform monolayer distribution of HDMECs 
was obtained within the channels, VEGF loaded collagen gels were placed 
onto the scaffold to determine whether HDMECs would migrate towards 
this pro-angiogenic growth factor, as was previously observed in the 
natural model.  Results showed that HDMEC outgrowth did indeed occur 
from within the channels into the collagen gel.  Furthermore the HDMECs 
appeared to have formed perfusable tubules within the gel. Unfortunately 
these results were not found in every experiment and indicate the need for 
further work to achieve reproducible results. The reason for the variation 
in the results was not determined and clearly indicates the complexity of 
these models.  Nevertheless, these results indicated promising steps 
towards the development of a synthetic in vitro platform upon which to 
study angiogenesis and vascular biology in a tissue engineering context.    
In the future, studies trying to standardise the thickness of the collagen 
gel, position of the holes pierced into the channels and the source of ECs 
could be trialled in an attempt to increase the reliability of this model.  If 
this could be improved to satisfactory levels the breath of experimentation 
that could be performed using this model is extensive.  As in the case of 
the natural net, different cell combinations, growth factors, perfusion 
conditions etc. could be studied in relation to angiogenesis.  Perfusion was 
not focussed upon when developing this model due to the even monolayer 
HDMEC distribution obtained under static conditions but it would be very 
interesting to observe the effects of perfusion on HDMEC distribution and 
outgrowth into the VEGF loaded collagen gel.  In addition, the link 
between inflammatory cells and the angiogenic process is gaining 
increasing interest with recent studies showing macrophage mediated 
angiogenic activation [260–262].  Indeed recent data from the Fitzpatrick 
laboratory have shown differing responses to M1 and M2 macrophages in 
3D models [263].  This model would be a useful platform to further study 
the effects of such cells on the angiogenic outgrowth of ECs from the 
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vascular channels and expand knowledge in this critical area.  This is a 
substantial challenge but should be achievable using this model.   
 
In the development of both of these models the majority of data obtained 
has been qualitative.  Future experiments would aim to convert many of 
the fluorescent images into quantitative measures of cell viability, 
distribution etc. via the measurement and comparison of fluorescence to 
arrive at objective conclusions.  
 
Overall, these two models offer novel ways to investigate factors affecting 
the angiogenic process.  The advantages and disadvantages of both models 
are summarised in Table 24.  They overcome limitations of current in vitro 
models since they offer the capability of combining pro-angiogenic cells 
with ECM components that can be monitored under flow conditions.  This 
could be very useful not only in understanding the basic science underlying 
angiogenesis but also in pre-clinical studies to develop and evaluate 
therapeutic treatments for tissue engineering and related applications.      
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Table 24 – Summary of the pros and cons associated with the synthetic and naturally 
derived angiogenesis models. 
 
  Synthetic Net Natural Net 
Pros 
Easy manufacture and scale up  Contains ECM components 
(and growth factors)   
Simple to cannulate Has physiologically relevant 
architecture 
Can vary geometry  Cells are able to break down 
matrix and sprout ‘naturally’ 
Can introduce flow  
 
Can introduce flow 
Can combine different cell 
types Can alter material 
choice/properties  
Simple to post process and 
analyse 
Can combine different cell 
types 
Cons 
Doesn’t contain any inherent 
ECM components  
Can’t vary geometry/size easily 
Requires holes to be punctured 
in scaffold for gel outgrowth 
experiments 
Difficult to cannulate – 
requires dissection microscope 
and practise 
Doesn’t contain as much 
geometrical detail as 
physiological vasculature 
Time consuming to retrieve 
tissue/decellularise/sterilise  
Batch-to-batch variation  
Requires a source of animals – 
relatively expensive  
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Appendix 
 
A. Materials list 
I. Bioscaffold preparation 
 
 
 
 
 
II. Decellularisation 
 
 
 
 
 
Chemical/Reagent Cat No. Supplier 
Isofluorane CDS019936 Sigma Aldrich 
Heparin sodium salt from porcine 
intestinal mucosa 
H3149-250KU Sigma Aldrich 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Material Cat No. Supplier 
24 gauge cannula 381212 BD Insyte 
Ethicon 4/0 sutures (Mersilk) W501H Medisave 
Universal tubes P4333 Sigma Aldrich 
10ml syringe 302188 BD Plastipak 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Straight sample container 216-2595 VWR International 
Measuring cylinder 1129469 Camlab 
500 ml Duran glass bottle Z305197 Sigma Aldrich 
Equipment Model Supplier 
Dissection kit N/A Thackeray 
Analytical balance AB204 Mettler Toledo 
Chemical/Reagent Cat No. Supplier 
Triton-X 100               BP151 Fisher Scientific 
Ammonium hydroxide 320145 Sigma Aldrich      
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III. Bioscaffold sterilisation 
 
 
 
IV. Bioscaffold Characterisation 
 
Vascular patency  
Material Cat No. Supplier 
2 L glass beaker (tall) BEA1166 SLS 
1 L Duran glass bottle Z305200 Sigma Aldrich 
Tubing Versilic 2x4 mm BxOD TUB1944 SLS 
ADCF male luer barb adapter EW-30800-
24 
Cole Parmer 
Petri dish (90 mm) SLS2000 SLS 
Magnetic stir bar VWR1442-
0521 
VWR International 
Syringe (1 ml) 300013 BD Plastipak 
Blue food colouring  2680374 Asda 
Equipment Model Supplier 
Dissection microscope M 3Z Wild Heerbrugg 
Multi-channel cassette pump 205U Watson Marlow 
Magnetic stirrer CD162 Bibby Scientific 
Forceps Prestige Morton medical supplies 
Automatic pipettes Various  Gilson 
Chemical/Reagent Cat No. Supplier 
Peracetic acid (40% v/v)               BP151 Fisher Scientific 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Material Cat No. Supplier 
Petri dish (90 mm) SLS2000 SLS 
5 ml syringe 302187 BD Plastipak 
Equipment Model Supplier 
Forceps Prestige Morton medical supplies 
Automatic pipettes Various  Gilson 
Appendix 
 
212 
 
 
 
 
 
 
 
Preparation of histological slides 
 
 
 
 
 
Hematoxylin and Eosin (H&E) staining 
Chemical/Reagent Cat No. Supplier 
Blue food colouring               2680374 Asda 
Fluorescein isothiocyanate 
(FITC)–dextran (250 kDa) 
FD250S Sigma Aldrich 
Material Cat No. Supplier 
Petri dish (90 mm) SLS2000 SLS 
Syringe (1 ml) 300013 BD Plastipak 
Equipment Model Supplier 
Forceps Prestige Morton medical supplies 
Dissection microscope M 3Z Wild Heerbrugg 
Confocal microscope Zeiss LSM 
510 
Zeiss 
Chemical/Reagent Cat No. Supplier 
Industrial methylated spirits (IMS) M/4450/17 Fisher Scientific 
Xylene  X/0100/17 Fisher Scientific 
Paraffin wax P3558 Sigma Aldrich 
Formaldehyde (37%) F8775 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Material Cat No. Supplier 
SuperFrost Plus slides 48311-703 VWR International 
Equipment Model Supplier 
Benchtop tissue processor TP1020 Leica  
Embedding centre, dispenser & hot 
plate 
EG1160 Leica 
Microtome RM2235 Leica 
Microtome blades S35 Feather 
Hot plate HI1210 Leica 
Water bath MH8516 Electrothermal 
Forceps Prestige Morton medical supplies 
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Glycosaminoglycan (GAG) staining 
 
 
 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
Harris haematoxylin solution HHS16 Sigma Aldrich 
IMS M/4450/17 Fisher Scientific 
Eosin Y solution HT110232 Sigma Aldrich 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
Measuring cylinder 1129469 Camlab 
Pasteur pipette PIP4208 SLS 
Equipment Model Supplier 
Light microscope DM-B1 Motic 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
Ethanol 10048291 Fisher Scientific 
Alcian blue 8GX A3157 Sigma Aldrich 
Glacial acetic acid 27222 Sigma Aldrich 
Periodic acid 395132 Sigma Aldrich 
Schiffs reagent 3952016 Sigma Aldrich 
Gills no. 3 hematoxylin GH5316 Sigma Aldrich 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
Measuring cylinder 1129469 Camlab 
Pasteur pipette PIP4208 SLS 
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Collagen staining 
 
 
 
 
 
Elastin staining 
 
 
Equipment Model Supplier 
pH meter SevenMulti Mettler Toledo 
Light microscope DM-B1 Motic 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
Ethanol 10048291 Fisher Scientific 
Glacial acetic acid 27222 Sigma Aldrich 
Direct red 80 365548 Sigma Aldrich 
Picric acid 36011 Sigma Aldrich 
Weigert’s hematoxylin HX384843 Merck 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
Measuring cylinder 1129469 Camlab 
Pasteur pipette PIP4208 SLS 
Equipment Model Supplier 
Light microscope (with polarised 
filter) 
BX50 Olympus 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
Ethanol 10048291 Fisher Scientific 
Hematoxylin solution HT25A Sigma Aldrich 
Weigert’s iodine solution HT25A Sigma Aldrich 
Ferric chloride solution HT25A Sigma Aldrich 
Van Gieson solution HT25A Sigma Aldrich 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
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Masson-Goldner trichrome staining 
 
 
 
 
 
Staining of cell nuclei 
 
Measuring cylinder 1129469 Camlab 
Pasteur pipette PIP4208 SLS 
Equipment Model Supplier 
Light microscope DM-B1 Motic 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
Ethanol 10048291 Fisher Scientific 
Weigert’s iron haematoxylin kit 115973 Merck Millipore 
Glacial acetic acid 27222 Sigma Aldrich 
Azophloxine solution 100485 Merck Millipore 
Tungstophosphoric acid orange G 
solution 
100485 Merck Millipore 
Light green SF solution 100485 Merck Millipore 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
Measuring cylinder 1129469 Camlab 
Pasteur pipette PIP4208 SLS 
Equipment Model Supplier 
Light microscope  DM-B1 Motic 
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Immunolabeling of laminin and fibronectin 
 
 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
4',6-diamidino-2-phenylindole 
(DAPI) 
D8417 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Universal container 1048636-1 SLS 
Aluminium foil 11247 Terinex 
PAP pen ab2601 abcam 
Pasteur pipette PIP4208 SLS 
Equipment Model Supplier 
Confocal microscope Zeiss LSM 
510 
Zeiss 
Chemical/Reagent Cat No. Supplier 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
Triton-X 100 BP151 Fisher Scientific 
Bovine serum albumin (BSA) A7030 Sigma Aldrich 
Polyclonal rabbit anti-fibronectin 
primary antibody 
ab2413 Abcam 
Polyclonal rabbit anti-laminin 
primary antibody  
ab11575 Abcam 
FITC anti-rabbit secondary 
antibody 
A-11008 Life Technologies 
4',6-diamidino-2-phenylindole 
(DAPI) 
D8417 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
DPX mountant D/5319/05 Fisher Scientific 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
Measuring cylinder 1129469 Camlab 
Universal container 1048636-1 SLS 
Microcentrifuge tube 1.5 ml 11558232 Fisher Scientific 
Pasteur pipette PIP4208 SLS 
Aluminium foil 11247 Terinex 
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Contact cytotoxicity assay 
 
 
PAP pen ab2601 abcam 
Equipment Model Supplier 
Confocal microscope Zeiss LSM 
510 
Zeiss 
Analytical balance AB204 Mettler Toledo 
Automatic pipettes Various  Gilson 
Chemical/Reagent Cat No. Supplier 
Collagen type I (rat tail) A10483-01 Gibco 
Cyanoacrylate contact adhesive Z105880 Sigma Aldrich 
Sodium hydroxide pellets  221465 Sigma Aldrich 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
D6546 Sigma Aldrich 
Fetal calf serum (FCS) F9565 Sigma Aldrich 
Penicillin/Streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
L-Glutamine G7513 Sigma Aldrich 
Trypsin ethylenediaminetetraacetic 
acid (EDTA) 
T3924 Sigma Aldrich 
Giemsa’s stain solution   352603R VWR International 
Formaldehyde F8775 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Material Cat No. Supplier 
6 well plate CC7682-
7506 
CytoOne 
Pasteur pipette PIP4208 SLS 
Syringe (50 ml) 300866 BD Plastipak 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Magnetic stir bar VWR1442- VWR International 
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V. Quantitative analysis  
 
DNA quantification 
 
 
 
0521 
Equipment Model Supplier 
Pipette boy Pipetboy 
acu 
Integra Biosciences 
Automatic pipette Various Gilson 
Haemocytometer AC1000 Hawksley 
Inverted microscope CK40 Olympus 
Magnetic stirrer CD162 Bibby Scientific 
Analytical balance AB204 Mettler Toledo 
Dissection kit N/A Thackeray 
Chemical/Reagent Cat No. Supplier 
DNeasy kit  69504 Qiagen 
Ethanol 10048291 Fisher Scientific 
Calf thymus DNA (5 mg 
lyophilised) 
D4522 Sigma Aldrich 
Nuclease free water 436912C VWR International 
L-cysteine hydrochloride C1276 Sigma Aldrich 
Di-sodium 
ethylenediaminetetraacetic acid 
E5134 Sigma Aldrich 
PBS containing calcium and 
magnesium 
14040-133 Life Technologies 
Material Cat No. Supplier 
Micro centrifuge tube 1.5 ml 11558232 Fisher Scientific 
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Collagen Quantification 
 
 
 
 
 
GAG quantification 
 
Equipment Model Supplier 
Automatic pipettes Various Gilson 
Analytical balance AB204 Mettler Toledo 
Freeze dryer FreeZone 
Triad 
Spectrum 
Centrifuge CL10 Thermo Scientific 
Dissection kit N/A Thackeray 
Nanodrop spectrophotometer  NanoDrop 
1000 
Thermo Scientific 
Pipette boy Pipetboy 
acu  
Integra Biosciences  
Whirlimixer MS2 IKA 
Chemical/Reagent Cat No. Supplier 
Hydrochloric acid 2611.5000 VWR International  
Citric acid (monohydrate) C1909 Sigma Aldrich 
Glacial acetic acid 27222 Sigma Aldrich 
Sodium acetate (trihydrate) BP334 Fisher Scientific 
Sodium hydroxide pellets 221465 Sigma Aldrich 
Propan-1-ol 20861.294 VWR International 
Chloramine T hydrate 857319 Sigma Aldrich 
p-dimethylaminobenzaldehyde 109762 Sigma Aldrich 
Perchloric acid (70%) 244252 Sigma Aldrich 
Trans-4-hydroxy-L-proline H54409 Sigma Aldrich 
Material Cat No. Supplier 
Flat bottomed 96 well plate 139006 Thermo Scientific 
Polypropylene universal container E1412-3020 Starlab Group 
Micro centrifuge tube 1.5 ml 11558232 Fisher Scientific 
Equipment Model Supplier 
Automatic pipettes Various Gilson 
Freeze dryer FreeZone 
Triad 
Spectrum 
Magnetic stirrer CD162 Bibby Scientific 
Absorbance microplate reader ELx800 BioTek 
pH meter SevenMulti Mettler Toledo 
Pipette boy Pipetboy 
acu  
Integre Biosciences 
Table shaker PSU-10i SLS 
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VI. General cell culture  
 
HDF culture 
 
Chemical/Reagent Cat No. Supplier 
Sodium di-hydrogen 
orthophosphate 
S5011 Sigma Aldrich 
Di-sodium hydrogen 
orthophosphate 
S9763 Sigma Aldrich 
1,9 dimethylene blue 341088 Sigma Aldrich 
Formic acid F0507 Sigma Aldrich 
Papain A3824 PanReac ApplChem 
L-cysteine hydrochloride C1276 Sigma Aldrich 
Di-sodium 
ethylenediaminetetraacetic acid 
E5134 Sigma Aldrich 
PBS containing calcium and 
magnesium 
14040-133 Life Technologies 
Ethanol 10048291 Fisher Scientific 
Sodium formate 30142LN VWR International 
Hydrochloric acid (6 M) 2611.5000 VWR International  
Sodium hydroxide pellets 221465 Sigma Aldrich 
Chondroitin sulphate B C3788 Sigma Aldrich 
Material Cat No. Supplier 
Flat bottomed 96 well plate 139006 Thermo Scientific 
Polypropylene universal container E1412-3020 Starlab Group 
Equipment Model Supplier 
Automatic pipettes Various  Gilson 
Magnetic stirrer CD162 Bibby Scientific 
Absorbance microplate reader ELx800 BioTek 
pH meter SevenMulti Mettler Toledo 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Table shaker PSU-10i SLS 
Water bath Fisherbrand Fisher Scientific 
Chemical/Reagent Cat No. Supplier 
Difco-trypsin powder 215240 BD  
Trypsin EDTA T3924 Sigma Aldrich 
D-glucose G8270 Sigma Aldrich 
Collagenase A 10103578001 Roche 
Phenol red P0290 Sigma Aldrich 
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Human dermal microvascular endothelial cell culture 
 
 
DMEM D6546 Sigma Aldrich 
FCS F9565 Sigma Aldrich 
Penicillin/Streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
L-Glutamine G7513 Sigma Aldrich 
Dimethyl sulphoxide (DMSO) 472301 Sigma Aldrich 
Sodium hydroxide pellets  221465 Sigma Aldrich 
Material Cat No. Supplier 
T25 flask 82051-074 VWR International  
T75 flask BD353136 VWR International  
Universal container 1048636-1 SLS 
Cryovial 72.377.992 Sarstedt 
Mr Frosty freezing container 5100-0001 Thermo Scientific  
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Syringe (50 ml) 300866 BD Plastipak 
Magnetic stir bar VWR1442-
0521 
VWR International 
Equipment Model Supplier 
Centrifuge CL10 Thermo Scientific 
Inverted microscope CK40 Olympus 
Automatic pipette Various Gilson 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Dissection kit N/A Thackeray 
pH meter SevenMulti Mettler Toledo 
Magnetic stirrer CD162 Bibby Scientific 
Water bath MH8516 Electrothermal 
Haemocytometer AC1000 Hawksley 
Chemical/Reagent Cat No. Supplier 
Proliferating HDMECs derived 
from human juvenile foreskin  
C-12260 PromoCell 
Endothelial cell growth medium 
MV kit 
C-22120 PromoCell 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
DetachKit (contains hepesBSS, 
trypsin/EDTA, trypsin 
neutralising solution) 
C-41210 PromoCell 
Pig skin gelatin G-2500 Sigma Aldrich 
Cryo-SFM C-29912 PromoCell 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
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VII. Melanin infusion of dermal fibroblasts  
 
 
 
 
Material Cat No. Supplier 
T25 flask 82051-074 VWR International  
Universal container 1048636-1 SLS 
Cryovial 72.377.992 Sarstedt 
Mr Frosty freezing container 5100-0001 Thermo Scientific  
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Syringe (50 ml) 300866 BD Plastipak 
Equipment Model Supplier 
Centrifuge CL10 Thermo Scientific 
Inverted microscope CK40 Olympus 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Automatic pipette Various Gilson 
Dissection kit N/A Thackeray 
Analytical balance AB204 Mettler Toledo 
Water bath MH8516 Electrothermal 
Chemical/Reagent Cat No. Supplier 
Melanin M0418 Sigma  
DMEM D6546 Sigma Aldrich 
FCS F9565 Sigma Aldrich 
Penicillin/Streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
Trypsin/EDTA T3924 Sigma Aldrich 
FCS F9565 Sigma Aldrich 
Material Cat No. Supplier 
T75 flask BD353136 VWR International 
Universal container  1048636-1 SLS 
Pipette straw 13-676-10H 
13-676-10J 
13-676-10K 
Fisher Scientific 
Equipment Model Supplier 
Centrifuge CL10 Thermo Scientific 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Ultrasonic bath Fisherbrand  Fisher Scientific  
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VIII. Bioscaffold recellularisation 
 
 
 
 
 
 
 
 
 
 
IX. Bioreactor design and preparation 
 
Chemical/Reagent Cat No. Supplier 
Endothelial cell growth medium 
MV kit 
C-22120 PromoCell 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
DetachKit (contains hepesBSS, 
trypsin/EDTA, trypsin 
neutralising solution) 
C-41210 PromoCell 
Pig skin gelatin G-2500 Sigma Aldrich 
DMEM D6546 Sigma Aldrich 
L-Glutamine G7513 Sigma Aldrich 
FCS F9565 Sigma Aldrich 
Trypsin EDTA T3924 Sigma Aldrich 
Material Cat No. Supplier 
Universal container  1048636-1 SLS 
Pipette straw 13-676-10H 
13-676-10J 
13-676-10K 
Fisher Scientific 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Syringe (50 ml) 300866 BD Plastipak 
Syringe (1 ml) 300013 BD Plastipak 
Syringe (5 ml) 302187 BD Plastipak  
Equipment Model Supplier 
Centrifuge CL10 Thermo Scientific 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Haemocytometer AC1000 Hawksley 
Forceps Prestige Morton medical supplies 
Automatic pipettes Various  Gilson 
Chemical/Reagent Cat No. Supplier 
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X. Perfusion of recellularised bioscaffold 
 
 
PA (40% v/v)               BP151 Fisher Scientific 
Material Cat No. Supplier 
A4 stainless M5 12 mm socket 
head cap screw 
- Westfield fasteners  
Lexan medical grade polycarbonate - The Plastic Shop 
Tubing Versilic 2x 4 mm BxOD TUB1944 SLS 
PharMed BPT tubing  
(1/8” × 3/16”) 
EW-96880-
05 
Cole Parmer 
Stainless steel grid - - 
Pipe fittings (plug), 10-32 UNF, 
9/32", 1/4" 
TW-31503-
30 
Cole Parmer 
Barbed to threaded adapters TW-40621-
07 
Cole Parmer 
Straight barbed tubing connector WZ-06365-
22 
Cole Parmer 
Silicon elastomer kit 1673921 Dow Corning 
2 L glass beaker (tall) BEA1166 SLS 
Square petri dish 10489282 Thermo Fisher Scientific 
Straight sample container 216-2595 VWR International 
Equipment Model Supplier 
Oven Heraeus 
vacutherm 
Thermo Scientific 
Laser cutter Epilog Laser 
Mini 
Epilog 
Analytical balance AB204 Mettler Toledo 
Autoclave  Touchclave 
II Osprey 
100 
LTE 
Chemical/Reagent Cat No. Supplier 
Endothelial cell growth medium 
MV kit 
C-22120 PromoCell 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
Material Cat No. Supplier 
Pipette straw 13-676-10K Fisher Scientific 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Bioreactor base and lid - - 
Silicon gasket - - 
Tubing Versilic 2 x 4 mm B x OD TUB1944 SLS 
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XI. LIVE/DEAD cell staining 
 
 
 
PharMed BPT tubing  
(1/8” × 3/16”) 
EW-96880-
05 
Cole Parmer 
Stainless steel grid - - 
Pipe fittings (plug), 10-32 UNF, 
9/32", 1/4" 
TW-31503-
30 
Cole Parmer 
Barbed to threaded adapters TW-40621-
07 
Cole Parmer 
Straight barbed tubing connector WZ-06365-
22 
Cole Parmer 
A4 stainless M5 12 mm socket 
head cap screw 
- Westfield fasteners  
Equipment Model Supplier 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Forceps Prestige Morton medical supplies 
Allen key 6867C Screwfix 
Multi-channel cassette pump 205U Watson Marlow 
Chemical/Reagent Cat No. Supplier 
Propidium iodide  P3566 Life Technologies 
Syto 9 S-34854 Life Technologies 
DMEM D6546 Sigma Aldrich 
Material Cat No. Supplier 
6 well plate CC7682-
7506 
CytoOne 
Universal container  1048636-1 SLS 
Aluminium foil 11247 Terinex 
Pipette straw 13-676-10J Fisher Scientific 
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XII. Collagen gel preparation 
 
 
 
 
XIII. Production of natural angiogenesis model 
 
 
Equipment Model Supplier 
Automatic pipette Various  Gilson 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Dissection kit N/A Thackeray 
Confocal microscope Zeiss LSM 
510 
Zeiss 
Chemical/Reagent Cat No. Supplier 
Collagen type I (rat tail) A10483-01 Gibco 
Sodium hydroxide pellets 221465 Sigma Aldrich 
Endothelial cell growth medium 
MV kit 
C22120 Sigma Aldrich 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
VEGF 165 human V7259 Sigma Aldrich 
Material Cat No. Supplier 
Magnetic stir bar VWR1442-
0521 
VWR International 
Syringe (50 ml) 300866 BD Plastipak 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Microcentrifuge tube 1.5 ml 11558232 Fisher Scientific 
Equipment Model Supplier 
Automatic pipette Various  Gilson 
Magnetic stirrer CD162 Bibby Scientific 
Chemical/Reagent Cat No. Supplier 
Collagen type I (rat tail) A10483-01 Gibco 
Sodium hydroxide pellets 221465 Sigma Aldrich 
Endothelial cell growth medium 
MV kit 
C22120 Sigma Aldrich 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
VEGF human V7259 Sigma Aldrich 
Material Cat No. Supplier 
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XIV. Chick CAM assay  
 
 
 
 
XV. Synthetic scaffold production 
 
Electrospinning PHBV 
 
Magnetic stir bar VWR1442-
0521 
VWR International 
Syringe (50 ml) 300866 BD Plastipak 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Microcentrifuge tube 1.5 ml 11558232 Fisher Scientific 
24 gauge cannula 381212 BD Insyte 
Stainless steel rings - - 
Equipment Model Supplier 
Automatic pipette Various  Gilson 
Magnetic stirrer CD162 Bibby Scientific 
Forceps Prestige Morton medical supplies 
Chemical/Reagent Cat No. Supplier 
IMS M/4450/17 Fisher Scientific 
Material Cat No. Supplier 
Fertilised chick eggs - Henry Stewart & Co. 
Parafilm P7793 Sigma Aldrich 
Masking tape 378-98 29 RS 
Equipment Model Supplier 
Chick egg incubator RCOM Suro Amazon 
Dissection kit N/A Thackeray 
Hacksaw blade 05260140 B&Q 
Digital microscope N43HH Maplin 
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Alginate printing  
 
 
 
Chemical/Reagent Cat No. Supplier 
Poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) pellets  
BV326301 Goodfellow 
Methanol M/4058/17 Fisher Scientific 
Dichloromethane (DCM) D/1850/17 Fisher Scientific 
Material Cat No. Supplier 
Magnetic stir bar VWR1442-
0521 
VWR International 
50ml Duran glass bottle  11782282 Fisher Scientific 
Syringe (5 ml) 302187 BD Plastipak  
Blunt tip needles (0.6 mm ID) FIS5601098 AMS Ltd. 
Flat metal sheet 3232636003958 B&Q 
Rule 12969084 Fisher Scientific 
Equipment Model Supplier 
Magnetic stirrer CD162 Bibby Scientific 
Syringe pump Genie Plus Kent Scientific 
High voltage power pack 7XX30 Genvolt 
Mandrel SSCY30X120 Linari engineering 
Retort stand 11548092 Fisher Scientific 
Retort stand clamp 11517722 Fisher Scientific 
Chemical/Reagent Cat No. Supplier 
Alginic acid sodium salt from 
brown algae  
A2033 Sigma Aldrich 
Calcium chloride dihydrate 100704Y BDH 
Glycerol G/0650/17 Fisher Scientific 
Eosin Y E4009 Sigma Aldrich 
Material Cat No. Supplier 
Glass beaker 13127374 Fisher Scientific 
Magnetic stir bar VWR1442-
0521 
VWR International 
Syringe barrel 7012072 Nordson  
Blunt tip needles (0.6 mm ID) FIS5601098 AMS Ltd. 
Appendix 
 
229 
 
 
 
Alginate removal 
 
 
 
 
  
XVI. Scanning electron microscopy 
 
 
Equipment Model Supplier 
Magnetic stirrer CD162 Bibby Scientific 
Positive displacement dispensing 
system 
Ultra2800 Nordson 
3D printer RepRap Mendel 
Chemical/Reagent Cat No. Supplier 
Anhydrous acid free 
ethylenediaminetetraacetic acid 
(EDTA) 
E6758 Sigma Aldrich 
Sodium hydroxide pellets 221465 Sigma Aldrich 
Material Cat No. Supplier 
Straight sample container 216-2595 VWR International 
Magnetic stir bar VWR1442-
0521 
VWR International 
Measuring cylinder 1129469 Camlab 
Equipment Model Supplier 
Magnetic stirrer CD162 Bibby Scientific 
pH meter SevenMulti Mettler Toledo 
See-saw rocker Stuart Fisher Scientific 
Chemical/Reagent Cat No. Supplier 
Glutaraldehyde  G6257 Sigma Aldrich 
Ethanol 10048291 Fisher Scientific 
Hexamethyldisilazane (HMDS) 440191 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Material Cat No. Supplier 
Pipette straw 13-676-10H 
13-676-10J 
13-676-10K 
Fisher Scientific 
6 well plate CC7682-
7506 
CytoOne 
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XVII. Synthetic scaffold sterilisation 
 
 
 
 
 
XVIII. Mechanical testing 
 
 
 
 
 
 
 
 
Equipment Model Supplier 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Gold sputter coater Emscope 
SC500 
Philips 
SEM Inspect F FEI 
Chemical/Reagent Cat No. Supplier 
Ethanol 10048291 Fisher Scientific 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Material Cat No. Supplier 
Petri dish (90mm) SLS2000 SLS 
24 gauge cannula 381212 BD Insyte 
Ethicon 4/0 sutures (Mersilk) W501H Medisave 
Equipment Model Supplier 
Dissection kit N/A Thackeray 
Dissection microscope M 3Z Wild Heerbrugg 
Material Cat No. Supplier 
Ethicon 4/0 sutures (Mersilk) W501H Medisave 
Digital callipers 11787105 Fisher Scientific 
Equipment Model Supplier 
Uniaxial load test system Electroforce 
3100 
Bose 
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XIX. Synthetic scaffold recellularisation 
 
 
 
 
 
XX. Production of synthetic angiogenesis model  
 
 
 
Chemical/Reagent Cat No. Supplier 
Endothelial cell growth medium 
MV kit 
C-22120 PromoCell 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
DetachKit (contains hepesBSS, 
trypsin/EDTA, trypsin 
neutralising solution) 
C-41210 PromoCell 
Pig skin gelatin G-2500 Sigma Aldrich 
DMEM D6546 Sigma Aldrich 
L-Glutamine G7513 Sigma Aldrich 
FCS F9565 Sigma Aldrich 
Trypsin EDTA T3924 Sigma Aldrich 
Material Cat No. Supplier 
Syringe (1 ml) 300013 BD Plastipak 
Universal container  1048636-1 SLS 
Pipette straw 13-676-10H 
13-676-10J 
13-676-10K 
Fisher Scientific 
Equipment Model Supplier 
Centrifuge CL10 Thermo Scientific 
Pipette boy Pipetboy 
acu  
Integra Biosciences 
Haemocytometer AC1000 Hawksley 
Forceps Prestige Morton medical supplies 
Automatic pipettes Various  Gilson 
Chemical/Reagent Cat No. Supplier 
Collagen type I (rat tail) A10483-01 Gibco 
Sodium hydroxide pellets 221465 Sigma Aldrich 
Endothelial cell growth medium 
MV kit 
C22120 Sigma Aldrich 
Penicillin/streptomycin P0781 Sigma Aldrich 
Amphotericin B A2942 Sigma Aldrich 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
VEGF human V7259 Sigma Aldrich 
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XXI. Immunohistochemistry 
 
 
 
 
Material Cat No. Supplier 
Magnetic stir bar VWR1442-
0521 
VWR International 
Syringe (50 ml) 300866 BD Plastipak 
Syringe filter (0.2 µm) 83.1826.001 Sarstedt 
Microcentrifuge tube 1.5 ml 11558232 Fisher Scientific 
24 gauge cannula 381212 BD Insyte 
Equipment Model Supplier 
Automatic pipette Various  Gilson 
Magnetic stirrer CD162 Bibby Scientific 
Forceps Prestige Morton medical supplies 
Chemical/Reagent Cat No. Supplier 
Monoclonal mouse anti-human 
CD31 primary antibody 
M082329 Dako 
Polyclonal rabbit anti-alpha 
smooth muscle Actin (αSMA) 
primary antibody   
ab5694 abcam 
Mouse anti-VE-cadherin (CD144) 
primary antibody 
610252 BD Biosciences 
Goat anti-mouse IgG secondary 
antibody, Alexa Fluor 546 
conjugate 
A-11030 Life Technologies 
Goat anti-mouse IgG secondary 
antibody, Alexa Fluor 488 
conjugate 
A-11001 Life Technologies 
DAPI D8417 Sigma Aldrich 
Glycine  23390 Serva 
BSA A9418 Sigma Aldrich 
TWEEN 20 P9416 Sigma Aldrich 
Xylene X/0100/17 Fisher Scientific 
IMS M/4450/17 Fisher Scientific 
PBS (Dulbecco A) tablets BR0014 Oxoid Ltd. 
Paraformaldehyde (PFA) 158127 Sigma Aldrich 
Hanks Balanced Salt Solution 
(HBSS) with calcium and 
magnesium 
14025050 Life Technologies 
Sodium hydroxide pellets  221465 Sigma Aldrich 
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XXII. FITC-lectin perfusion 
  
 
 
 
Material Cat No. Supplier 
Slide rack 70312-24 EMS 
Staining dish 70312-23 EMS 
Cover slips MNJ350020 Thermo Fisher Scientific  
SuperFrost Plus slides 48311-703 VWR International 
Measuring cylinder 1129469 Camlab 
Universal container 1048636-1 SLS 
Microcentrifuge tube 1.5 ml 11558232 Fisher Scientific 
Pasteur pipette PIP4208 SLS 
Aluminium foil 11247 Terinex 
PAP pen ab2601 abcam 
24 well plate 3524 SLS 
Magnetic stir bar VWR1442-
0521 
VWR International 
Equipment Model Supplier 
Automatic pipettes Various  Gilson 
Confocal microscope Zeiss LSM 
510 
Zeiss 
Forceps Prestige Morton medical supplies 
Magnetic stirrer CD162 Bibby Scientific 
Chemical/Reagent Cat No. Supplier 
PFA 158127 Sigma Aldrich 
HBSS with calcium and 
magnesium 
14025050 Life Technologies 
FITC conjugated lectin from 
Lycopersicon esculentum (tomato) 
L0401 Sigma Aldrich 
Material Cat No. Supplier 
Petri dish (90 mm) SLS2000 SLS 
Syringe (1 ml) 300013 BD Plastipak 
Equipment Model Supplier 
Automatic pipette Various  Gilson 
Syringe pump Genie Plus Kent Scientific 
Forceps Prestige Morton medical supplies 
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B. Preparation of general reagents 
 
I. PBS solution 
 
To prepare PBS solution, one PBS tablet (Dulbecco A) was added to 
every 100 ml of distilled water in a bottle able to withstand autoclaving.  
PBS was autoclaved for 10 minutes at 115 °C and stored at room 
temperature.   
 
Supplemented PBS was prepared by adding 5ml of penicillin/streptomycin 
and 1.5 ml of amphotericin B to 500 ml of PBS to give final concentrations 
of 100 U/ml, 0.1 mg/ml and 0.75 µg/ml respectively.    
 
II. 0.1% Peracetic acid (PA) solution 
 
PA solution was prepared to a final concentration of 0.1% (v/v) by adding 
1.25 ml of PA stock solution (40% v/v) to 500 ml of distilled water.   
 
III. Formaldehyde (3.7% w/v) 
 
A formaldehyde working solution was prepared by adding 50 ml of 
formaldehyde stock solution (37% w/v) to 450 ml of PBS to give a final 
concentration of 3.7% (w/v).    
 
IV. IMS 
 
Absolute IMS was diluted in distilled water to produce solutions with final 
concentrations of 70%, 80%, 90% and 95% (v/v). 
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V. Sodium hydroxide (1M) solution 
 
To prepare a 1 M sodium hydroxide solution, 4 g of sodium hydroxide 
pellets were added to a clean bottle containing 100 ml of distilled water.  
A magnetic stir bar was added and the solution was stirred using a 
magnetic stirrer until the pellets had completely dissolved.  The solution 
was filter sterilised in a class II biological safety cabinet.       
VI. Gluteraldehyde (2.5%) solution 
 
Gluteraldehyde stock solution was diluted in PBS at a ratio of 1:10 to 
obtain a 2.5% (w/v) glutaraldehyde working solution.     
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C. Bioscaffold characterisation  
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Figure 67 – Calibration curve used to determine the GAG content in the decellularized jejunum. 
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Figure 68 – Calibration curve used to determine the hydroxyproline content in the 
decellularised jejunal segments. 
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Figure 69 – CAD drawing of the assembled bioreactor produced using the software SolidWorks.   
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Figure 70 – CAD drawing of the base of the bioreactor produced using the software package SolidWorks. 
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Figure 71 – CAD drawing of the lid of the bioreactor produced using the software package SolidWorks. 
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Figure 72 – Calibration curve for Watson Marlow pump attached to the assembled 
bioreactor to determine the required RPM setting associated with the desired flow rate.  
